# 1 Sulpho 2 oxoazetidine derivatives, their production and pharmaceutical compositions thereof.

## Abstract
The invention relates to novel 1 sulpho 2 oxoazetidine derivatives, which are shown by the formula

## Claims
CLAIMS 1. A compound of the formula EMI184.1 wherein R1 is amino, acylated amino or protected amino and X is hydrogen or methoxy, or a salt thereof. 2. A compound as claimed in claim 1, wherein R1 is amino with an acyl group selected from a a group of the formulaEMI184.2 wherein R7 is hydrogen an optionally substituted amino acid residue an amino protecting group a group of the formula R8 CH2 n CO in which R8 is an optionally substituted heterocyclic group, an optionally substituted phenyl, an optionally substituted lower alkyl, an optionally substituted phenylthio or lower alkylthio, n is O or an integer of 1 to 4 and the group CR2 n may optionally be substituted a group of the formulaEMI184.3 in which R8 and R8 may be same or different, and are hydrogen lower alkyl, lower alkyl carbamoyl, optionally substituted phenylcarbonyl or sulpho or a group of the formula R8 S02 in which R8t is optionally substituted lower alkyl and R9 is hydrogen, optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted heterocyclic group, cycloalkenylene or optionally substituted heterocycle carbonylamino in which an alkylene chain may stand between the heterocycle and carbonylamino moieties, and b a group of the formula R10 R11 CO wherein R10 is a group of the formulaEMI185.1 in which R12 is an optionally substituted heterocyclic group or optionally substituted phenyl, R13 is hydrogen, an optionally substituted lower acyl, lower alkyl or a group of the formula R14 Rl5 where R14 is lower alkylene or lower alkenylene and R15 is carboxyl, ester thereof or heterocyclic group and R11 is a mere bond or a group of the formulaEMI185.2 in which R16 is a lower alkyl, optionally substituted phenyl or optionally substituted heterocyclic group. 3. A compound as claimed in claim 1, wherein R1 is amino with a protective group selected from the protective groups used in the field of peptide synthesis. 4. A compound as claimedin claim 1, selected from 3 amino 3 methoxy 2 oxoazetidine 1 sulphonic acid 3 benzyloxycarboxamido 3 methoxy 2 oxoazetidine l sulphonic acid and 3 phenylacetamido 3 methoxy 2 oxoazetidine 1 sulphonic acid. 5. A compound as claimed in claim 1, selected from 3 D N 4 ethyl 2,3 dioxo l piperazino carbonyl phenylglycinamido 3 methoxy 2 oxoazetidine l sulphonic acid 3 amino 2 oxoazetidine 1 sulphonic acid 3 benzyloxycarboxamido 2 oxoazetidine 1 sulphonic acid 3 phenylacetamido 2 oxoazetidine 1 sulphonic acid 3 2 2 amino 4 thiazolyl 2 methoxyiminoamido 2 oxoazetidine I sulphonic acid 3 D N 4 ethyl 2,3 dioxo 1 piperazinocarbonyl phenylglycinamido 2 oxoazetidine 1 sulphonic acid 3 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 2 amino 4 thiazolyl acetamido 2 oxoazetidine l sulphonic acid 3 DL 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 thienylacetamido 2 oxoazetidine 1 sulphonic acid 3 ED 2 4 ethyl 2,3 dioso 1 piperazinocarboxamido 2 thienylacetamido 2 oxoazetidine 1 sulphonic acid 3 ID 2 4 n octyl 2,3 dioxo l piperazino carbo xamido 2 phenylacetamido 2 oxoazetidine 1 sulphonic acid 3 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2 2 amino 4 thiazolyl0acetamido 2 oxoazetidine l sulphonic acid 3 rD 2 r 2 oxo 3 furfurylideneaminoimidazolidin 1 yl carboxamido 2 phenylacetamido 2 oxoazetidine l sulphonic acid 3 DL 2 4 n octyl 2,3 dioxo 1 piperazino carboxamido 2 thienylacetamido 2 oxoazetidine l sulphonic acid 3 D 2 4 n octyl 2,3 dioxo 1 piperazino carboxamido 2 thienylacetamido 2 oxoazetidine l sulphonic acid 3 rD 2 2 oxo 3 thiophen 2 aldoimino imidazolidin l yl carboxamido 2 phenyl acetamido 2 oxoazetidine l sulphonic acid and 3 2 o2ro 3 furfurylideneaminoimidazolidin l yl carboxamido 2 thienylacetamido 2 oxoazetidine l sulphonic acid. 6. A method for the production of a compound of the formula EMI187.1 wherein R1 is amino, acylated amino or protected amino and X is hydrogen or methoxy, or a salt thereof, which comprises sulphonating a compound of the formula EMI187.2 wherein R2 is acylated amino or protected amino and X is as defined above, and optionally removing the aminoprotecting group, or acylating the compound thus obtained of the formula EMI188.1 wherein X is as defined above, and optionally converting the product into a salt. 7. A pharmaceutical composition containing a compound as claimed in any one of claims 1 to 5. CLAIMS AUSTRIA 1. A method for the production of a compound of the formula EMI189.1 wherein R1 is amino, acylated amino or protected amino and X is hydrogen or methoxy, or a salt thereof, which comprises sulphonating a compound of the formula EMI189.2 wherein R2 is acylated amino or protected amino and X is as defined above, and optionally removing the aminoprotecting group, or acylating the compound thus obtained of the formula EMI189.3 wherein X is as defined above, and optionally converting the product into a salt. 2. A method as claimed in claim 1, wherein R1 or R2 is amino with an acyl group selected from a a group of the formulaEMI190.1 wherein R7 is hydrogen an optionally substituted amino acid residue amino protecting group a group of the formula R8 CE2 n CO in which R8 is an optionally substituted heterocyclic group, optionally substituted phenyl, optionally substituted lower alkyl, optionally substituted phenylthio or lower alkylthio, n is O or an integer of 1 to 4 and the group CH2 n may optionally be substituted a group of the formulaEMI190.2 in which R8 and R8 may be same or different, and are hydrogen lower alkyl, lower alkyl carbamoyl, optionally substituted phenylcarbonyl or sulpho or a group of the formula R8 S02 in which R8 is optionally substituted lower alkyl and R9 is hydrogen, optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted heterocyclic group, cycloalkenylene or optionally substituted heterocycle carbonylamino in which an ylene chain may stand between the heterocycle carbonylamino moieties, and b a group of the formula R10 R11 CO wherein R10 is a group of the formulaEMI190.3 in which R12 is an optionally substituted heterocyclic group or optionally substituted phenyl, R13 is hydrogen, optionally substituted lower acyl, lower alkyl or a group of the formula R14 R15 where R14 is lower alkylene or lower alkenylene and R15 is carboxyl, ester thereof or heterocyclic group and R11 is a mere bond or a group of the formulaEMI191.1 in which R16 is a lower alkyl, optionally substituted phenyl or optionally substituted. heterocyclic group. 3. A method as claimed in claim 1, wherein R1 or R2 is amino with a protective group selected from the protective groups used in the field of peptide synthesis. 4. A method as claimed in claim 1, wherein the compound produced is 3 amino 3 methoxy 2 oxoazetidine l sulphonic acid 3 benzyloxycarboxamido 3 methoxy 2 oxoazetidine l sulphonic acid or 3 phenylacetamido 3 methoxy 2 oxoazetidine l sulphonic acid. 5. A method as claimed in claim 1, wherein the compound produced is 3 D N 4 ethyl 2,3 dioxo 1 piperazino carbonyl phenylglycinamido 3 methoxy 2 oxoazetidine l sulphonic acid 3 amino 2 oxoazetidine l sulphonic acid 3 benzyloxyearboxamido 2 o toazetidine 1 sulphonic acid 3 phenylacetamido 2 oxoazetidine 1 sulphonic acid 3 2 2 amino 4 thiazolyl 2 metho2cyiminoacetamido 2 oxoazetidine l sulphonic acid 3 D N 4 ethyl 2,3 dioxo 1 piperazinocarbonyl phenylglycinamido 2 oxoazetidine 1 sulphonic acid 3 r2 4 ethyl 2,3 dio o 1 piperazinocarbowamido 2 2 amino 4 thiazolyl acetamido 2 oxoazetidine l sulphonic acid 3 DL 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 thienylacetamido 2 oxoazetidine 1 sulphonic acid 3 D 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 thienylacetamido 2 oxoazetidine 1 sulphonic acid 3 rD 2 4 n octyl 2,3 dioso l piperasinocarbo2ramido 2 phenylacetamido 2 oxoazetidine 1 sulphonic acid 3 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2 2 amino 4 thiazolyl acetamido 2 oxoazetidine 1 sulphonic acid 3 f 1 2 f 2 oxo 3 furfurylideneaminoimidazolidin l yl carboxamido 2 phenylacetamido 2 oxoazetidinel sulphonic acid 3 Do2 4 n octyl 2,3 dio2ro l piperazinocarbosamido 2 thienylacetamido 2 oxoazetidine 1 sulphonic acid 3 rD 2 4 n octyl 2,3 dio o 1 piperazinocarboTamido 2 thienylacetamido 2 oxoazetidine 1 sulphonic acid 3 D 2 2 oxo 3 thiophen 2 aldoimino imidazolidin1 yl carboxamido 2 phenylacetamido 2 oxoazetidine l sulphonic acid or 3 2 oxo 3 furfurylideneaminoimidazolidin 1 yl carbosamido 2 thienylacetamido 2 osoazetidine 1 sulphonic acid.

## Description
l Sulpho 2 Oxoazetidine Derivatives and Their Production This invention relates to novel azetidine derivatives and methods for producing these compounds. In our search for new and useful azetidine derivatives, we have discovered that azetidine derivatives having a sulpho group in the l position satisfy this demand. Our finding was followed by further studies which have culminated in the completion of this invention. Thus, the present invention provides a l sulpho 2oxoazetidine derivative of the general formula EMI1.1 wherein R1 is amino, acylated amino or protected amino and X is hydrogen or methoxy, or a salt thereof. The objective compounds of the formula I may be produced by sulphonating a compound of the formula EMI1.2 wherein R2 is acylated amino or protected amino and X is as defined above, and optionally removing the aminoprotecting group, or acylating the compound of the formula IV thus obtained EMI2.1 wherein X is as defined above. Referring to the above general formulae, the acyl groups on the acylated amino groups R1, R2 and R3 may, for example, be the acyl groups which are found as substitutents on the 6 amino group of known penicillin derivatives and the 7 amino group of known cephalosporin derivatives. Specific examples of such acyl groups include the following a groups of the formula R6 CO wherein R6 is a lower alkyl group or a substituted or unsubstituted heterocyclic group b groups of the formula EMI2.2 wherein R7 is hydrogen, an optionally substituted amino acid residue, an amino protecting group, a group of the formula R8 CH2 n C0 R8 is an optionally substituted heterocyclic group, optionally substituted phenyl, optionally substituted lower alkyl, optionally substituted phenylthio or lower alkylthio n is an integer ofO to 4, the group CH2 n optionally being substituted , a group of the formulaEMI3.1 R8 and Rg may be same or different, and are hydrogen, lower alkyl, lower alkyl carbamoyl, optionally substituted phenylcarbonyl or sulpho or a group of the formula R8 S02 R8 is an optionally substituted lower alkyl R9 is hydrogen, an optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted heterocyclic group, cycloalkenylene or optionally substituted heterocyclecarbonylamino in which an alkylene chain may stand between the heterocyclic and carbonylamino moieties c groups of the formula R10 R11 COwherein R10 is a group of the formulaEMI3.2 LR12 is an optionally substituted heterocyclic group or optionally substituted phenyl, R13 is hydrogen, optionally substituted lower acyl, lower alkyl or a group of the formula R14 R15 R14 is a lower alkylene or lower alkenylene group, R15 is carboxyl, ester thereof or heterocyclic group , R11 is a bond or a group of the formulaEMI3.3 R16 is a lower alkyl, optionally substituted phenyl or optionally substituted heterocyclic group d groups of the formula EMI4.1 wherein R17 is hydroxyl, sulphoxy, carboxyl, optionally substituted sulphamoyl, sulpho, optionally substituted phenoxycarbonyl, benzyloxycarbonyl or formyloxy R18 is hydrogen, a lower alkyl group, a lower alkoxy group, halogen, nitro or hydroxyl and e groups of the formula R19 R2oCH2 COI wherein R19 is a cyano, optionally substituted phenyl, optionally substituted phenoxy, optionally substituted lower alkyl, optionally substituted alkenylene or optionally substituted heterocyclic group R20 is a bond or S . The lower alkyl group R6 is preferably a group of 1 to 6 carbon atoms. The heterocyclic moiety of the optionally substituted heterocyclic group R6 is a 5or 6 membered heterocyclic group including 1 or 2 nitrogen atoms and may optionally include a single oxygen atom. Examples of this heterocyclic group include isoxazolyl, piperazinyl, imidazolinyl etc. The substituents on such heterocyclic groups may, for example, be lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, oxo, thioxo and optionally substituted phenyl. The substituent on the aforementioned optionally substituted phenyl group may include, for example, lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro and amino. As examples ofthe amino acid residue of the optionally substituted amino acid residue R7, there may be mentioned glycyl, alanyl, valyl, leucyl, isoleucyl, seryl, threonyl, cysteinyl, cystyl, methionyl, a or p aspartyl, a or y glutamyl, lysyl, arginyl, phenylalanyl, phenylglycyl, tyrosyl, histidyl, tryptophyl, prolyl, etc. However, in the case ofX methoxy, an example R7 glutamyl, Rg methyl is eliminated. The substituent on the aforementioned optionally substituted amino acid residue may include, for example, amino, lower alkyl amino, amino protecting group, carbamoyl, methylcarbamoyl, sulphamoyl, benzyl, 4 ethyl 2 , 3 dioxo l piperadinocarbonyl and 4 ethyl 2, Sdioxo l piperadinocarbonylamino. The lower alkyl moiety of the lower alkylamine is preferably alkyl of 1 to 3 carbon atoms. The amino protecting group may, for example, be one of the protective groups mentioned hereinafter for amino groups. The amino protecting group R7 may, for example, be one of the protective groups mentioned hereinafter for amino groups. The optionally substituted heterocyclic group R8 in the group represented by the formula R8 CH2 n CO includes, for example, 5 or 6 membered heterocyclic groups including one sulphur, nitrogen or oxygen atom, 5 or 6 membered heterocyclic groups including 2 to 4 nitrogen atoms, and 5 or 6 membered heterocyclic groups including one or two nitrogen atoms and one sulphur or oxygen atom. These heterocyclic groups may each be fused to a 6 membered ring including 1 or 2 nitrogen atoms, a benzene ring or a 5 membered ring including one sulphur atom.As examples of this heterocyclic group R8, there may be mentioned 2pyridyl, 3 pyridyl, 4 pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperazinyl, pyrazolinyl, imidazolidinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrido 2, 3 d pyrimidinyl, benzopyranyl, 1, 8 naphthyridinyl, 1,5 naphthyridinyl, 1,6 naphthyridinyl, 1,7naphthyridinyl, 2, 7 naphthyridinyl, 2, 6 naphthyridinyl, quinolyl, thieno 2,3 bXpyridinyl, tetrazolyl, thiadiazolyl, oxadiazolyl, triazinyl, thienyl, pyrrolyl, furyl, etc.The substituents on such optionally substituted heterocyclic groups R8 include, for example, optionally substituted alkyl of 1 to 12 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, hydroxyl, oxo, thioxo, formyl, trifluoromethyl, amino, halogen, lower alkylsulphonyl of 1 to 3 carbon atoms, coumarin3 carbonyl, 4 formyl l piperaziny1, pyrrolaldoimino, furanaldoimino, thiophenaldoimino, mesyl, aminoprotecting group, acylamino of 2 to 4 carbon atoms which may be substituted by halogen, etc. The aminoprotecting group may, for example, be one of the protective groups mentioned hereinafter for amino groups. The substituents on the optionally substituted alkyl of 1 to 12 carbon atoms include, for example, phenyl, halogen, hydroxy, dialkylamino, etc. The alkyl moiety of the dialkylamino is preferably alkyl of 1 to 3 carbon atoms. The substituents on the optionally substituted phenyl group R8 include, for example, lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, hydroxyl and amino. The lower alkyl moiety of the lower alkylthio group R8 is preferably alkyl of 1 to 3 carbon atoms. The substituents on the optionally substituted phenylthio group R8 include, for example, lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, hydroxy, amino, etc. The substituents which may optionally be substituted on the group represented by the formula CR2n include, for example, amino and a group of the formula NH COR8 is is amino or optionally substituted piperazinyl . As examples of the substituent on the optionally substituted piperazinyl group R8 , there may be mentioned lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, hydroxy, oxo, thioxo and halogen. Referring to the above formula, the lower alkyl represented by R 8 and or R8 is preferably a group of 1 to 3 carbon atoms. The lower alkyl moiety of the lower alkylcarbamoyl is preferably a group of 1 to 3 carbon atoms. As examples of the substituents on the optionally substituted phenylcarbonyl group, there may be mentioned lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, hydroxy, sulphoxy, benzyloxy, etc. The lower alkyl moiety of the optionally substituted lower alkyl group R8 in the formula Rt 8 S02 is preferably a moiety ofl to 6 carbon atoms, which may be substituted by one or two of substituents such as amino, carboxyl, benzyloxycarbonyl or protected amino. The protective group in the protected amino may, for example, be one of the protective groups mentioned hereinafter for amino groups. The lower alkyl moiety of the optionally substituted lower alkyl group R9 is preferably a moiety of 1 to 3 carbon atoms. As examples of the substituent on the optionally substituted lower alkyl, there may be mentioned phenyl, carbamoyl, methylcarba moyl, methylthio, thienylacetamide, ethoxycarbonyl methylcarbamoyS, N methyltetrazolylthio, halogen and sulphamoyl. The substituents on optionally substituted phenyl groups R9 include, for example, lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, hydroxy, sulphoxy, benzylo.xy, benzoyloxy, trimethylsilyl, acyloxy of 2 to 10 carbon atoms, etc. The heterocyclic ring on the optionally substituted heterocyclic group R9 may, for example, be a five membered heterocyclic group with one sulphur, nitrogen or oxygen atom, a five membered heterocyclic group with one or two nitrogen atoms and one sulphur or oxygen atom or a five or six membered heterocyclic group with 2 to 4 nitrogen atoms. Examples of such heterocyclic groups are thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, thienyl, furyl, pyrrolyl, imidazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, piperazinyl, triazinyl, tetrazolyl, thiadiazolyl, oxadiazolyl, etc. The substituents in these cases are lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, hydroxy, nitro, sulphoxy, amino and acylamino of 2 to 4 carbon atoms which may optionally be substituted by halogen, to name but a few. The cycloalkenylene Rq is preferably five to sixmembered cycloalkenylene, such as cyclohexenyl or cyclohexadienyl. The heterocyclic moiety of the optionally substituted heterocycle carbonylamino which may optionally have an alkylene chain between the heterocyclic and carbonylamino group represented byR9 includes, for example, a six membered heterocyclic group with two nitrogen atoms. Among such heterocyclic groups is piperazinyl. The substituents may, for example, be alkyl of 1 to 12 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, oxo, thioxo, amino and so forth. The alkylene chain is preferably an alkylene chain of 1 to 3 carbon atoms and as examples of the chain there may be mentioned methylene, ethylene and n propylene. Referring, further, to the above formulae, the heterocyclic ring of the optionally substituted heterocyclic group R12 in the group Rlo represented by the formula EMI9.1 includes, for example, five membered heterocyclic groups including one nitrogen, sulphur or oxygen atom, which five membered heterocyclic groups may optionally include one nitrogen atom or no nitrogen atom. Among examples of the heterocyclic group are 2 thiazolyl, 4 thiazolyl, 5 thiazolyl, 2 thienyl, 3 thienyl, 2furyl, 3 furyl, 2 pyrrolyl, 3 pyrrolyl, etc. The substituents on such heterocyclic group include, for example, lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, hydroxy, halogen, amino, and acylamino group of 2 to 4 carbon atoms which may optionally be substituted by halogen. The substituents on the optionally substituted phenyl group R12 include, for example, lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, hydroxy and substituted hydroxy. The substituents of the substituted hydroxy may, for example, be benzyl, benzoyl, acyl of 2 to 10 carbon atoms, y D glutamyl or 3 amino 3 carboxypropyl. The lower alkyl group R13 is preferably a group of 1 to 3 carbon atoms. The optionally substituted lower acyl group R13 is preferably a group of 2 to 4 carbon atoms and the substituents of this acyl group may, for example, be halogen. The lower alkylene R14 in the group R14 R15 of the group R13 is preferably a group of 1 to 3 carbon atoms, such as methylene, ethylene, propylene, isopropylene, etc. The lower alkenyleneR14 is preferably a group of 1 to 3 carbon atoms, such as vinylene, propenylene, etc. The carboxyl ester R15 may, for example, be the methyl ester, ethyl ester, propyl ester, etc.The heterocyclic group R15 may, for example, be six membered heterocyclic groups with one nitrogen and oxygen atom, such as morpholino, etc. The lower alkyl group R16 in the group R11 as represented by the, formula EMI10.1 is preferably a group of 1 to 3 carbon atoms. As examples of substituents on optionally substituted phenyl groups R16, there may be mentioned lower alkyl of L to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, acyloxy of 2 to 10 carbon atoms, etc. The optionally substituted heterocyclic group R16 may, for example, be fivemembered heterocyclic groups with one sulphur, nitrogen or oxygen atom, five membered heterocyclic groups with one or two nitrogen atoms and one sulphur or oxygen atom and five membered heterocyclic groups with two to four nitrogen atoms, such as thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, thienyl, furyl, pyrrolyl, thiadiazolyl, oxadiazolyl, triazinyl, tetrazolyl, imidazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, piperazinyl, etc. Substituents on the optionally substituted heterocyclic group include, for example, lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, hydroxy, amino and acylamino group of 2 to 4 carbon atoms which may optionally be substituted by halogen. Substituents on optionally substituted sulphamoyl groups R17 include, for example, lower alkyl of 1 to 3 carbon atoms, amidino, etc. Substituents on the optionally substituted phenoxycarbonyl group R17 include, for example, lower alkyl of 1 to 3 carbon atoms and lower alkoxy of 1 to 3 carbon atoms. The lower alkyl or lower alkoxy R18 is preferably a group of 1 to 3 carbon atoms, respectively. Substituents on optionally substituted phenyl groups R19 include, for example, lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, hydroxy, optionally substituted aminomethyl, etc. Substituents on the optionally substituted aminomethyl may, for example, be carbamoyl, 2 oxo 3 benzylideneamino imidazolidin l yl carbonyl, 2 oxoimidazolidin l yl carbonyl, etc. Substituents on the optionally substituted phenoxy group R19, for example, include lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, hydroxy and aminomethyl. The optionally substituted lower alkyl group Rl9 is preferably a group of 1 to 6 carbon atoms, the substituents being exemplified by halogen, hydroxy, cyano, trifluoromethyl, etc. The alkenylene of the optionally substituted alkenylene group Rl9 may, for example, be vinylene, propenylene, etc., and the substituents may, for example, be carboxyl, cyano, etc. Examples of the heterocyclic ring of the optionally substituted heterocyclic group R19 include five to six membered heterocyclic groups including one sulphur atom or one to four nitrogen atoms and five or six membered heterocyclic groups including one sulphur atom and one nitrogen or oxygen atom. Thus, 2 thienyl, 3 thienyl, 2 pyridyl, 3 pyridyl, 4 pyridyl, 2 thiazolyl, 4thiazolyl, 5 thiazolyl, isothiazolyl, l tetrazolyl, 5 tetrazolyl, pyrrolidinyl, imidazolyl, 1,4 oxathiinyl, etc., may be mentioned by way of example.Substituents on such optionally substituted heterocyclic group Rl9 include, for example, lower alkyl of 1 to 3 carbon atoms, lower alkoxy of 1 to 9 carbon atoms, halogen, nitro, hydroxy, amino, carboy, oxo, acylamino of 2 to 4 carbon atoms which may optionally be substituted by halogen, acyl of 2 to 4 carbon atoms and so forth. The alkyl group of 1 to 12 carbon atoms, mentioned hereinbefore, may, for example, be methyl, trifluoromethyl, ethyl, n propyl, isopropyl, n butyl, isobutyl, sec butyl, tertbutyl, pentyl, isopentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, or the like. The lower alkyl group of 1 to 6 carbon atoms, mentioned hereinbefore, may, for example, be methyl, trifluoromethyl, ethyl, n propyl, isopropyl, n butyl, isobutyl, sec butyl, tertbutyl, pentyl, isopentyl, hexyl, isohexyl, etc. The lower alkyl group of 1 to 3 carbon atoms, also mentioned hereinbefore, may, for example, be methyl, trifluoromethyl, ethyl, n propyl, isopropyl or the like. The lower alkoxy group of 1 to 3 carbon atoms, mentioned hereinbefore, may, for example, be methoxy, ethoxy, n propoxy, isopropoxy or the like. The halogen includes chlorine, bromine, iodine and fluorine. The lower alkylsulphonyl group containing 1 to 3 carbon atoms includes, for example, methylsulphonyl, ethylsulphonyl, n propylsulphonyl, isopropylsulphonyl, etc. The acylamino group of 2 to 4 carbon atoms includes, for example, acetylamino, propionylamino, n butyrylamino, isobutyrylamino, etc. The acyloxy group of 2 to 10 carbon atoms includes, for example, acetoxy, n propionyloxy, n butyryloxy, isobutyryloxy, n pentanoyloxy, n hexanoyloxy, n heptanoyloxy, n octanoyloxy, n nonanoyloxy, n decanoyloxy, etc. Referring to the aforementioned acyl group, the acyl group represented by the formula R6 CO whereinR6 has the same meaning as defined hereinbefore includes, for example, 3 2,6 dichlorophenyl 5methylisoxazol 4 yl carbonyl, 4 ethyl 2,3 dioxo 1piperazinocarbonyl, 2 oxoimidazolidin 1 yl carbonyl, etc. The acyl group represented by the formula EMI13.1 wherein R7 and R9 have the same meanings as defined hereinbefore includes, for example, D alanyl, D phenylalanyl, a benzyl N carbobenzoxy y D glutamyl D alanyl, D phenylglycyl D alanyl, N carbobenzo y D phenylglycyl, D alanyl D phenylglycyl, D glutamyl D alanyl, N carbobenzoxy D alanyl D phenylglycyl, Dcarbamoyltryptophyl D phenylglycyl, methylamidoasparaginyl D phenylglycyl, N carbobenzoxymethyl amidoasparaginyl D phenylglycyl, N carbobenzoxy Dphenylglycyl D phenylglycyl, 2 2 , 3 diaminopropion amido 2 phenylacetyl, D alanyl D alanyl, 2 2 amino3 N methylcarbamoyl propionamido acetyl, 2 2 amino 3 sulphamoylpropionamido 2 phenylacetyl, 2 2 amino3 4 ethyl 2,3 dioxo 1 piperazinocarboxamido propionamido 2 phenylacetyl, D 2 4 ethyl 2,3 dioxo l piperazinocarbosamido 2 4 methoxyphenyl acetyl, 4 ethyl 2,3 dioxo l piperazinocarbonyl, D2 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 3 Nmethylcarbamoyl propionamido 2 phenylacetyl, D 2 2 4 ethyl 2,3 dioso 1 piperazinocarboxamido acetamidou 2 phenylacetyl, D 2 3 sulphamoyl 2 benzyloxy carboxamiopropionamido 2 phenylacetyl, D 2 2 benzyloxycarboxamido 3 4 methoxyphenyloxycarboxamido propionamido 2 phenylacetyl, 2 2 benzyloxycarboxamido3 N methylcarbamoyl propionamido acetyl, 2 Ncarbobenzoxy D phenylglycylamino 3 N methylcarbamoyl propionyl, N carbobenzoxy D alanyl, 2 benzyloxy carboxamido 2 phenylacetyl, 2 benzyloxycarboxamido 3N methylcarbamoylpropionyl, N 4 ethyl 2, 3 dithioxo l piperazinocarbonyl D phenylglycyl, 2 2 amino 4thiazoyl 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido acetyl, 2 2 phenylacetamido propionyl, 2 4 ethyl 2, 3 dioxo 1 piperazinocarboxamido 2 thienylacetyl, 2 3 furfurylideneamino 2 oxoimidazolidine 1carboxamido 2 4 hydroxyphenyl acetyl, 2 8 hydroxy1,5 naphthyridine 7 carboxamido 2 phenylacetyl, 2 4ethyl 2,3 dioxo 1 piperazinocarboxamido 2 phenylacetyl, 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2phenylacetyl, 2 4 ethyl 2,3 dioxo l piperazinocarbox amido 2 4 sulphoxyphenyl acetyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 4chlorophenyl acetyl, 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2 4 hydroxysulphonyloxyphenyl acetyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 4 methoxyphenyl acetyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 4 trimethylsilylphenyl acetyl, 2 4 ethyl 2 ,3 dioxo l piperazinocarboxamido 2 3 chloro 4 methoxyphenyl acetyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 3 chloro 4 hydroxysulphonyloxyphenyl acetyl, 2 4 ethyl 2,3 dioso 1 piperazinocarbosamido 2 3 chloro 4 hydroxyphenyl acetyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarbonyl 2 4benzyloxyphenyl acetyl, 2 4 n octyl 2,3 dioso l piperazinocarbo2amido 2 4 hydroxyphenyl acetyl,N 4 ethyl 2,3 dioso 1 piperazineocarbonyl glutaminyl,N 4 ethyl 2 , 3 dioxo l piperazinocarbonyl phenylalanyl,N 4 ethyl 2 , 3 dioxo l piperazinocarbonyl D alanyl, 2 4 ethyl 2 ,3 dioxo l piperazinocarboxamido 2 4 hydroxyphenyl acetyl, 2,2 bis 4 ethyl 2,3 dioxo 1piperazinocarboxamido acetyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 1cyclohexen l yl acetyl, 2 4 n octyl 2,3 dioxo l piperazinocarboxamido 2 thienylacetyl, 2 4 ethyl 2,3 dioxo 1piperazinocarboxamido 2 2 amino 4 thiazolyl acetyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 2 chloroacetamido 4 thiazolyl acetyl, 2 4 ethyl 2, 3 dioxo l piperazinocarboxamido 2 2 methyl 4 thiazolyl acetyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 2 acetamido 4 thiazolyI acetyl, 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2 2 amino 4 thiazolyl acetyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2furylacetyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 2 pyrrolyl acetyl, 2 4 ethyl 2,3 dithio o 1 piperazinocarbosamido 2 4 hydroxyphenyl acetyl, 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2 2 chloroacetamido 4 thiazolyl acetyl, N 4 ethyl 2, 3 dioxo l piperazinocarbonyl D methionyl, D 2 4 2phenylethyl 2,3 dioxo 1 piperazinocarboxamido phenylacetyl, D 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 4 benzoyloxyphenyl acetyl, 2,5 bis 4 ethyl 2,3 dioso 1 piperazinocarbosamido pentanoyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 3 Nmethylcarbamoyl propionyl, 2,3 bis 4 ethyl 2,3 dioxo 1piperazinocarboxamido propionyl, 2 4 ethyl 2,3 dioxo1 piperazinocarboxamido 3 chloropropionyl, 2 4 ethyl2,3 dioxo 1 piperazinocarboxamido 2 4 n octanoyloxyphenyl acetyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 3sulphamoylpropionyl, 2 4 ethyl 2,3 dioxo 1piperazinocarboxamido 3 1 methyl 1H tetrazol 5 yl thio propionyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido acetyl,D 2 C4 2 hydroxyethyl 2,3 dioxo 1 piperazinocarbos amido 2 phenylacetyl, D 2 4 2 chloroethyl 2,3dioxo 1 piperazinocarboxamido 2 phenylacetyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 3 ethoxycarbonylmethylcarbamoyl propionyl, 2 4 ethyl 2,3 dioxo l piperazinocarboxamido 3 thienylacetamido propionyl, 2 4 ethyl 2,3 dioxo l piperazinocarboxamido 3 2 1H tetrazl 1 yl acetamido propionyl, 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 1htetrazol l yl acetyl, 2 2 oxo 3 furfurylideneaminoimidazolidin 1 yl carboxamido 2 phenylacetyl, 2 2 oxo 3 furfurylideneaminoimidazolidin 1 yl carboxamido 2 4 hydroxyphenyl acetyl, 2 2 oxo 3furfurylideneaminoimidazolidin 1 yl carboxamido 2 4hydroxysulphonyloxyphenyl acetyl, 2 2 oxo 3 thiophen 2 aldiomino imidazolidin 1 yl carboxamido 2 phenylacetyl, 2 2 oxo 3 furfurylidene aminoimidazolidin l yl carbosamido 2 thienylacetyl, 2 3 methylsulphonyl 2 osoimidazolidine 1 carboxamido 2 phenylacetyl, 2 oxo 3 furfurylideneaminoimidazolidin 1 yl carboxamido 2 2 amino 4 thiazoyl acetyl, 2 2 oxo 3 furfurylideneaminoimidazolidin l yl carbosamido 2 2 chloroacetamido 4 thiazolyl acetyl, 2 r 3 esyl 2 oxoimidazolidin 1 yl carbo amido 2 phenylacetyl, 2 2 oso 3 thiophen 2 aldoimino imidazolidin 1 yl carboxamido 2 thienylacetyl, 2 3 mesyl 2 oxoimidazolidin 1 yl carboxamido 2 thienylacetyl,D 2 2 oxo 3 furfurylideneaminoimidazolidin 1 yl carboxamido propionyl, 2 4 hydroxy 6 methylnicotin amido 2 phenylacetyl, 2 4 hydroxy S methylnicotin amido 2 4 hydroxyphenyl acetyl, 2 5,8 dihydro 2 4 formyl l piperazinyl 5 osopyrido 2,3 d pyrimidine 5 carboxamido 2 phenylacetyl, 2 3,5 dioxo 1,2,4 triazine 6 carboxamido 2 4hydroxyphenyl acetyl, 2 3 furfurylideneamino 2oxoimidazolidine 1 carboxamido 2 phenylacetyl, 2 courmarine 3 carboxamido 2 phenylacetyl, 2 4 hydroxy 7 methyl 1,8 naphthyridine 3 carbosamido 2 phenylacetyl, 2 4 hydroxy 7 trifluoromethylquinoline 3 carboxamido 2 phenylacetyl, N I 2 2 amino 4 th iaz oly1 acetyl D phenylglycyl, 2 6 bromo 1 ethyl 1,4 dihydro 4 oxothieno 2,3 b pyridine 3 carboxamido 2 phenylacetyl, 2 2 2 amino 4 thiazolyl acetamido 2 phenylacetyl, 2 2 2chloroacetamido 4 thiazolyl acetamido 2 phenylacetyl, 2 2,5 dioxo 1,2,4 triazino 6 carboxamido 2thienylacetyl, 2 2,4 dioxopyrimidino 5 carboxamido 2 thienylacetyl, 2 6 hydroxy 1,5 naphthyridinylcarboxamido 2 phenylacetyl, 2 2 4 ethyl 2, 3 dioxo l piperazinocarboxamido 2 thienylacetamido 2 phenylacetyl, 2 2 ureido 2 thienylacetamido 2 phenylacetyl, 2 2 ureido 2 thienylacetamido 2 4 hydroxysulphonyl oxyphenyl acetyl, 2 2 ureido 2 thienylacetamido 2 4hydroxyphenyl acetyl, 2 N carbobenzoxypropylamihno 2furylacetyl, a thienylmethylcarbonyl alanyl, 2 4 chlorobenzoylureido 2 thienylacetyl, 2 2 thienylacetamido acetyl,N benzylcarboxamido D alanyl,N 4 hydroxybenzoyl D alanyl, 2 4 chlorobenzamido propionyl, 2 4 aminobenzamido acetyl,N 4 ethyl 2,3 dioxo 1 piperazinocarbonyl methionyl Dphenylglycyl, D 2 2 2,6 dichlorophenylthio acetamido 2 phenylacetyl, 2 carbamoyl amino 2 thienylacetyl, Ncarbamoyl D phenylglycyl, 2 3 methylcarbamoyl 3methyl 1 ureido 2 phenylacetyl, 2 3 methylcarbamoyl3 methyl 1 ureido 2 4 hydroxyphenyl acetyl, 2 3methylcarbamoyl 3 methyl 1 ureido 2 thienylacetyl, 2 L3 2 hydroxybenzoyl 1 ureido 2 phenylacetyl, 2 3 2 benzyloxybenzoyl 1 ureido 2 4 hydroxysulphonyloxyphenyl acetyl, 2 3 2 hydroxybenzoyl l ureido 2 4 hydroxyphenyl acetyl, 2 3 2 benzyloxybenzoyl 1 ureido 2 phenylacetyl, 2 3 2 benzylo2ybenzoyl l ureido 2 4 hydrogy phenyl acetyl, D 2 2 benzyloxycarboxamido 2 benzyloxycarbonyl ethanesulphonamido 2 phenylacetyl, N mesyl D phenylglycyl, etc. The acyl group represented by the formula Rlo Rll CO wherein R10 and R11 have the same meanings as defined hereinbefore includes, for example, N 2 2 amino 4 thiazolyl 2 methoxyiminoacetyl D alanyl, N 2 2 amino 4 thiazolyl 2 methoxyiminoacetyl D phenylglycyl, 2 2 amino 4 thiazolyl 2 2 2 amino 4 thiazolyl 2 methoxyiminoacetamido acetyl, 2 2 chloroacetamido 4 thiazolyl 2 2 2 chloro acetamido 4 thiazolyl 2 methoxyiminoacetamido acetyl, 2 2 chloroacetamido 4 thiazolyl 2 methoxyiminoacetyl, 2 2 amino 4 thiazolyl 2 methoxyiminoacetyl, 2 2amino 4 thiazolyl 2 oxyiminoacetyl, 2 thienyl 2methoxyiminoacetyl, 2 furyl 2 methoxyiminoacetyl, 2 4 hydroxyphenyl 2 methoxyiminoacetyl, 2 phenyl 2methoxyiminoacetyl, 2 phenyl 2 oxoiminoacetyl, 2thienyl 2 oxyiminoacetyl, 2 thienyl 2dichloroacetyloxyiminoacetyl, 2 4 gamma D glutamyloxy phenyl 2 oxyiminoacetyl, 2 4 3 amino 3 carboypropoxy phenyl 2 oxyiminoacetyl, 2 thienyl 2 3 morpholinopropoxyimino acetyl, 2 2 2 amino 4 thiazolyl 2 methoxyiminoacetamido 2 phenylacetyl, 2 2 2 chloroacetamido 4 thiazolyl 2 methoxyiminoacetamido 2 phenylacetyl, 2 2 2 amino4 thiazolyl 2 methoxyiminoacetamido acetyl, etc. The acyl group represented by the formula EMI20.1 wherein R17 and R18 have the same meanings as defined hereinbefore includes, for example, a sulphophenyl acetyl, sulphoxyphenylacetyl, a hydroxyphenylacetyl, a sulphamoylphenylacetyl, a phenoxycarbonylphenyl acetyl, alpha p tolyloxycarbonyl phenylacetyl, a formyloxyphenylacetyl, a carboxyphenylacetyl, a benzyloxycarbonylphenylacetyl, 2 N, N dimethyl sulphamoyl 2 phenylacetyl, etc. The acyl group of the formula R19 R20 CH2 C0 wherein R19 and R20 have the same meanings as defined hereinbefore includes, for example,cyanoacetyl, phenylacetyl, phenoxyacetyl, trifluoromethylthioacetyl, cyanomethylthioacetyl, lH tetrazoyl l acetyl, 2 thienylacetyl, 2 2 amino 4 thiazolyl acetyl, 2 2 chloroacetamido 4 thiazolyl acetyl, 4 pyridylthioacetyl, 2 thienylthioacetyl, 3,5 dichloro 1, 4 dihydro 4 oxopyridine l acetyl, B carboxyvinylthioacetyl, 2 2 aminomethylphenyl acetyl, 2 2 N carbobenzoxyaminomethylphenyl acetyl, 2 2 ureidomethylphenyl acetyl, 2 2 2 oxoimidazolidin l yl carbonylaminomethyl phenyl acetyl, 2 2 2 oxo 3 benzylideneaminoimidazolidin 1 yl carbonylaminomethylphenyl acetyl, 2 5,6 dihydro 1,4 oxathiin 2 yl acetyl, 2 2,5 dioxopyrrolidin 3 yl acetyl, 2 succinimidoacetyl, 2 l acetyl 2,4 dioxoimidazolidin 3 yl acetyl, etc. The amino and or carboxyl group in the acyl group described above may optionally carry a protective group. Such amino protecting groups include those groups which will be mentioned hereinafter as aminoprotecting groups . The carboxyl protecting groups include any and all groups, such as ester and silyl residues, which are usually employed for the protection of carboxyl in the field of lactam chemistry and in organic chemistry in general, such as ester and silyl residues.Thus, for example, the ester and silyl residues may be methyl, ethyl, propyl, isopropyl, tert butyl, tert amyl, benzyl, p nitrobenzyl, p methoxybenzyl, benzhydryl, phenacyl, phenyl, p nitrophenyl, methoxymethyl, ethoxymethyl, benzyloxymethyl, acetoxymethyl, pivaloyloxymethyl, p methylsulphonylethyl, methylthiomethyl, trityl, P ,P ,P trichloroethyl, P iodoethyl, trimethylsilyl, dimethylsilyl, acetylmethyl, p nitrobenzoylmethyl, p mesylbenzoylmethyl, phthalimidomethyl, propionyloxymethyl, l,l dimethylpropyl, 3 methyl 3 butenyl, succinimidomethyl, 3,5 di tert butyl 4hydroxybenzyl, mesylmethyl, benzenesulphonylmethyl, phenylthiomethyl, dimethylaminoethyl, pyridine l oxide 2 methyl, methylsulphinylmethyl, bis pmethoxyphenyl methyl, 2 cyano l, 1 dimethylethyl, etc. This invention provides new monocyclic compounds and the selection of such protective groups is only marginal to the gist of this invention. Especially, benzyl, P ,P ,P trichloroethyl, p nitrobenzyl or p methoxybenzyl is preferable. The tamino protecting groups which is used to protect the amino group in the practice of this invention may expediently be one of those groups used in the field of ss lactam chemistry or in the field of peptide synthesis. Thus, use may be made, for example, of aromatic acyl groups such as phthaloyl, p nitrobenzoyl, p tert butylbenzoyl, p tertbutylbenzenesulphonyl, benzenesulphonyl, toluenesulphonyl, etc. aliphatic acyl groups such as formyl, acetyl, propionyl, monochloroacetyl, dichloroacetyl, trichloroacetyl, methanesulphonyl, ethanesulphonyl, trifluoroacetyl, maloyl, succinyl, etc. esterified carboxyl groups such as methoxycarbonyl, ethoxycarbonyl, t butoxycarbonyl, isopropoxycarbonyl, 2 cyanoethoxycarbonyl, B,B,B trichloroethoxycarbonyl, benzyloxycarbonyl, p nitrobenzyloxycarbonyl, p methoxybenzyloxycarbonyl, diphenylmethyloxycarbonyl, methoxymethyloxycarbonyl, acetylmethyloxycarbonyl, isobornyloxycarbonyl, phenyloxycarbonyl methylene groups such as hexahydro lH azepin l yl methylene sulphonyl groups such as 2 amino 2 carboxyethylsulphonyl, etc. and amino protecting groups other than acyl groups, such as trityl, 2 nitrophenylthio, benzylidene, 4 nitrobenzylidene, di or trialkylsilyl, benzyl, p nitrobenzyl, etc. The present invention is not particularly concerned with limitations on the selection of amino protecting groups as it is not regarding the carboxyl protecting groups. Especially, monochloroacetyl, benzyloxycarbonyl, p methoxybenzyloxycarbonyl or p nitrobenzyloxycarbonyl is preferable. The starting compound II according to this invention can be produced, for example, by the following procedures. Procedure 1 EMI24.1 tb SEP o SEP 9r SEP OH7 SEP ocif7 tb SEP d SEP S YOt SEP c0i.u1fiCizinr SEP ar nt SEP Pt tb SEP 1 SEP t7 SEP H SEP C tb SEP 0N SEP SEP N SEP SEP C SEP SEP Cx SEP 2 tb SEP d SEP CCCR,, tb SEP V SEP SEP VI tb SEP SEP diSulfi iZill tb SEP agent tb SEP OCH SEP OCH SEP S S R tb SEP R SEP N SEP SEP C SEP SEP 0OH3 SEP Rif SEP I SEP tb SEP i3 SEP j SEP C SEP SEP C SEP reduction SEP ss tb SEP 0 SEP COOT SEP 0 SEP 0 SEP COOR4 SEP CH3 tb SEP viii SEP VlT tb SEP SEP ox SEP io . tb SEP i SEP C SEP X tb c zono1ysis SEP OCH tb SEP OCH SEP SEP R3 tb SEP R1S SEP SEP RI SEP num tb SEP VI SEP 3 tb SEP 0 SEP Coot4 tb SEP clx SEP IL tb Procedure 2 EMI25.1 tb R SEP OCH3 tb SEP 1 SEP v SEP R tb SEP 1 SEP 0 SEP oCR3 SEP methoxylatiort SEP CHg tb SEP 0 SEP COOT4 SEP CR3 SEP 0 SEP , SEP N SEP SEP IC SEP C SEP 3 tb SEP x tb SEP vIII tb SEP oxidation tb SEP OCH, tb SEP R1 SEP t tb SEP o tb SEP it1 tb Procedure 3 EMI25.2 tb R1 SEP R1 tb SEP R1 SEP 0CR3 SEP oxidation NH tb SEP SEP CHy SEP CR tb SEP O SEP COOR4 SEP 3 SEP 0 tb SEP x SEP IT tb Regarding the symbols used in the above reaction formulae, R1 has the same meaning as defined hereinbefore R4 is an ester residue and R5 is a thiol residue. Exemplary species of the members defined in the above deinitions are as follows. The ester residue R4 includes, for example, methyl, ethyl, propyl, isopropyl, n butyl, t butyl, pentyl, cyclopentyl, cyclohexyl, benzyl, p nitrobenzyl, benzhydryl, alkoxyalkyl, alkanoyloxymethyl, alkenyl, trichloroethyl, methylsulphonylethyl, benzoylmethyl, methoxybenzyl, trityl, methylthiomethyl, pivaloyloxymethyl, a acetoxybutyl, etc. The thiol residue R5 includes, for example, alkyl groups e.g. methyl, ethyl, propyl, isopropyl, n butyl, t butyl, isobutyl, n amyl, vinyl, 1isopropenyl, etc. , substituted alkyl groups e.g.methoxymethyl, ethoxymethyl, benzyl, phenethyl, xylylmethyl, p chlorobenzyl, p nitrobenzyl, pmethoxybenzyl, etc. , unsubstituted and substituted aryl groups e.g. phenyl, xylyl, tolyl, naphthyl, chlorophenyl, nitrophenyl, methoxyphenyl, etc. , heterocyclic groups e.g. benzothiazolyl, benzoxazolyl, thiazolyl, thiadiazolyl, oxazolyl, thienyl, pyridyl, oxadiazolyl, oxatriazolyl, imidazolyl, benzimidazolyl, triazolyl, tetrazolyl, etc. , acyl groups e.g. acetyl, propionyl, benzoyl, thioacetyl, thiopropionyl, thiobenzoyl, etc. carbamoyl groups e.g.methylcarbamoyl, dimethylcarbamoyl, phenylcarbamoyl, etc. , the corresponding and other thiocarbamoyl groups, and groups of the formula EMI27.1 The above mentioned procedures for producing the azetidine derivate I of this invention will be described in detail.Procedure 1 This method is related to a fundamental synthetic method for optically active azetidine derivatives in . The compound vY used as a starting material can be easily prepared, for example by the method described in Journal of the American Chemical Society 95, 2401 1973 or a method analogous thereto. In the first stage, compound V is reacted with a disulphidizing agent. The term disulphidizing agent is used herein to include all the reactants that are capable of disulphidizing the sulphur in the l position of compound V and, in particular, thiol compounds of the formula R5 SH and disulphides of the formula R5 S S R5 R5 has the same meaning as defined hereinbefore . This reaction is carried out in the absence of a solvent or in an appropriate solvent. The solvent includes, for example, dioxane, N,N dimethylacetamide,N,N dimethylformamide, benzene, toluene, tert butanol, isopropanol, methyl ethyl ketone, etc., mixtures of such solvents, and other solvents which will not interfere with the reaction. While the reaction temperature is not particularly critical, it is normally advantageous to carry out the reaction at a temperature between 700C and 1500C, When a disulphide compound of R5 S S R5 is employed as the disulphidizing agent, the reaction is catalytically accelerated by the presence of an acid or a base.This acid includes, for example, sulphuric acid, phosphoric acid, hydrochloric acid and other mineral acids, p toluenesulphonic acid, methanesulphonic acid, phenylphosphonic acid, acetic acid , formic acid and other organic acids, and Lewis acids such as ferric chloride, zinc chloride, boron trifluoride, etc. When such an acid is employed, there is predominantly obtained a l a isopropenyl azetidine VI which contains a double bond in the exo position. The base mentioned above includes, for example, pyridine, quinoline, N,N dimethyl aniline, triethylamine, etc. In this case, depending on the reaction solvent, time, temperature etc., there is obtained a l isopropylidene azetidine VII having a double bond in the endo position in addition to the l a isopropenyl azetidine VI .This 1 isopropyliden azetidine VII can also be easily obtained by treating l a isopropenyl azetidine VI with a base. The reaction according to this procedure is preferably carried out in streams of an inert gas such as nitrogen, helium or the like. The useful molar ratio of disulphidizing agent to starting compound V depends on the S nucleophilicity of the disulphidizing agent used but, generally speaking, about 1 to about 10 equivalents of the agent are employed. After completion of the reaction, the product compound VI can be isolated in optional purity by purification procedures known per se, e.g.extraction with solvents, recrystallization, chronatography, etc. The compound VI , on treatment with a base, yields the compound VII . The base used for this purpose may be the above mentioned base which can be used as a catalyst in the reaction between compound VI and disulphidizing agent. In carrying out this reaction, the base need not be employed in a large amount. Thus, relative to compound VI , about 0.01 to about 0.2 mol equivalent is sufficient. The reaction is generally carried out in a solvent such as dichloromethane, chloroform, benzene, toluene, tert butanol, methanol, ethanol, tetrahydrofuran, dioxane, methyl ethyl ketone, N,N dimethyl acetamide,N,N dimethylformamide, etc., or a mixture of such solvents. Any other solvent that will not interfere with the reaction may also be employed. While the reaction temperature is not particularly critical, the reaction proceeds at room temperature in many instances. The product derivative viz in which R5 is a group of the formula EMI29.1 is a compound which is obtained simultaneously or partially in this reaction step and can be converted to compound VIII by treatment with a reducing agent. The compound VII is then subjected to a reductive desulphurization reaction. The reductive desulphurizing agent used for this purpose may, for example, be Raney nickel, Raney cobalt or the like.This reaction is usually carried out in a solvent. The solvent includes, for example, methanol, ethanol, propanol, tetrahydrofuran, dioxane, ethyl acetate, water, etc., although other common organic solvents which do not interfere with the reaction may also be employed. This reaction proceeds readily under mild conditions, e.g. at room temperature to about 800C. The compound VIII is then oxidized in order to remove the N side chain. This oxidation reaction includes an oxidization reaction with an oxidizing agent and a subsequent solvolysis with a solvent or a basic or acidic catalyst. The oxidizing agent used in the above oxidation reaction includes, for example, ozone, alkali metal permanganate e.g. potassium permanganate, sodium permanganate, etc. , alkaline earth metal permanganate e.g. barium permanganate, etc. , osmium tetraoxide, lead tetraacetate, etc. This oxidation reaction is usually carried out in a solvent. This solvent includes, for example, tetrahydrofuran, dioxane,N, N dimethylformamide, N,N dimethylacetamide, benzene, acetone, pyridine, methanol, ethanol, proanol, butanol, water, chloroform, dichloromethane, carbon tetrachloride, etc. It may be a mixture of such solvents. The proportion of the oxidizing agent relative to compound VIII may be about 1.0 to 4.0 molar equivalents, preferably about 1.0 to 1.2 molar equivalents, although excess ozone if it is used may be employed.While the reaction temperature is not particularly critical, the reaction usually proceeds under cooling or at room temperature. The reaction normally goes to completion with a short time. When a permanganate, for instance, is employed as the oxidizing agent, it is preferable to employ a buffer solution such as phosphate buffer and carry out the reaction in the neutral pH region so as to minimize the decomposition of the starting compound VI or and product compound I . When ozone is used as the oxidizing agent, the conversion of compound VIII to compound IX can be effected by ozonolysis e.g. by carrying out the reaction in a solvent such as chloroform, dichloromethane or carbon tetrachloride, followed by removing the excess ozone and decomposing the ozonide of compound VIII with dimethyl sulphide. The conversion of compound IX to compound II is effected by subjecting compound IX to solvolysis.This reaction is carried out in a suitable solvent and may be optionally conducted with the aid of a basic or acidic catalyst. The base used in such a procedure includes, for instance, inorganic bases such as the hydroxides, carbonates, etc., of alkali metals such as lithium, potassium, sodium, etc., or alkaline earth metals such as calcium, magnesium, etc. organic bases such as metal alkoxides, organic amines, quaternary ammonium salts, etc. basic ion exchange resins and so forth. The acid used in a similar manner includes inorganic acids and their salts such as hydrochloric acid, sulphuric acid, phosphoric acid, zinc chloride, zinc sulphate, ferric chloride, ferric sulphate, etc., organic acids such as formic acid, acetic acid, p toluenesulphonic acid, trifluoroacetic acid, etc., silica gel, acidic ion exchange resins and so forth.The solvent used for this reaction includes, for example, water, methanol, ethanol, propanol, tetrahydrofuran, dioxane, ethyl acetate, etc., as well as mixtures thereof. Any other solvent that will not interfere with the reaction may also be employed likewise. This reaction usually proceeds easily under mild conditions, e.g. under cooling to a slightly elevated temperature. The reaction product in each step can be separated in optional purity by a purification procedure known per se, e.g. extraction with solvents, recrystallization, chromatography, etc.Procedure 2 This procedure relates to a fundamental route of synthesis for the production of optically inactive azetidine derivative in . The starting compound x can be easily prepared by the method described in Molecular Modification inDrug Design 45, 15 1964 or a method analogous thereto. The methoxylation reaction of compound X to compound VIII is carried out by reacting an alkali metal salt of methanol, which is of the formula MOCHa wherein M is an alkali metal , and a halogenating agent with the compound X in the presence of methanol. As examples of the alkali metal salt of methanol, there may be mentioned lithium methoxide, sodium methoxide, potassium methoxide, etc. The halogenating agent is a halogen compound capable of acting as a positive halogen donor, e.g. halogen chlorine, bromine, etc. , N haloimides Nchlorosuccinimide, N bromosuccinimide, etc. , N ha lo sulphonamide s N chlorobenzenesulphonamide, Nchloro p toluenesulphonamide, etc. , 1halobenzotriazoles, organic hypochlorite, etc. . This reaction is carried out in a solvent.Examples of the solvent include tetrahydrofuran, dioxane, dichloromethane, chloroform , acetonitrile, methanol,N, N dimethylformamide, N,N dimethylacetamide, etc. as well as various mixtures thereof. Any other solvent that will not interfere with the contemplated reaction may likewise be employed. To carry out the reaction, the starting compound X is dissolved or suspended in the above mentioned solvent and, then, the alkali metal salt of methanol, methanol and halogenating agent are added. The desirable proportions of these agents, relative to each mol of starting compound X , are not less than 1 mol of methanol, about 1 to 3.5 mols of the alkali metal salt of methanol and about 1 to 2 mols of halogenating agent. The reaction proceeds readily under cooling or at room temperature to about 30 0C. The reaction can be quenched by making the reaction system acidic. A suitable acid to quench the reaction may, for example, be formic acid, acetic acid or trichloroacetic acid. After the reaction has.thus been quenched, any excess halogenating agent can be removed by treatment with a reducing agent such as sodium thiosulphate or a trialkyl phosphite, for instance. After completion of the above reaction, the product compound VIII can be isolated in an optional purity by conventional separation purification procedures, for example, by extraction with a solvent, recrystallization, chromatography, etc. The compound VIII is then subjected to procedures similar to the oxidation procedures described hereinbefore in connection with the conversion of compound VIII to compound lit , whereby an optically inactive form of compound lit is obtained.Procedure 3 In this procedure, the compound X obtained, for example, by the method described in MolecularModification in Drug Design 45, 15 1964 or a method analogous thereto is oxidized to compound II . This oxidation reaction can be effected by procedures similar to those used in the conversion of compound VIII to compound II according to the above procedure 1 . The sulphonation reaction according to this invention is a reaction by which a sulpho group is introduced into the substrate compound. Thus, for example, it can be carried out by reacting the compound II with sulphur trioxide or a reactive derivative of sulphur trioxide. The above mentioned reactive derivative of sulphur trioxide includes, for example, sulphur trioxide pyridine, sulphur trioxide diosane, sulphur trioxide trimethylamine, sulphur trioxide chloro sulpilonic acid and other addition compounds of sulphur trioxide, To conduct this reaction, about 1 to 5 mols, preferably about 1 to 2 mols, of sulphur trioxide or the reactive sulphur trioxide derivative is added to one mol of compound II . The reaction temperature is about Oo to 800C and preferably about 100 to 4000. The above reaction may be carried out in a solvent.The solvent includes, for example, water, ethers e.g. dioxane, tetrahydrofuran, diethyl ether, etc. , esters e.g. ethyl acetate, ethyl formate, etc. , halogenated hydrocarbons e.g. chloroform, dichloromethane, etc. , hydrocarbons e.g. benzene, toluene, n hexane, etc. , amides e.g. dimethylformamide, dimethylacetamide, etc. and other common organic solvents. These solvents may be used alone or in combination. After completion of the reaction, the compound I can be isolated in an optional purity by conventional separation purification procedures, for example, by extraction with a solvent, recrystallization, chromatography, etc. The compound I wherein R1 is amino, i.e.compound IV , is useful as an intermediate for the production of a useful medicine. The compound I wherein R1 is acylated amino, i.e. compound III , can be produced by acylating the compound IV The compound III is represented by the formula EMI35.1 wherein R3 is an acylated amino group and x is hydrogen or methoxy. The acylation according to this invention is accomplished by reacting the compound IV with an acylating agent containing the acyl group corresponding to the one contained in the acylated amino group which is represented by R1, R2 or R3. The acylating agent used in this reaction may, for example, be an organic carboxylic acid containing such an acyl group R3 or a reactive derivative of such acid. The reactive derivative of the organic acid includes, for example, the acid anhydride, activated amide, activated ester or the like. More specifically, the following reactive derivatives of organic acids may be mentioned.1 Acid anhydrides The acid anhydrides include, for example, hydrogen halides e.g. hydrochloric acid, hydrobromic acid, etc. mixed acid anhydrides, monoalkyl carbonic acid mixed acid anhydrides, aliphatic carboxylic acid mixed acid anhydrides mixed acid anhydrides with e.g acetic acid, pivalic acid, valeric acid, isopentanoic acid, trichloroacetic acid, etc. , aromatic carboxylic acid mixed acid anhydrides mixed acid anhydrides with e.g. benzoic acid, etc. , symmetric acid anhydrides, etc.2 Activated amides The activated amides include, for example, the amides with pyrazole, imidazole, 4 substitutedimidazole, dimethylpyrazole, benzotriazole, etc.3 Activated esters The activated esters include, for example, methyl ester, ethyl ester, methoxymethyl ester, propargyl ester, 4 nitrophenyl ester, 2,4dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, ester of said carboxylic or other acids with l hydroxy lR 2 pyridone, N hydroxysuccinimide, N hydroxyphthalimide, etc. The reactive derivative of the organic acid is selected according to the type of acid chosen and, when a free acid is used as the acylating agent, the reaction is desirably carried out in the presence of a condensing agent. The condensing agent includes, for example, N,Nt dicyclohexylcarbodiimide, N cyclohexyl N morpholinoethylcarbodiimide, N cyclohegyl N 4 diethylaminocyclohesyl carbodiimide, N ethyl N 3 dimethylaminopropyl carbodiimide, etc. This acylation reaction is generally carried out in a solvent. The solvent includes, for example, water, acetone, dioxane, acetonitrile, dichloromethane, chloroform, dichloroethane, tetrahydrofuran, ethyl acetate, dimethylformamide, pyridine, etc., as well as the common organic solvents which do not interfere with the reaction. These solvents, if they are hydrophilic, may be used in a mixture with water. Furthermore, the acylation reaction can be conducted in the presence of a base, for example, alkali metal carbonates, trialkylamines e.g. trimethylamine, triethylamine, tributylaznine, N methylmorpholine, N methylpiperidine, etc. , N,Ndialkylaniline, N,N dialkylbenzylamine, pyridine, picoline, lutidine, 1,5 diazabicyclo 4, 3, O non 5 ene, 1,4 diazabicyclo 2, 2, 2 octane, 1,8 diazabicyclo 5, 4, 4 undecene 7, etc. The base, as well as the condensing agent, may be used as the solvent as well, only if it is liquid. The reaction temperature is not particularly critical and, in many cases, the reaction is carried out under cooling to room temperature. Referring to the acylation reaction, when the reactive derivative of the starting compound IV with respect to its amino group or a salt thereof and the acylating agent respectively contain an asymmetric carbon atom, the corresponding stereoisomers can be employed respectively or as a ixture. Moreover, when the reaction yields such isomers in admixture, they may be fractionally isolated by procedures known per se, for example, by column chromatography, recrystallization, etc. The compound I which has a protective group is useful as an intermediate for the production of a useful medicine. For example, the compound I which does not have a protective group can be obtained by the removal of the protective group. The removal of the protective group from the azetidine derivative I can be effected by a choice of the hitherto known procedures, the choice depending on the type of protective group. Thus, for example, the method may comprise the use of an acid, a base or hydrazine, or may be a reductive method or a method comprising permitting an iminohalogenating agent to act on the substrate compound and, then, an iminoetherifying agent to act thereon and, finally and if necessary, hydrolyzing the same. In the method employing an acid, while the choice depends on the type of protective group and other conditions, the acid may, for example, be an inorganic acid e.g.hydrochloric acid, sulphuric acid, phosphoric acid, etc. , an organic acid e.g. formic acid, acetic acid, trifluoroacetic acid, propionic acid, benzenesulphonic acid, p toluenesulphonic acid, etc. or an acidic ion exchange resin. In the method involving the use of a base, while the choice depends on the type of protective group and other conditions, the base may, for example, be an inorganic base such as the hydroxide or carbonate of an alkali metal e.g.sodium, potassium, e tc. or alkaline earth metal e.g.calcium, magnesium, etc. , an alkali metal alkoxide, an organic base e.g. organic amines, quaternary ammonium salts, etc. or a basic ion exchange resin. When, in the above methods involving the use of a base or an acid, a solvent is employed, it is generally desirable, in many cases, to use a hydrophilic organic solvent, water or a mixture thereof. The reductive method, while the choice depends on the type of protective group and other conditions, may be a method employing a metal e.g. tin, zinc, etc. or a metal compound e.g. chromous dichloride, chromous acetate, etc. and an organic, inorganic or other acid e.g. acetic acid, propionic acid, hydrochloric acid, etc. , or a method involving the presence of a metal catalyst for catalytic reduction.As examples of the catalyst used for such catalytic reduction, there may be mentioned platinum catalysts such as platinum wire, platinum sponge, platinum black, platinum oxide, colloidal platinum, etc., palladium catalysts such as palladium sponge, palladium black, palladium oxide, palladium barium sulphate, palladium barium carbonate, palladium carbon, palladium silica gel, colloidal palladium, etc., and nickel catalysts such as reduced nickel, nickel oxide, Raney nickel, Urushibara nickel, etc. In the reductive method employing a metal and an acid, the combination of a metal compound, e.g. a compound of iron, chromium or the like, with an inorganic acid, e.g. hydrochloric acid, or an organic acid, e.g. formic acid, acetic acid, propionic acid or the like, may be employed. The reductive procedure is normally carried out in a solvent. In the case of catalytic reduction, alcohols such as methanol, ethanol, propanol, isopropyl alcohol, etc., and ethyl acetate, etc., are commonly employed. In the procedure involving the use of a metal and an acid, the solvent is usually water, acetone or the like, but when the acid is liquid, it may be utilized as the solvent as well. The reaction is usually carried out under cooling to under warming, preferably in a temperature range of about OOC to about 300C. Referring to the procedure comprising the use of an iminohalogenating agent and, then, an iminoetherifying agent, followed by hydrolysis to remove the protective group, the iminohalogenating agent may, for example, be phosphorus trichloride, phosphorus pentachloride, phosphorus tribromide, phosphorus pentabromide, phosphorus oxychloride, thionyl chloride or phosgene. The reaction temperature is not critical and, in many cases, the reaction is carried out under room temperature to under cooling. The iminoetherifying agent which is then permitted to act on the resulting reaction product may, for example, be an alcohol or a metal alkoxide.Thus, the alcohol includes, for example, alkanols such as methanol, ethanol, propanol, isopropyl alcohol, n butanol, tert butanol, etc. and compounds wherein the alkyl moieties of such alkanols as mentioned above have been substituted by alkoxy groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, etc. The metal alkoxide includes, for example, alkali metal alkoxides sodium alkoxides, potassium alkoxides, etc. and alkaline earth metal alkoxides calcium alkoxides, barium alkoxides, etc. as may be derived from the above mentioned and other alcohols. When, for example, the protective group is an organic carboxylic acid residue and the carbon atom adjacent to its carbonyl group carries a certain substituent such as a free amino, hydroxyl, mercapto, carboxyl or sulpho group, it is advantageous first to carry out a treatment for enhancing the adjacent group effect of such group so as to increase the reactivity of the carbonyl group before carrying out the removal of the protective group. In this connection, the case in which the substituent group on the carbon atom adjacent to the carbonyl group is a free amino group will be described by way of illustration. Thus, the free amino group may be converted to a thioureido group and, then, the necessary deacylation reaction is carried out. This and other procedures known in the art of cleavage of peptide bonds can be utilized to remove the protective group. The temperature for this reaction is not especially critical but may be suitably selected according to the type of protective group and the method then applied for removing the protective group.It is preferable, after all, that the reaction to be carried out under cooling to a slightly elevated temperature. There are cases in which the derivative in the carboxyl function of the compound wherein R1 is a group containing such a carboxyl group is transformed into a carboxyl group in the course of this reaction and such cases are also included in the concept and ambit of this invention. The compound I thus obtained by removal of the protective group can be converted, if desired, to a desired salt thereof in a conventional manner. The compound I , which contains a sulpho group, is generally capable of forming a salt with a base. Therefore, the compound I may then be isolated as a salt which, in turn, may be converted to the free form or to a different salt. The free compound I may, of course, be converted to a salt. The base mentioned above may be an inorganic base, e.g. lithium, potassium, sodium, calcium, ammonium, etc., or an organic base, e.g. pyridine, collidine, triethylamine, triethanolamine, etc. The salt form of compound I is also included in the scope of this invention. To convert the salt form of compound I to the free compound I , a method using an acid, for example, can be employed. The type of acid varies with different protective groups and other conditions.However, such inorganic acids as hydrochloric acid, sulphuric acid, phosphoric acid, etc., and such organic acids as formic acid, acetic acid, p toluenesulphonic acid, etc., are generally employed.Apart from the types of acids mentioned above, acidic ion exchange resins are also useful. The solvent may, for example, be acetone, tetrahydrofuran, methanol, ethanol, dioxane or the like, water, or a mixture of water and such a solvent. The compound IV , as the starting compound for the acylation reaction, may be used in the form of a salt. The salt may be any of the salts mentioned in connection with salts of compound I . The acylation reaction, where the starting material is a salt as mentioned above, may give rise to a salt of compound III . In such cases, the salt of compound III can be converted to a different salt and isolated as such, just as mentioned for compound I . Such salts may be converted to free compound III and isolated as such. This conversion oi a salt to the free compound III can be effected in the same manner as described hereinbefore in connection. with compound I . The compound I may exist as diastereoisomers or optical isomers. In such cases, the respective isomers and their mixtures are also included in the scope of this invention. These isomers, separately or as mixtures, can be used as medicines. When such mixtures of isomers are recovered as products, each mixture may be resolved into the component isomers by a conventional optical resolution method or other purification methods, e.g. extraction with solvent, recrystallization, chromatography, etc. The compound I thus obtained is useful as a drug, being active against certain gram positive and gram negative bacteria. By way of example, the compounds are active against. the following microorganisms. The media and compounds employed in the antibacterial test are as follows Media TSA Trypticase soy agar Baltimore Biologicals U.S.A. B TSA Blood trypticase soy agarCompounds Compound A Sodium 3 2 2 amino 4 thiazolyl 2 methoxyiminoacetamido 2 oxo azetidine l sulphonate Compound B Sodium 3 D N 4 ethyl 2,3 dioxo l piperazinocarbonyl phenylglycin amido 2 oxoazetidine l sulphonate Compound C Sodium 3 D N 4 ethyl 2,3 dioxo l piperazinocarbonyl phenylglycin amido 3 methoxy 2 oxoazetidine 1 sulphonateCompound D Sodium 3 2 4 ethyl ,3 dioxo 1 piperazinocarboxamido 2 2 amino 4 thiazolyl acetamido 2 oxoazetidine l sulphonateCompound E Sodium 3 DL 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 thienyl acetamido 2 oxoazetidine 1 sulphonateCompound F Sodium 3 D 2 4 ethyl 2,3 dioxo 1 pigerazinocarboxamido 2 thienyl acetamido 2 oxoazetidine 1 sulphonateCompound G Sodium 3 D 2 4 n octyl 2,3 dioxo I piperazinocarboxamido 2 phenyl acetamido 2 oxoazetidine l sulphonate Compound H Sodium 3 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2 2 amino 4 thiazolyl acetamido 2 oxoazeitidine l sulphonateCompound I Sodium 3 D 2 2 oxo 3 furfurylidene aminoimidazolidin 1 yl carboxamido 2 phenylacetamido 2 oxoazetidine 1 sulphonateCompound J Sodium 3 2 4 n octyl 2,3 dioxo l piperazinocarboxamido 2 thienyl acetamido 2 oxozetidine 1 sulphonateCompound RTI ID 44.10 E Sodium 3 D 2 2 oxo 3 thiophen 2 aldoimino imidazolidin l yl carboxamidol 2 phenylacetamido 2 oxoazetidine l sulphonateCompound L Sodium 3 2 2 oxo 3 furfurylidene amino imidazo lidin l yl carboxamido thienylacetamido 2 oxoazetidine 1 sulphonate Table 1 Minimum inhibitory concentration g ml Test organism Medium Compound A Compound BStaphylococcus aureus FDA209P TSA 50 6,25Staphylococcus aureus 308A 1 TSA 25 3.13Staphylococcus aureus 1840 TSA 100 25Staphylococcus aureus EDA209P B TSA 50 6.25. Escherichia coil NIHJ JC 2 TSA 0,78Escherichia coil 0 111 TSA 0.39 0,2Escherichia coil T 7 TSA 100 RTI ID 45.5 100 Citrobacter freundii IFO 12681 TSA 1.56 6.25Klebsiella pheumonia DT TSA 0.78 0.2Enterobacter cloacae IFO 12937 TSA 10C 50Serratia narcescens IFO 12648 TSA 12,5 3.13Proteus vulgaris IFO 3988 TSA 1,56 0,1Proteus inirabilis IFO 3849 TSA 6,25 0,78Proteus morganii IFO 3168 TSA 25 25Pseudomonas aeruginosa IFO 3455 TSA 6.25 1.56Pseudomonas aeruginosa U 31 TSA 100 100Acinetobacter calcoaceticus TSA 6.25 25 IFO 13006Candida albicans TA TSA 100 100Streptococcus pyogenes E 14 B TSA 3.13 3.13Streptococcus pyogenes S 8 B TSA 3.13 0.25Streptococcus mitis rica B TSA 25 25Streptococcus faecium IFO 3128 B TSA 100 100 Minimum inbibitory concentration g ml Test organism Hedium Compound A Compound BStreptococcus pneumoniae Type I B TSA 12.5 6.25 Corynebacterium diphtheriae B TSA 1.56 3.13TorontBordetella brnchiseptica B TSA 100 100Sagami Table 2 Minimum inhibitory Test orgnism Medium concentration g ml of Compound CStaphylococcus FDA209P TSA 100Escherichia coli NIHJ JO 2 TSA 50Escherichia coli O 111 TSA 12.5Klebsiella pheumoniae DT TSA 12.5Enterobacter cloacas IFO 12937 TSA 100Serratia marcescens IFO 12648 TSA 50Proteus vulbaris IFO 3988 TSA 12.5Proteus mirabilis IFO 3849 TSA 50Pseudomonas morganii IFO 3168 TSA 100Pseudomonas aeruginosa U 31 TSA 100Candida albicans TA TSA 100Streptococcus pyogenes E 14 B TSA 50Streptococcus pyogenes S 8 B TSA 50 RTI ID 46.5 Coryn bacterium di htheriaeTorot B TSA 50 Table 3 Minimum inhibitory concentration MIC g ml EMI47.1 SEP SEP SEP tb SEP unsl SEP Ccs SEP oul SEP Cr SEP Oc.r r .ounci SEP Coc roi nr SEP COtrffj SEP oun SEP Gol SEP OI1,OUnr tb SEP D SEP E SEP F SEP G SEP H tb SEP 1 ..JSt SEP orani. tb SEP 1 tb Staphylococcus SEP TSA SEP 12.5 SEP 6.25 SEP 6,25 SEP 1.56 SEP 6,25 tb rus SEP FDA SEP 209P tb Staphylococcus SEP TS SEP 6,25 SEP 6.25 SEP 6.25 SEP 0,78 SEP 3,13 tb aureus SEP 308A 1 tb Staphylococcus SEP TSA SEP 25 SEP 25 SEP 25 SEP 25 SEP 12.5 tb aureus SEP 18roc tb Escherichia SEP coli SEP TSA SEP .59 SEP 1.56 SEP 0,78 SEP 3,13 SEP 12,5 tb EJIHJ SEP JC 2 tb Escherichia SEP coli SEP TSA SEP 0,1 SEP 0,2 SEP 0,2 SEP 0,78 SEP 3.13 tb 0 111 tb Escherichia SEP coli SEP TSA SEP 100 SEP SEP 100 SEP 100 SEP SEP 100 SEP 100 tb T 7 tb Citrobacter SEP TSA SEP 1,56 SEP 3.13 SEP 1.56 SEP 2 SEP 3,13 SEP SEP 5 SEP 12,5 tb frecii SEP IFO tb 1261 tb Flebsiella SEP TSA SEP S L SEP 0.2 SEP 0.78 SEP 0.2 SEP 0.78 SEP 12,5 tb pneirionlac SEP DT tb Enterobacter SEP TSA SEP 25 SEP 3.13 SEP 50 SEP 6,25 SEP 50 tb cloacae SEP IFO tb 12937 tb Serratia SEP TSA SEP 0,78 SEP 3,13 SEP 1,56 SEP 1,56 SEP 12,5 tb m.arcescens SEP IFO tb 12648 tb Proteus SEP vulgaris SEP TSA SEP 0,1 SEP 0,1 SEP 0,1 SEP 0,78 SEP 6.25 tb IFO SEP 3988 tb roteus SEP TSA SEP 25 SEP 0,78 SEP 0,78 SEP 3.13 SEP 25 tb uirabilis SEP IFO tb 3849 tb DrOtous SEP organic SEP TSA SEP 12,5 SEP 12.5 SEP 12.5 SEP 1.56 SEP 6,25 tb IFO SEP 3168 tb Pscuc o .ons SEP Ts SEP 3,13 SEP a SEP 6.25 SEP 1,56 SEP 12,5 tb a. rulnosri SEP IFO tb 54fizz tb Sseuro onas SEP TSA SEP SEP 100 SEP SEP 100 SEP SEP 100 SEP 25 SEP 50 tb iruinosa SEP U SEP 31 tb EMI48.1 tb SEP 4 SEP 0c Mmun5Cot j SEP OUnI SEP Ol1T C USSR SEP C SEP UrKr1 SEP ourir SEP COU1oOU1R tb SEP N tb SEP Us SEP D SEP E SEP F SEP .G SEP H tb SEP i SEP orani tb rcint tobacter SEP TSA SEP 50 SEP 50 SEP 25 SEP ,.13 SEP ry SEP 50 tb SEP calcoaceticus SEP IFO tb SEP 13CG6 tb SEP Can SEP albicans SEP TSA SEP 100 SEP 100 SEP 100 SEP 100 SEP 100 tb SEP TA tb SEP Stawhylococcus SEP B TSA SEP 1.2.5 SEP 6.25 SEP 6.25 SEP 3.13 SEP 12,5 tb SEP aurcus SEP FDA SEP 209P tb SEP Strertoccocus SEP B TSx SEP 3.13 SEP 1.56 SEP 3.13 SEP 1.56 SEP 3.13 tb SEP gones SEP E 14 tb SEP Streptococcus SEP B TSA SEP a.13 SEP 3.13 SEP 3.13 SEP 1.56 SEP 1.56 tb SEP iyogenes SEP 5 8 tb SEP Streptococcus SEP B TSA SEP 25 SEP 25 SEP 25 SEP 25 SEP 25 tb SEP ,itis SEP America tb SEP Strer,.tococcus SEP B TSA SEP 100 SEP SEP 100 SEP SEP 100 SEP SEP 100 SEP SEP 100 tb SEP f SEP aeciwm SEP IF03128 tb S l tococcus SEP bOCOCCUS SEP E T SEP 6.25 SEP 3.1 w SEP 6.25 SEP 3.13 tb SEP nrulnoniae SEP T e SEP . tb SEP Corynebacteriun SEP B TSA SEP ,.13 SEP 0.39 SEP 0.78 SEP 25 SEP 0.78 tb SEP ihtheriae tb SEP Tronto tb SEP Bordetella SEP B TSh SEP 10 SEP SEP 100 SEP SEP 100 SEP SEP 100 SEP SEP SEP 100 tb SEP brorchiseptica tb SEP Sagai tb Table 4 Minnimum inhibitory concentration MIC g ml EMI48.2 tb SEP Con. SEP T.ound SEP Compoun.8 SEP Cor ound SEP Cotipound SEP Confound tb SEP ei1 SEP i SEP I SEP J SEP K SEP XJ tb SEP Test SEP oranl tb Stahy1ccoccus SEP aureus SEP TSA SEP 6.25 SEP 1.56 SEP 6.25 SEP 6.2 tb FD. . SEP 209P tb Stahylocccus SEP aurcus SEP TSA SEP 3.lot., SEP 1.56 SEP , SEP Ij SEP 313 tb 3CIj SEP iL EMI49.1 tb M SEP tb SEP SEP Ce SEP ur. SEP e uur, SEP Cc . SEP our SEP Wn SEP CGW SEP UrT SEP CC SEP j.1 tb SEP 1v SEP iCLA SEP I SEP J SEP K tb SEP lest SEP nrlanlcrrz tb it SEP rlococcus SEP tureus SEP ToA SEP 50 SEP 6.25 SEP 50 SEP 25 tb SEP 18 tb SEP Eschevrichia SEP coli SEP TSA SEP 1.5G SEP 3.13 SEP 1.56 SEP 1,56 tb SEP jIHJ SEP JC 2 tb SEP Escherichia SEP coll SEP 0 111 SEP TSA SEP 3.13 SEP 1.56 SEP 0.39 SEP SEP 0.1 tb Eschr SEP richia SEP coil SEP T 7 SEP TSA SEP SEP lOC SEP SEP 100 SEP SEP 100 SEP SEP 100 tb SEP Citrobacter SEP freundli SEP TSA SEP 6.25 SEP .13 SEP 1.56 SEP 1. SEP 56 tb SEP IFO SEP 12681 tb SEP Klebsiella SEP neuionlae SEP TSA SEP 0.2 SEP 1. SEP 0,39 SEP SEP O SEP .1 tb SEP DT tb SEP Enterobacter SEP eloaeae SEP TSA SEP 25 SEP 6,25 SEP 12.5 SEP 25 tb SEP IFO SEP 12977 tb SEP Sorratla SEP wlareescens SEP TSA SEP 1.56 SEP 1.56 SEP 1.56 SEP 1.56 tb SEP IFO SEP 12so3 tb SEP .W.rotbus SEP vt SEP ri SEP s SEP TSA SEP O. SEP 2 SEP 156 SEP .5C3 SEP C.2 tb SEP IFO SEP 3988 tb SEP Froteus SEP nirabilis SEP TSA SEP 1.56 SEP 3.13 SEP 1.56 SEP 0,78 tb SEP IFO SEP 3849 tb SEP Proteus SEP i ioraIIii SEP TSA SEP 12.5 SEP 1.56 SEP 1 SEP 12.5 SEP 12.5 tb SEP IFO SEP 3168 tb SEP Pssudonellas SEP aenginosa SEP TSA SEP 3.13 SEP r SEP 6,25 SEP 3.13 SEP 3.13 tb SEP IFO SEP 3455 tb SEP Pseudomonas SEP at ruginosa SEP TSA SEP SEP 100 SEP 25 SEP SEP 100 SEP SEP 100 tb SEP U SEP 31 tb SEP Aeinetobaeter SEP TSA SEP 25 SEP 6.25 SEP 50 SEP 50 tb SEP calcoaceticus SEP IFO SEP lzOC6 tb SEP Car.c it a SEP albicans SEP TA SEP TSA SEP SEP 100 SEP SEP 100 SEP SEP 100 SEP SEP 100 tb SEP StaEwh,ylococcus SEP aurcus SEP B TSA SEP 6.25 SEP SEP G.25 SEP 6.25 tb SEP FDs. SEP 209P tb SEP . Stra tc c occus SEP , jril .s SEP TD SEP Q. 9 SEP 1.5fn SEP Ca SEP C.7g tb SEP Stri ltccoccvs SEP . 3rOg cl SEP s SEP 3 T1 SEP 0 SEP 78 SEP 1,55 SEP 1.56 tb SEP S F , SEP . tb EMI50.1 tb Compound SEP Compound SEP Compound SEP Compound SEP Compound tb SEP Medium SEP I SEP J SEP K SEP L tb SEP Test SEP organism tb I tb SEP Streptococcus SEP mitis SEP B TSA SEP 3.13 SEP 25 SEP 1.56 SEP 6.25 tb SEP America tb SEP Streptococcus SEP faecium SEP B TSA SEP SEP 100 SEP SEP 100 SEP SEP 100 SEP SEP 100 tb SEP IFO SEP 3128 tb SEP Streptococcus SEP B TSA SEP 1.56 SEP 1.56 SEP 1.56 SEP 1.56 tb SEP pneumoniae SEP Type SEP I tb SEP Corynebacterium SEP B TSA SEP 0.78 SEP 0.78 SEP 1 SEP 1.56 tb SEP diphtheriae SEP Tronto tb SEP Bordetella SEP B TSA SEP SEP 100 SEP 100 SEP SEP 100 SEP SEP 100 tb SEP bronchiseptica SEP Sagami tb The acute toxicity LD50 , of compound I in mice, by intravenous administration, is generally not less than 500 mg kg. The compound I is of value in the treatment of mammalian animals e.g. mouse, rat, human being, etc. infected by the above mentioned and other microorganisms. As a bacterial infection remedy, the compound I can be applied, for example, to the treatment of respiratory organ infections, urinary tract infections, suppurative diseases, bile duct infections, intestinal infections, gynecological and obstetric infections, surgical infections, etc., in the above mentioned mammals. The daily dose is about 20 to about 200 mg kg body weight as compound I and is preferably administered in 2 to 4 portions daily, i.e. about 5 to about 100 mg kg body weight per dose. The compound 1 , or a physiologically acceptable salt thereof, can be orally administered in dosage forms such as tablets, capsules, drops, etc., which can be prepared by established pharmaceutical procedures.The compound and salt each can also be processed into injectable preparations by routine pharmaceutical procedures, for instance, and after mixing with a sterile vehicle which is obtainable by conventional procedures, be administered parenterally. This invention will be further described by way of the following reference and working Examples. Reference Example 1 A mixture of 4.1 g of methyl 6ss benzyloxy carboxamido 6ss methoxypenicillanate 1 oxide and 10 ml of n amylmercaptan is stirred at 110 0C for 24 hours0The excess n amylmercaptan is distilled off and the residue is chromatographed on a column of silica gel eluted with n hexane ethyl acetate 2 1 to give 2.5 g of methyl 4ss n amyldithio 3ss benzyloxy carboxamido 3a methoxy 2 oxoazetidine l a i sopropenyl acetate.EMI52.1 NMR CDCl3, ppm 0.93 t, CH3 , 1.2 1.7 m, CH , 1.92 s, CH3 , 2.76 t, S CH2 , 3.60 s, CH3 , 3.83 s, CR3 , 4.92 s, C R , 5.07 s, CH , 5.20 m, CH2 , 5.23 s, CH2 , 5.66 s, NH , 7.42 s, aromatic H . Reference Example 2 0.15 g of triethylamine is added to a solution of 2.3 g of methyl 4ss n amyldithio 3ss benzyloxy carboxamido 3a methoxy 2 oxoazetidine l a isopropenyl acetate in 60 ml of methylene chloride and the mixture is stirred at room temperature for 1.5 hours. The solvent is distilled off and the residue is chromatographed on a column of silica gel eluted with n hexane ethyl acetate 4 1 to give 2.2 g of methyl 4ss n amyltithio 3ss benzyloxycarboxamido 3 alpha methoxy 2 oxoazetidine l a isopropylidene acetate.EMI52.2 NMR CDCl3,ppm 0.92 t, CH3 , 1.15 1.98 m, CH2 , 2.08 s, CH3 , 2.32 s, CH3 , 2.65 t, S CH2 , 3.64 s, CH3 , 3.83 s, CH3 , 5.23 s, CH2 , 5.32 s, CH , 5.70 s, NH , 7.42 s, aromatic H . Reference Example 3 18 ml of Raney nickel are added to a solution of 2.1 g of methyl 4ss n amyldithio 3ss benzyloxy carbowamido 3a methoxy 2 oxoazetidine 1 a isopropyli dene acetate in 40 ml of ethanol, and the mixture is stirred at room temperature for one hour. After removal of Raney nickel by filtration, the solvent is removed under reduced pressure and the residue is chromatographed on a column of silica gel eluted with n hexane ethyl acetate 3 1 to give 0.62 g of methyl 3 benzyloxycarboxamido 3 methyoxy 2 oxoazetidine l a isopropylidene acetate.EMI53.1 NMR CDC13, ppm 1.93 s, CR3 , 2.20 s, CH3 , 3.50 s, CH3 , 3.70 s, CH3 , 3.91 dd, J 4,6Hz, C4 H , 5.13 s, CH2 , 6.o3 s, NH , 7.26 aromatic H . Reference Example 4 6.o g of methyl 3 benzyloxycarboxamido 3 methoxy 2 oxoazetidin 1 alpha isopropylidene acetate are dissolved in 150 ml of methylene chloride, and ozone gas is introduced into the solution at 500C to 300C. The reaction mixture is blue after one hour. Then, the excess ozone is removed by the introduction of nitrogen gas, followed by addition of dimethyl sulphide. After stirring at room temperature for an hour, the reaction mixture is washed with water and the solvent is evaporated to give 6.1 g of methyl 3 benzyloxycarboxamido 3 methoxy 2 oxoazetidine 1 alpha ketoacetate. This product is dissolved in 75 ml of methanol, and to the solution is added 19 ml of 0.002 sodium methoxide in methanol. After stirring at room temperature for 15 minutes, 0.3 g of acetic acid is added, and the solvent is distilled off. The residue is dissolved in ethyl acetate and the solution is washed with water.After removal of the solvent, the residue is chromatographed on a column of silica gel eluted with ethyl acetate n hexane 1 to give 2.7 g of 3 benzyloxycarboxamido 3 methoxy 2 oxoazetidine as crystals. Optical rotation alpha 25 68.2 c 1, MeOH EMI54.1 NMR CDC13, ppm 3.45 s, CH3 , 3.60 d,J 6Hz, C4 H , 3.80 d, J 6Hz, C4 H , 5.14 s, CH2 6.74 broad s, NH , 7.34 s, aromatic H . Reference Example 5 5.7 ml of t butyl hypochlorite are added to a solution of 14 g of methyl 3 benzyloxycarboxyamido 2 oxoazetidine l a isopropylidine acetate in 400 ml of dry tetrahydrofuran THF and, then, a solution of 0.348 g lithium in 32 ml methanol is added with stirring at 30 to 20 C. The mixture is maintained at 15 C for 30 minutes, and 1 ml of acetic acid is added, and the solvent is distilled off. The residue is dissolved in ethyl acetate, and after washing with water, the solvent is distilled off. The residue is chromatographed on a column of silica gel eluted with n hexane ethyl acetate 1 1 to give 11.1 g of methyl 3 benzyloxycarboxamido 3 methoxy 2 oxoazetidine 1 alpha isopropylidene acetate as crystals. m.p. 77 CEMI55.1 NMR CDCl3, ppm 1.91 s, CH3 , 2.22 s, CH3 3.53 s, CR3 , 3.73 s, CH3 , 4.l ABq, J 6Hz, C4 H , 5.20 s, CR2 , 6.58 s, NH , 7.35 s, aromatic H . Reference Example 6 7.2 g of the methyl 3 benzyloxycarboxamido 3 methoxy 2 oxoazetidine 1 alpha disopropylidene acetate obtained in Reference Example 5 are dissolved in 150 ml of methylene chloride and ozone gas is introduced into the solution at 50 C to 300C. The reaction mixture is blue after 55 minutes. Then, nitrogen gas is introduced until the solution becomes colourless. Then, 6 ml of dimethyl sulphide are added, followed by stirring at room temperature for 30 minutes. The reaction mixture is washed with water and the solvent is evaporated to give 8.1 g of methyl 3 benzyloxycarboxamido 3 methoxy 2 oxoacetidine l a ketoacetate.This is dissolved in 100 ml of methanol, followed by the addition of 25 ml of 0.002 sodium methoxide in methanol. After stirring at room temperature for 15 minutes, the solvent is distilled off, and the residue is dissolved in ethyl acetate. The solution is washed with water, and the solvent is evaporated to give 3.3 g of 3 benzyloxycarboxamido 3 methoxy 2 oxo azetidine as crystals. In IR and NMR, this product is in agreement with the optically active compound obtained in Reference Example 4. Optical rotation 25 Oo c l, MeOH . Reference Example 7 A solution of 47.5 g of methyl 3 phenylacetamido 2 oxoazetidine l a isopropylidene acetate in 750 ml of methylene chloride is cooled to a temperature below 70 C, followed by the addition of 93.7 g of finely divided phosphorus pentachioride and 71.2 g of pyridine.The mixture is stirred in ice water for 70 minutes. The reaction mixture is cooled to 700C and after addition of 150 ml of n butanol, the temperature is returned gradually to 0 0C. After an hour, 300 ml of cold water is added and the water layer is adjusted to pH 6.2 with sodium hydrogen carbonate. It is extracted with chloroform and the solvent is distilled off. By the above procedure 26 g of methyl 3 amino 2 oxoazetidine l a isopropylidene acetate are obtained.EMI56.1 Reference Exampel 8 While a solution of 58 g of methyl 3 amino 2 oxoazetidine l a isopropylidene acetate in 240 ml of methylene chloride is stirred under ice cooling, 120 ml of propylene oxide and, then, 56.3 g of carbobenzoxy chloride are added. The reaction mixture is returned to room temperature and, then, stirred for 30 minutes.The solvent is distilled off and diethyl ether is added to the residue, whereupon crystals separate out.By the above procedure 82.6 g of methyl 3 benzyloxy carbowamido 2 osoazetidine isopropylidene acetate are obtained.EMI57.1 NMR CDC13, ppm 1.95 s, CR3 , 2.19 s, CH3 , 3.4 3.9 m, CH2 , 3.74 s, OCH3 , 4.89 m, CH , 5.11 s, CR2 , 5.66 d, NK , 7.34 s, aromatic H . Reference Example 9 13.3 g of methyl 3 benzyloxycarboxamido 2 oxoazetidine 1 alpha isopropylidene acetate are dissolved in 400 ml of methylene chloride, and ozone gas is introduced under cooling at 10 C to 200C. The reaction mixture is blue after 2 hours. Nitrogen gas is introduced to remove the excess ozone and, after addition of 20 ml of dimethyl sulphide, the mixture is stirred at room temperature for an hour. The reaction mixture is washed with water and the solvent is distilled off to give 19.9 g of methyl 3benzyloxycarboxamido 2 oxoazetidine l a ketoacetate.This product is dissolved in 200 ml of methanol, then 30 ml of 0.002 sodium methoxide in methanol are added, and the mixture is stirred at room temperature for 15 minutes. To this reaction mixture is added 0.5 g of acetic acid, the solvent is distilled off and cold water methanol 3 1 are added, whereby 7.62 g of 3 benzyloxycarboxamido 2 oxoazetidine are obtained.EMI57.2 NMR DJ4SO d6, ppm 3.08 3.40 m, CH2 , 4.63 m, CH , 5.00 s, CH2 , 7.28 s, aromatic H , 7.80 5 , NH , 7.85 d, NH . Reference Example 10 220 mg of 3 benzyloxycarboxamido 2 ox and 400 mg of 10 palladium carbon are susl 12 ml of alcohol and the suspension is stir intensely in a hydrogen gas stream. After the catalyst is filtered off and the filtrat concentrated to give 76 mg of 3 amino 2 oxoa as crystals.EMI58.1 NMR D SO d6, ppm 2.63 br, s, NH2 , 2.8C m, CE2 , 4.00 m, CH , 7.63 s, NE . Reference Example 11 A mixture of 0.20 g of 3 benzyloxyearbosami methoxy 2 oxoazetidine, 0.50 g of palladium black 5 ml of THF is stirred in a hydrogen gas stream fc 90 minutes. The catalyst is filtered off and the filtrate is concentrated to give 0.09 g of 3 aminomethoxy 2 oxoazetidine.EMI58.2 NMR CDCl3, ppm 2.35 broad s, NH2 , 3.40 dd, J 6Hz, C4 H , 3.45 s, CH3 , 6.7 broad s, NH . Reference Example 12 0.20 g of 3 amino 3 methoxy 2 oxoazetidine is dissolved in 20 ml of methylene chloride and under cooling at 15 C, 10 ml of propylene oxide are added, followed by addition of a solution of the acid chloride prepared from 0.76 g of D N 4 ethyl 2,3 dioxo l piperazinocarbonyl phenylglycine in 10 ml of methylene chloride. The mixture is stirred at the same temperature for 30 minutes, after which 0.475 g of pyridine is added, followed by stirring for an additional hour. The reaction mixture is concentrated under reduced pressure and after cold water is added to the residue, it is extracted with TEF ethyl acetate.The extract is washed with water and concentrated under reduced pressure, and the residue is purified by silica gel column chromatography. The above procedure provides 0.43 g of 3 N 4 ethyl 2,3 dioxo l piperazinocarbonyl D phenylglycinamido 3 methoxy 2oxoazetidine.EMI59.1 NMR i MSO d6, ppm 1.10 t,J 7Hz, CH3 . 3.02 dd,J 3,6Hz, C4 ssH , 3.39 t,J 6Hz, C4 aH , 3.41 q,J 7Hz, CR2 , 3.45 3.65 m, CE2 , 3.30 4.00 m, CR2 , 4.86 ddd, J 3,6,8Hz, C3 H , 5.46 d,J 8Hz, CH , 7.2 7.5 m, aromatic H , 8.00 s, NH , 9.12 d,J 8Hz, NH , 9.81 d,J 8Hz, NH . Reference Example 13 0.5 g of 10 palladium carbon is added to a solution of 0.331 g of 3 benzyloxycarboxamido 2oxoazetidine in 25 ml of ethanol, and the mixture is stirred in a hydrogen gas stream for an hour. The catalyst is filtered off and the filtrate is concentrated. The resulting 3 amino 2 osoazetidine is dissolved in 5 ml of DMF, followed by addition of 0.535 g of D N 3 furfurylideneamino 2 oxo 1 imidazolidinocarbonyl phenylglycine and 0.341 g of dicyclohexylcarbodiimide. The mixture is stirred for 2 hours and the crystals separated are filtered off.The filtrate is concentrated to provide 0.514 g of 3 D 2 3 furfurylideneamino 2 oxoimidazolidin 1 yl carboxamido 2 phenylacetamido 2 oxoazetidine. EMI60.1 Reference Example 14 A solution of 0.693 g of 1 hexamethyleneimine carboxaldehyde dimethyl acetal in 6 ml of methylene chloride is added to a solution of 0.344 g of 3 amino2 oxoazetidine in a mixture of DMF 6 ml and methylene chloride 6 ml . The mixture is stirred at room temperature for an hour, after which methylene chloride is added. It is then washed with water and concentrated to obtain 0.20 g of 3 hesahydro lH azepin 1 yl methyleneamino 2 oxoazetidine.EMI60.2 NMR DMSO d6, ppm 1.64 5.40 m, CH2 , 3.36 t,J 6Hz, C4 pH , 3.90 dd,J 2,6Hz, C4 aH , 4.40 dd,J 2,6Ez, C3 H , 7.46 s, CH N Reference Example 15 2.5 g of the 3 benzyloxyearbowamido 3 methoxy 2 oxoazetidine obtained in Reference Example 4 are dissolved in 25 ml of THF, and after 0.5 g of palladium black is added, the mixture is stirred in a hydrogen gas stream for an hour, at the end of which time the catalyst is filtered off. On the other hand, a solution of 4.46 g of N carbobenzoxy D alanine in 35 ml of THF is cooled to 40 C and 1.89 g of diphosgene and 4.2 g of triethylamine are added.To this solution is added the above filtrate at 40 C and the mixture is stirred at room temperature for 2 hours.After filtration, the filtrate is concentrated under reduced pressure and the residue is purified by silica gel column chromatography. The above procedure provides 0.905 g of 3 N carbobenzoxy D alaninamido 3 methoxy 2 oxoazetidine. alpha 22 79.5 c 1, MeOH .EMI61.1 NMR DMSO d6, ppm l.22 d,J 7Hz, CR3 , 3.32 s, OCH3 , 3.40, 3.48 each d,J 7Hz, C4 H , 4.12 m, CH , 5.04 s, CH2 , 7.36 s, aromatic H , 8.26 s, NH , 8.98 d, J 7Ez, NH . Reference Example 16 A mixture of 0.482 g of 3 N carbobenzoxy Dalanylamino 3 methoxy 2 oxoazetidine, 0.5 g of palladium black, 10 ml of THF and 5 ml of methanol is stirred in a hydrogen stream for 30 minutes, the catalyst is filtered off and the filtrate is concentrated to dryness under reduced pressure. The residue is dissolved in 2 ml of dimethylacetamide, followed by addition of O.2 g of triethylamine. While the mixture is stirred under ice cooling, a solution of 0.337 g of 4 ethyl 2,3 dioxo 1 piperazinocarbonyl chloride is added. The mixture is stirred at room temperature for an hour, after which it is filtered and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel chromatography. By the above procedure 0.432 g of 3 D N 4 ethyl 2,3 dioxo 1 piperazinocarbonyl alanylamino 3 methoxy 2 oxoazetidine is obtained.EMI61.2 NMR DMSO d6, ppm l.lO t,J 7Hz, CH3 , 1.34, 1.44 each d.J 7Hz, CH3 , 3.36 s, CH3 , 3.90 m, CH2 , 4.48 m, CR , 8.31 broad s, NH , 9.74 d,J 7Hz, NH , 9.82 5, NH . Reference Example 17 In the same manner as Reference Example 12 A,Reference Example 13 B, Reference Example 14 C,. Reference Example 15 D and Reference Example 16 E, 3 amino 2 oxoazetidine or 3 amino 3 methoxy 2 oxoaze tidine is reacted with acylating agents to obtain the compounds described below. In the following description, a is the product, b the starting material, c the method used and d the physicochemical constants of the product. 1 a 3 Phenylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine e AEMI62.1 NMR DMSO d6, ppm 3.05 dd,J 3,5Hz, C4 pH , 3.40 t,J 5Hz, C4 aH , 3.46 s, CE2 , 4.38 ddd,J 3,5,8Hz, C3 H , 7.28 s, aromatic H , 7.92 broad s, NH , 8.67 d,J 8Hz, NH . 2 a 3 Thienylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c AEMI62.2 NMR DMSO d6, ppm 3.07 dd,J 3.5Hz, C4 ssH , 3.42 t,J 5Hz, C4 alpha H , 3.69 s, CR2 , 4.85 ddd,J 3,5,8Hz, C3 H , 6.8 7.4 m, thienyl H , 7.96 br.s, NH , 8.77 d, J 8Rj, NH . 3 a 3 2 2 Chloroacetamido 4 thiazolyl 2 methoxyimino acetamido 2 oxoazetidine syn isomer b 3 Amino 2 oxoazetidine c AEMI63.1 NMR DMSO d6, ppm 3.14 dd, J 3,5Hz,C4 ssH , 3.49 t, J 5Hz, C4 alpha H , 3.90 s, CH3 , 4.37 s, ClCH2 , 4.99 ddd, J 3,5,8Ez, C3 H , 7.43 s, , 8.02 s, NH , 9.22 d, J 8Hz,NH , 12.86 br.s, NH . 4 a 3 2 2 Chloroacetamido 4 thiazolyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c A 5 a 3 a Sulphophenylacetamido 2 oxoazetidine sodium salt b 3 Amino 2 oxoazetidine c AEMI63.2 NMR DMSO d6, ppm 3.03 dd, J 2.5,5Hz, C4 ssH , 3.39 t, J 5Hz, C4 alpha H , 4.54 s, CH , 4.82 ddd, J 2.5,5,8Hz, C3 H , 7.1 7.6 m, aromatic H , 7.92 broad s, NH , 8.77 d, J 8Hz, NH .EMI63.3 6 a 3 D 2 Benzyloxycarboxamido 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI64.1 NMR DMSO d6, ppm 2.92 dd, J 3,6Hz, C4 ssH , 3.33 t, J 6Hz, C4 alpha H , 4.82 ddd, J 3,6,8Hz,C3 H , 5.03 s, CR2 , 5.23 d, J 8Hz, CR , 7.31 s, aromatic H , 7.81 d,J 8Hz, NH , 7.93 s, NH , 8.88 d,J 8Hz, NH . 7 a 3 2 2 Chloroacetamido 4 thiazolyl 2 methoxy iminoacetamido 3 methoxy 2 oxoazetidine syn isomer b 3 Amino 3 methoxy 2 oxoazetidine c AEMI64.2 NMR d6 DMSO, ppm 3.44 s, CH3 , 3.60 ABq,J 6,20Hz, C4 H2 , 3.92 s, CR3 , 4.38 s, CH2 , 7.42 s, aromatic H , 8.33 s, NH , 9.78 s, NH , 12.75 s, NH . 8 a 3 Cyanoacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c AEMI64.3 NMR DMSO d6, ppm 3.10 dd,J 2,6Hz, C4 ssH , 3.35 s, CH2 , 3.40 t,J 6Hz,C4 ssH , 3.72 s, CH2 , 4.80 ddd,J 2,6,8Hz,C3 H , 7.93 s,NH , 8.84 d,J 8Hz,NH . 9 a 3 1H Tetrazole 1 acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c A EMI65.1 10 a 3 3 2,6 Dichlorophenyl 5 methylisoxazol 4 yl carboxamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c AEMI65.2 NMR DMSO d6,ppm 2.68 s,CH3 , 3.07 dd, J 2,5Hz, C4 ssH , 3.39 t,J 5Hz,C4 ssH , 4.87 ddd,J 2,5,8Hz, C3 H , 7.53 s,aromatic H , 8.60 d,J 8Hz,NH . 11 a 3 N Carbobenzoxy D alaninamido 2 oxo azetidine b 3 Amino 2 oxoazetidine c BEMI65.3 NMR DMSO d6,ppm 1.22 d,J 7Hz, CH3 , 3.06 dd,J 2,6Hz, C4 ssH , 3.40 t,J 6Hz,C4 alpha H , 4.06 dd,J 7,8Hz, CH , 4.85 ddd,J 2,6,8Hz, C3 H , 5.05 s, CH , 7.38 s, aromatic H , 7.94 broad s,NH , 8.52 d,J 8Hz,NH . 12 a 3 alpha Benzyl N carbobenzoxy Y D glutamyl D alaninamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI65.4 NMR DMSO d6, ppm 1.17 d,J 7Hz,C 1.93 m, CH2 , 2.22 dd,J 7Hz, CH2CO , 3.03 dd, J 2,6Hz,C4 ssH , 3.38 t,J 6Hz,C4 alpha H , 4.84 ddd,J 2,6,8Hz,C3 alpha H , 5.05 s, CH2 , 5.12 s, CH2 , 7.37 s,aromatic H , 7.73 d,J 8Hz, NH , 7.92 s,NH , 7.95 d,J 8Hz,NH , 8.48 d, J 8Ez,NE . 13 a 3 alpha Ureidophenylacetamido 2 oxoazetidine b 3 Amino 2 o oazetidine c BEMI66.1 NMR DMSO d6, ppm 2.97 dd,J 3,6Hz,C4 ssH , 3.38 t,J 6Hz, C4 alpha H , 4.86 ddd,J 3,6,8Hz,C3 H , 5.32 d,J 8Hz, CH , 5.70 s,NH2 , 6.82 d,J 8Hz,NH , 7.35 broad s, aromatic H , 7.99 s,NH , 9.02 d,J 8Hz,NH . 14 a 3 D 2 4 Ethyl 2, 3 dioxo 1 pipera zino carboxamido 2 phenylacetamido 3 methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 osoacetidine c AEMI66.2 NMR DMSO d6,ppm 1.09 t,J 7Hz,CH3 , 3.36 s, CH3 , 5.60 d,J 7Hz, CH , 8.25 s,NH , 9.60 s,NH , 9.78 d,J 7Hz,NH . 15 a 3 D 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 2 4 hydroxyphenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c AEMI67.1 NMR DMSO d6,ppm 1.09 t,J 8Hz, CH3 , 4.86 m,C3 H , 5.32 d,J 7Hz, CH , 6.98 ABq,J 9, 46Hz, phenyl H , 7.96 s,NH , 8.99 d,J 8Rz, NH , 9.70 d,J 7Hz, NH . 16 a 3 4 Ethyl 2,3 dioxo l piperazinocarboxamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c AEMI67.2 NMR DMSO d6,ppm 1.11 t,J 7Hz,CH3 , 3.27 dd,J 3,6Hz, C4 ssH , 3.42 t,J 6Hz,C4 alpha H , 3.42 q,J 7Hz, CH2 , 3.5 4.1 m, CH2 , 4.87 ddd,J 3,6,8Rz,C3 R , 7.98 s,NH , 9.18 d,J 8Hz,NH . 17 a 3 N 4 Ethyl 2,3 dioxo 1 piperazinocarbonyl D alaninamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c AEMI67.3 NMR DMSO d6,ppm 1.10 t,J 7Hz, CH3 , 1.30 d,J 7Hz, CH3 , 3.06 dd,J 3,6Hz,C4 ssH , 3.44.1 m, CH2 , 3.43 q,J 7Hz, CH2 , 3.46 t, J 6Hz,C4 alpha H , 4.34 quintet,J 7Hz, CH , 4.88 ddd,J 3,6,8Hz,C3 H , 7.99 s,NH , 8.78 d,J 8Hz,NH , 9.25 d,J 7Hz,NH . 18 a 3 2 Methoxyimino 2 phenylacetamido 2 oxoazetidine syn isomer b 3 Amino 2 oxoazetidine c B d NMR CDCl3,ppm 3.26 dd,J 2,5Hz,C4 ssH , 3.52 t,J 5Hz, C4 aH , 3.92 s,CH3 , 4.96 ddd,J 2,5,8Hz,C3 H , 6.47 br.s,NH , 7.2 7.7 m,aromatic H . 19 a 3 D 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 2 4 methoxyphenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c AEMI68.1 NMR DMSO d6,ppm 1.09 t,J 7Hz, CH3 , 2.94 dd,J 3,6Hz, C4 ssH , 3.38 t,J 6Hz,C4 alpha H , 3.41 q,J 7Hz, CH2 , 3.4 4.1 m, CH2 , 3.76 s, CH3 , 4.86 ddd,J 3,6,8Hz, C3 H , 5.38 d,J 7Hz, CH , 6.93, 7.33 ABq,J 9Hz, aromatic H , 7.98 s,NH , 9.04 d,J 8Hz,NH , 9.74 d,J 7Hz,NH . 20 a 3 D 2 2 2 Chloroacetamido 4 thiazolyl 2 methoxyiminoacetamido 2 phenylacetamido 2 oxoazetidine a mixture of syn and anti isomers b 3 amino 2 oxoazetidine c EEMI68.2 21 a 3 D 2 6 Bromo 1,4 dihydro l ethyl 4 oxothieno 2,3 b pyridine 3 carboxamido 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c EEMI69.1 NMR DMSO d6.ppm 1.43 t,J 7Hz,CH3 , 2.97 dd,J 3,6Hz,C4 ssH , 3.40 t,J 6Hz,C4 alpha H , 4.27 q,J 7Hz, CH2 , 4.90 ddd,J 3,6,8Hz,C3 H , 5.70 d,J 7Hz, CH , 7.2 7.6 m,phenyl H , 7.63 s,aromatic H , 7.98 s,NH ,8.70 s,aromaticH , 9.11 d,J 8Hz,NH , 10.95 d,J 7Hz,NH . 22 a 3 2 4 Ethyl 2,3 dioxo l piperazino carboxamido 2 2 chloroacetamido 4 thiazolyl acetamido 2 oxoazetidine b 3 Ajnino 2 oxoazetidine c BEMI69.2 NMR DMSO d6,ppm 1.10 t,J 7Hz,CH3 , 3.40 q,J 7Hz, CH2 , 3.4 4.1 m, CH2 , 4.87 broad s,C3 H , 4.37 s,C1CR2 , 5.55 d,J 7Hz, lCH , 7.22 s,aromatic H ,7.98 s,NE , 8.91 d,J 8Hz,NH , 9.76 d,J 7Hz,NH , 12.6 broad s, NH . 23 a 3 2 4 Ethyl 2,3 dioxo 1 piperazinocarbox amido 2 2 acetamido 4 thiazolyl acetamidol 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI69.3 EMI70.1 24 a 3 2 2 2 Chloroacetamido 4 thiazolyl 2 methoxyiminoacetamido 2 2 chloroacetamido 4 thiazolyl acetamido 2 oxoazetidine syn isomer b 3 Amino 2 osoazetidine c BEMI70.2 25 a 3 D 2 2,3 Dioxo 4 n octyl 1 piperazino carboxamido 2 phenylacetamido 2 oxo azetidine b 3 Amino 2 oxoazetidine c BEMI70.3 NMR DMSO d6,ppm 0.7 1.7 m, CH2 ,CH3 , 2.93 dd,J 3,6Hz, C4 ssH 3.36 t,J 6Hz,C4 alpha H , 3.2 4.1 m, CH2 , 4.85 ddd,J 3,6,8Hz,C3 H m 5.42 d,J 7Hz, CH ,7.2 7.5 m,aromatic H , 7.98 s,NH , 9.12 d,J 8Ez,NH ,9.83 d,J 7Ez, NH . 26 a 3 D 2 Courmarin 3 carboxamido 2 phenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c EEMI71.1 NMR DMSO d6,ppm 3.01 dd,J 3,6Hz,C4 H , 3.43 t,J 6Hz, C4 H , 4.95 ddd,J 3,6,8Hz,C3 H , 5.72 d,J 7Hz, CH ,7.3 9.0 m, aromatic H , 9.23 d,J SRz,NH , 9.68 d,J 7Hz,NH . 27 a 3 2 2,3 Dioxo 4 n octyl 1 piperazino carboxamido 2 2 chloroacetamido 4 thiazolyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI71.2 28 a 3 D 2 4 Hydroxy 7 trifluoromethylquinoline 3 carboxamido 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI71.3 NMR DMSO d6,ppm , 3.12 dd,J 3,5Hz,C4 ssH , 3.45 t,J 5Hz, C4 alpha H , 4.87 m,C3 H , 5.72 d,J 8Hz, CH , 7.99 s,NH ,9.07 d,J 8Hz,NH , 10.86 d,J 8Hz,NH . 29 a 3 2 2,3 Dioxo 4 n octyl 1 piperazino carboxamido 2 thienylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI72.1 NMR DMSO d6,ppm 0.86 t,J 7Hz,CH3 , 3.01, 3.09 dd,J 3,6Hz,C4 ssH , 3.37 t,J 7Hz, CH2 , 3.4 4.1 m, CH2 , 4.86 m,C3 H , 5.73 d,J 7Hz, lH , 6.9 7.6 m, aromatic H , 8.01 s,NH , 9.14, 9.17 d,J 8Hz,NH , 9.76 d,J 7Hz, NH . 30 a 3 D 2 2,3 Dioxo 4 n octyl 1 piperazino carboxamido 2 4 hydroxyphenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI72.2 NMR DMSO d6,ppm 0.86 t,J 7Hz,CH3 , 2.95 dd,J 3,6Hz,C4 ssH , 4.86 ddd,J 3,6,8Hz,C3 H , 5.32 d,J 7Hz, lCH ,6.97 ABq,J 8,46Hz, aromatic H , 7.98 s,NH ,8.99 d,J 8Hz,NH , 9.42 s,OH , 9.70 d,J 7Hz,NH . 31 a 3 D 2 3 Furfurylideneamino 2 oxoimidazo lidin 1 yl carboxamido 2 4 hydroxyphenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI72.3 NMR DMSO d6,ppm 2.97 dd,J 3,6Hz,C4 ssH , 3.35 t,J 6Hz, C4 aH , 3.80 broad s, CH2 , 4.88 ddd,J 3,6,8Hz,C3 H , 5.33 d,J 7Hz, CH , 6.6 7.9 m,furyl H ,6.74, 7.22 ABq,J 46,9Hz,phenyl H , 7.74 s, CH , 7.98 s,NH , 8.92 d,J 7Hz,NH , 9.00 d,J 7Hz,NH ,9.44 s,OH . 32 a 3 D 2 3 Furfurylideneamino 2 oxoimidazo lidin 1 yl carboxamido 2 thienylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI73.1 33 a 3 D 2 3 Thiophen 2 aldoimino 2 oxoimidazolidin l yl carboxamido 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 osoazetidine c BEMI73.2 34 a 3 2 4 Ethyl 2,3 dioxo 1 piperazinocarbox amido 2 2 pyrrolyl acetamido 2 oxo azet idine b 3 Amino 2 oxoazetidine c BEMI73.3 NMR DMSO d6,ppm 1.10 t,J 7Hz, CH3 , 3.03 3.10 dd,J 3,6Hz,C4 ssH , 3.40 q,J 7Hz, CH2 , 3.4 4,1 m, CH2 ,4.86 m,C3 E ,5.46 d,J 7Hz, CH , 5.9 6.8 m,pyrrolyl H ,7.98 s,NH , 8.89, 8.91 d,J 8Hz,NH , 9.48 d,J 7Hz,NH , 10.72 broad s,NH . 35 a 3 2 2,3 Dioxo 4 n octyl 1 piperazino carboxamido 2 thienylacetamido 3 S methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 oxoazetidine c AEMI74.1 NMR d6 DMSO,ppm 0.86 t,CH3 , 3.20 s,OCH3 , 3.4 4.l m,ring CH2 , 3.44, 3.57 ABq,J 6, 13Hz,C4 E , 5.90 d,J 7Hz, CH , 6.9 7.6 m, thienyl H , 8.36 s,NH ,9.74 d,J 7Hz,NH . 36 a 3 2 2,3 Dioxo 4 n octyl 1 piperazino carboxamido 2 thienylacetamido 3 R methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 oxoazetidine c AEMI74.2 NMR d6 IMSO,ppm 0.86 t,CR3 ,3.36 s,OCR3 , 3.39, 3.48 ABq,J 9,6Hz,C4 E ,3.4 4.1 m,ring CH2 , 5.89 d,J 7Hz, CH , 6.9 7.6 m,thienylH , 8.3L s,NH ,9.67 s,NH , 9.70 d,J 7Rz,NH . 37 a 3 D alpha Sulphophenylacetamido 3 methoxy 2 oxoazetidine sodium salt b 3 Amino 3 methoxy 2 oxoazetidine c AEMI74.3 NMR DMSO d6, ppm 3.31, 3.41 s,CH3 , 3.47 ABq,J 6,12Hz,C4 H , 5.65, 5.70 s, CH , 7.2 7.5 m,aromatic H ,8.29 s,NH , 9.2, 9.29 s,NH . 38 a 3 N Carbobenzoxy D alanyl D phenylglycin amido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI75.1 NMR DMSO d6,ppm 1.20 d,J 6Hz,CH3 , 2.91 dd,J 2,6Hz,C4 ssH , 3.35 t,J 6Hz,C4 alpha H , 4.17 m, CH , 4.83 ddd,J 2,6,SRz,C3 R , 4.99 s, CH2 , 5.42 d,J 9Hz, CH , 7.30 s,aromatic H 7.94 br.s,NH , 8.97 d, J 9Hz,NH . 39 a 3 D 2 2 Ureido 2 thienylacetamido 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 osoazetidine c BEMI75.2 40 a 3 Cyanomethylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI75.3 NMR DMSO d6,ppm 3.10 dd,J 2,6Hz,C4 ssH , 3.35 s, CH2 ,3.72 s, CH2 , 3.40 t,J 6Hz, C4 aH , 4.80 ddd,J 2,6,8Hz, C3 H , 7.93 s,NH , 8.84 d,J 8Hz,NH . 41 a 3 D 2 2 2 Chloracetamido 4 thiazolyl acetamido 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c EEMI75.4 42 a 3 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 2 thienylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c AEMI76.1 NMR DMSO d6,ppm 1.08 t,J 7Hz,CH3 ,3.02 dd,J 3,6Hz,C4 ssH , 3.3 4.1 m, CH2 ,C4 alpha H , 4.86 ddd,J 3,6,8Hz, C3 H , 5.71 d,J 7Hz, CH , 6.9 7.5 m, thienyl H , 8.01 s,NH , 9.20, 9.18 each d,J 8Hz,NH , 9.77 d,J 7Hz,NH . 43 a 3 2 Methoxyimino 2 thienylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI76.2 44 a 3 2 Thienyl 2 3 morpholinopropoxyimino acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c REMI76.3 NMR DMSO d6,ppm 3.18 dd,J 3,6Hz,C4 , 4.21 t,J 6Hz, C4 E , 4.93 ddd,J 2,6,8Hz, C3 H , 8.01 s,NH , 9.25 d,J 8Hz,NH . 45 a 3 D 2 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 2 thienylacetamido 2 phenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c B EMI77.1 46 a 3 2 2,5 Dioxo 1,2,4 triazino 6 carboxamido 2 osoazetidine b 3 Amino 2 oxoazetidine c BEMI77.2 NMR DMSO d6,ppm 3.10 dd,J 2,6Hz,C4 H , 3.40 t,J 6Hz, C4 H , 4.85 ddd,J 2,6,SHz,C3 H , 5.85 d,J 7Hz, CH , 8.00 s,NH , 9.16, 9.19. each d,J 8Hz,NH , 9.60 d,J 7Hz,NH 47 a 3 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 2 2 methyl 4 thiazolyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI77.3 48 a 3 2 3 4 Chlorobenzoyl ureido 2 thienylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI77.4 1463, 1282.NMR DMSO d6,ppm 3.25 dd,J 3,6Hz,C4 H , 3.57 t,J 6Hz,C4 H , 4.94 ddd,J 2,6.8Hz, C3 H , 5.82 s, CH . 49 a 3 Cyanomethylthioacetamido 3 methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 oxoazetidine c AEMI78.1 NMR DMSO d6,ppm 3.33 s,CH3 ,3.33, 3.70 each s, CH2 , 3.2 3.8 m,C4 H , 8.27 s,NH , 9.28 s,Nff . 50 a 3 2 Benzyloxycarbonyl 2 phenylacetamido 3 methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 oxoazetidine c AEMI78.2 51 a 3 2 5,6 Dihydro 1,4 oxathiin 2 yl acetamido 2 osoazetidine b 3 Amino 2 oxoazetidine c BEMI78.3 52 a 3 N Carbamoyl D tryptophyl D phenylglycin amido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI78.4 NMR DMSO d6,ppm 2.97 dd,J ,6Hz,C4 H , EMI79.1 53 a 3 ss D N 4 Ethyl 2,3 dioxo 1 piperazino carbonyl phenylalaninamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI79.2 NMR DMSO d6,ppm 1.08 t,J 7Hz,CH3 , 2.90 dd,J 2,6Hz,ssH , 3.38 m, CH2 , 3.42 t,J 6Hz, C4 alpha H , 4.56 dd,J 6,8Hz, CH , 4.84 ddd,J 2, 6,8Hz,C H , 7.2l s,aromatic H , 7.95 s,NH , 8.79 d,J 8Hz,NH , 9.15 d,J 8Hz,NH . 54 a 3 2 2,4 Dioxopyrimidino 5 carboxamido 2 thienylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI79.3 NMR DMSO d6ppm 3.04 dd,J 2,6Hz,C4 ssH , 3.42 t,J 6Hz,C4 alpha H , 4.84 ddd,J 2,6,8Hz,C3H , 5.85 d,J 8Hz, CH , 7.99 s,NH , 9.16, 9.19 each d,J 8Hz,NH , 9.60 d,J 8Hz,NH . 55 a 3 D 2 2 Ureido 2 thienylacetamido 2 4 hydroxyphenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI79.4 56 a 3 D N 4 Ethyl 2,3 dioxo 1 piperazino carbonyl glutaminylamino 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI80.1 57 a 3 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 2 1 cyclohexen 1 yl acetamido 2 oxoazetidine b 3 Amino 2 axoazetidine c BEMI80.2 NMR DMSO d6,ppm 1.10 t,J 8Hz,CH3 , 1.33 1.70 m, CH2 , 1.70 2.13 m, CH2 , 3.40 q, CH2 , 4.76 d,J 8Hz, CH ,5.73 broad s, H , 7.93 s,NH , 8.73, 8.76 d,J 8Hz,NH , 9.40 d,J 3Hz,NH . 58 a 3 C2 4 Ethyl 2,3 dioxo l piperazino carboxamido 2 4 chlorophenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidineEMI80.3 NMR DMSO d6,ppm 1.10 t,J 7Hz,CH3 , 3.0 m,C4 H , 3.42 q,J 7Hz, CH2 , 4.85 m,C3 H , 5.44, 5.46 d,J 7Hz, CH , 7.46 s,aromatic H , 8.02 broad s,NH , 9.16 d,J 8Hz,NH , 9.84 d,J 7Hz,NH . 59 a 3 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 2 4 trimethylsilylphenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine EMI81.1 NMR DMSO d6,ppm 0.26 s,CH3 , 3.0 m, C4 R , 4.85 m,C3 H , 5.42, 5.44 d,J 8Rz, CH , 7.40 d,J 8Hz,phenyl H , 7.54 d,J 8Hz, phenyl H , 8.02 broad s,NH , 9.l0 s,NH , 9.84 d,J 8Hz,NH . 60 a 3 D N 4 Ethyl 2,3 dioxo 1 piperazino carbonyl methionyl D phenylglycinamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI81.2 NMR DMSO d6,ppm 1.08 t,J 7Hz,CH3 , 2.06 s,CH3 , 2.96 dd,J 2,6Hz,C4 ssH , 5.54 d,J 8Hz, CH , 4.86 m,C3 H , 7.96 broad s,NH , 9.26 d,J 3Hz,NH . 61 a 3 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 2 1 cyclohexen 1 yl acetamido 3 methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 oxoazetidine c BEMI81.3 62 a 3 D 2 3 Methylcarbamoyl 3 methyl 1 ureido 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI82.1 NMR DMSO d6,ppm 2.72 d,J 4Hz, CH3 , 3.11 s,CH3 , 3.42 t,J 5Hz,C4 alpha H , 4.93 m,C3 H , 5.42 d,J 7Hz, CH , 7.43 s,aromatic H,NH , 8.03 s,NH , 9.15 d,J 9Hz,NH , 10.08 d,J 7Hz,NH . 63 a 3 2 3 Methylcarbamoyl 3 methyl 1 ureido 2 thienylacetamido 2 oxoazetidine b 3 Amino 2 osoazetidine c BEMI82.2 64 a 3 D 2 3 Methylcarbamoyl 3 methyl 1 ureido 2 4 benzyloxy phenylacetamido 2 oxoazetidine b 3 Amino 2 osoazetidine c BEMI82.3 65 a 3 D 2 3 2 Benzyloxybenzoyl l ureido 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI82.4 NMR DMSO d6,ppm 3.03 dd,J 3,6Hz,C4 H , 3.47 t,J 5Hz, C4 H , 4.93 m,C3 H , 5.37 s, CH2 , 5.56 d,J 7Hz, CH , 7.47 s, aromatic H , 7.25 8.10 m,aromatic H , 8.17 s,NH , 9.27 d,J 7Hz,NH , 9.63 d,J 7Hz,NH , 10.43 s,NH . 66 a 3 D 2 3 2 Benzyloxybenzoyl 1 ureido 2 4 hydroxyphenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI83.1 67 a 3 D 2 3 Chloro 4 hydroxyphenyl 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido acetamido 2 oxoazetidine b 3 mino 2 oxoazetidine c BEMI83.2 NMR DMSO d6,ppm 1.13 t,J 7Hz, CH3 , 3.05 dd, J 2,5Hz,C4 H , 3.30 3.53 m, CH2 ,C4 H , 3.53 4.2 m, CH2 , 4.97 m,C3 H , 5.47 d,J 7Hz, CH , 7.00 7.73 m,aromatic H , 8.13 s,NR , 9.25 d,J 9Hz,NH , 9.97 d,J 7Hz,NH . 68 a 3 D 2 3 Chloro 4 methoxyphenyl 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI83.3 69 a 3 D 2 2 Benzyloxycarboxamido 3 N methylcarbamoyl propionamido 2 phenyl acetamido 2 oxoazetidine a mixture of diastereoisomers b 3 Amino 2 oxoazetidine c B EMI84.1 70 a 3 D 2 3 Benzyloxycarboxamido 3 N methylcarbamoyl propionamido 2 phenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI84.2 71 a 3 2 2,5 Dioxopyrrolidin 3 yl acetamido 2 oxoazetidine b 3 Amino 2 oxoazet idine c BEMI84.3 NMR DMSO d6,ppm 2.3 3.6 m, CH2 ,C4 H , 4.6 5,0 m,C3 H , 7.95 broad s,NH , 8.64 d,J 8Hz,NH . 72 a 3 2 Succinimidoacetamido 2 oxoazetidine b 3 Amino 2 osoazetidine c BEMI84.4 NMR DMSO d6,ppm 2.68 s, CH2 CH2 , 3.02 dd,J 3,5,6Hz, C4 ssH , 3.41 t,J 6Hz, C4 alpha H , 3.98 s, CH2 , 4.6 5.0 m, C3 H , 7.95 broad s,NH , 8.72 d,J 8Hz,NH . 73 a 3 2 2 Carbobenzoxyaminomethylphenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI84.5 NMR DMSO d6,ppm 3.04 dd,J 3,6Hz,C4 ssH , 3.37 t,J 6Hz,C4 alpha H , 3.54 s, CH2 , 4.25 d,J 6Hz, CR2 , 4.65 5.0 m, C3 H , 5.02, s, CH2 , 7.20 s,aromatic H , 7.35 s, aromatic H , 7.98 broad s,NH , 7.98 d,J 6Hz,NH , 8.72 d,J 8Hz,NH 74 a 3 2 Methoxyimino 2 furylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI85.1 75 a 3 2 2 3 Trichloroacetylureidomethyl phenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI85.2 NMR DMSO d6,ppm 2.8 3.6 m,C4 H , 3.58 s, CH2 , 4.42 d,J 6Hz, CH2 , 4.6 5.1 m, C3 H , 7.27 s,aromatic H , 7.97 broad s,NE , 8.23 d,J 6Hz,NH , 8.26 broad s,NH , 8.79 d,J 8.5Hz,NH . 76 a 3 2 3,5 Dichloro 4 pyrridon 1 yl acetamido 2 oxoazetidine b 3 Amino 2 osoazetidine c AEMI85.3 EMI86.1 77 a 3 2 Benzyloxycarbonyl 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI86.2 78 a 3 2 N Carbobenzoxyprolinamido 2 furyl acetamido 3 2 oxoazetidine b 3 Amino 2 oxoazetidine c B d IR maxKBrcm 1 3270, 1765, 1700, 1665. 79 a 3 2 1 Acetyl 2,4 dioxoimidazolidin 3 yl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI86.3 NMR DMSO d6,ppm 2.45 s,CH3 , 3.01 dd,J 6, 3.5Hz, C4 ssH , 3.44 t,J 6Hz,C4 alpha H , 4.07 s, CH2 , 4.28 s, CH2 , 4.87 ddd,J 3.5, 6Hz,C3 H , 7.99 broad s,NE , 8.83 d,J 8Rz,NH . 80 a 3 2 2 Oxoimidazolidin 1 yl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c AEMI86.4 NMR DMSO d6,ppm 3.1 4.0 m, CH2 ,C4 H , 4.6 5.0 m,C3 H , 7.54 broad s,NH , 7.88 broad s,NH , 8.56 d,J 8.5Hz,NH . 81 a 3 2 4 Ethyl 2,3 dioxo l piperazino carboxamido 2 furylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI87.1 82 a 3 D alpha Thienylmethylcarbonyl alaninamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c EEMI87.2 83 a 3 N Carbobenzoxy D alaninamido 3 methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 oxoazetidine c DEMI87.3 NMR DMSO d6,ppm , 1.22 d,J 7Hz, CH3 , 3.32 s,CH3 , 3.40, 3.48 each m,C4 H , 4.12 m, CH , 5.04 s,CH2 , 7.36 s,aromatic H , 8.26 s,NH , 8.98 d,J 7Hz,NH . 84 a 3 N 4 Ethyl 2,3 dioxo 1 piperazino carbonyl D alaninamido 3 methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 oxoazetidine c EEMI88.1 NMR DMSO d6,ppm 1.10 t,J 7Hz,CH3 , 1.34, 1.44 d,J 7Hz,CH3 , 3.36 s,CH3 , 3.90 m, CH2 , 4.48 m, CH , 8.31 broad s,NH , 9.74 d,J 7Hz,NH , 9.82 s,NH . 85 a 3 N Carbobenzoxy D phenylglycol D phenylglycinamido 3 methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 osoazetidine c EEMI88.2 NMR DMSO d6,ppm 3.06, 3.26 s,CH3 , 3 40 m,C4 H , 5.05 s, CH2 , 5.46 d,J 8Hz, CH , 5.60 d,J 8Hz, CH , 7.84 broad s, NH , 8.73 d,J 8Hz,NE , 9.40 s,NH . 86 a 3 N 4 Ethyl 2,3 dioxo l piperazino carbonyl D methioninamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI88.3 NMR DMSO d6,ppm 1.10 t,J 7Hz,CH3 , 1.96 m, CH2 , 2.05 s,CH3 , 2.44 t,J 7Hz, CH2 , 3.08 q,J 2,6Hz,C4 ssH , 3.41 q,J 7Hz, CH2 , 3.58 m, CH2 , 3.90 m, CH2 , 4.43 q,J 7Hz, CH , 4.84 m,C3 H , 7.97 broad s,NH , 8.82 d,J 7Hz,NH , 9.43 d,J 7Hz,NH . 87 a 3 D 2 2,3 Dioxo 4 2 phenethyl 1 piperazinocarboxamido 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI89.1 NMR DMSO d6,ppm 2.84 t,J 7Hz, CH2 , 2.95 dd,J 3,6Hz, C4 ssH , 4.88 ddd,J 3,6,8Hz,C3 H , 5.46 d,J 7Hz, CH 7.25 7.5 m, aromatic H , 8.00 s,NH , 9.12 d,J 8Hz,NH , 9.80 d,J 7Hz,NH . 88 a 3 D 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 2 4 benzoyloxyphenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI89.2 NMR d6 DMSO, ppm 1.10 t, CH3 , 2.99 dd,J 3,6Hz,C4 H , 3.41 q, CH2 , 3.42 t,J 6Hz, C4 R , 3.4 4.l m,ring CH2 , 4.91 ddd,J 3, 6,8Hz,C3 H , 5.53 d,J 7Hz, CH , 7.2 8.2 m, phenyl H , 8.02 s,NH , 9.19 d,J SHz,NH , 9.88 d,J 7Rz,NH . 89 a 3 2 Benzyloxycarboxamido 3 N methyl carbamoylpropionamido 3 methoxy 2 oxoazetidine b 3 Amino 7 methoxy 2 oxoazetidine c BEMI89.3 NMR CDCl3,ppm 2.73 m,CH3, CH2 , 3.43 s,CH3 , 3.66 m,C4 H , 4.63 m, CH , 5.12 s, CH2 , 6.70 d,J 7Hz, NH , 6.77 m,NH , 7.12 m,NH , 8.53 s,NH . 90 a 3 2 2 Chloroacetamido 4 thiazolyl 2 3 furfurylideneamino 2 oxoimidazolidin 1 yl carboxamido acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI90.1 91 a 3 D 2 2 Phenylacetamido propionamido 3 methoxy 2 oxoazet idine b 3 Amino 3 methoxy 2 oxoazetidine c EEMI90.2 NMR DMSO d6,ppm 1.23, 1.24 each d,J 7Az, CR3 , 2.79, 2.95 each s, CH2 , 3.31, 3.47 each s,CR3 , 4.46 m, CH , 7.27 s,aromatic H , 8.1 8.35 m,NH , 8.98 d,J 7Hz,NH . 92 a 3 2 2 Oxo 3 thiophen 2 aldoimino imidazolidin 1 yl carboxamido 2 thienyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI90.3 93 a 3 D 2 3 Mesyl 2 oxoimidazolidin 1 yl carboxamido 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c B EMI91.1 94 a 3 2 3 Mesyl 2 oxoimidazolidin 1 yl carboxamido 2 thienylacetamido3 2 oxoazet idine b 3 Amino 2 oxoazetidine c BEMI91.2 95 a 3 D 2 2,6 Dichlorophenylthioglycolamido 2 phenylacetamido 2 oxoazatidine b 3 Amino 2 oxoazetidine c BEMI91.3 NMR DMSO d6,ppm 2.97 dd,J 3,6Hz,C4 H , 3.36 t,J 6Hz,C4 H , 3.93 s, CH2 , 4.86 ddd,J 2,6,8Hz,C3 H , 5.47 d,J 7Hz, CH , 7.25, 8.0 m,aromatic H , 8.98 d,J 7Hz,NH , 9.09 d,J 8Hz,NH . 96 a 3 D 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 3 phenylpropionamido 3 methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 oxoazetidine c AEMI91.4 NMR DMSO d6,ppm 1.09 t,J 7Hz,CH3 , 4.72 m, CH , 5.32 s,NH , 9.15 d,J 7Hz,NH , 9.43 s,NH . 97 a 3 2 Dichloroacetoxyimino 2 thienylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c A EMI92.1 NMR DMSO d6,ppm 3.18 dd,J 2,6Hz,C4 ssH , 3.45 t,J 6Hz,C4 alpha H , 4.92 ddd,J 2,6,8Hz,C3 H , 6.44 s, CH , 7.06, 7.71 m,thienyl H , 7.91 s,NH , 9.14 d,J 8Hz,NH . 98 a 3 2 Phenyl 2 sulphamoylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI92.2 NMR DMSO d6,ppm 3.20 dd,J 3,6Hz,C4 H , 3.50 t,J 6Hz, C4 R , 4.87, 4.98 each dd,J 3,6Hz,C3 H , 5.17 s, CH , 7.3 7.8 m, aromatic H . 99 a 3 2 N,N Dimethylsulphamoyl 2 phenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI92.3 NMR DMSO d6,ppm 2.63, 2.67 s,CH3 , 3.02 m,C4 H , 3.40, 3.46 t,J 6Hz,C4 H , 4.82 m,C3 H , 5.28 s, CE , 8.01 s,NH , 9.06 d,J 8Hz, NH . 100 a 3 2,5 Bis 4 ethyl 2,3 dioxo 1 piperazino carboxamido pentanamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI92.4 EMI93.1 101 a 3 2,5 Bis 4 ethyl 2,3 dioxo 1 piperazino carboxamido pentanamido 3 methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 oxoazetidine c BEMI93.2 NMR DMSO d6,ppm 1.09 t,J 7Hz,CH3 , 3.33 s,CH3 , 4.51 m, lCH , 8.29 s,NH , 8.83 t,J 6Hz,NH , 9.20 d,J 7Hz,NH , 9.37 s,NH . 102 a 3 D 2 4 2 Chloroethyl 2,3 dioxo 1 piperazinocarboxamido 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI93.3 103 a 3 D 3 Chloro 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido propionamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI93.4 NMR DMSO d6,ppm 1.10 t,J 7Hz,CH3 , 3.05 dd,J 2,6Hz, C4 ssH , 3.42 q,J 7Hz, CH2 , 3.56 m, CH2 , 3.92 m, CH2 , 4.72 m, CH , 4.90 m,C3 H , 8.00 broad s,NH , 8.92 d,J 7Hz,NH , 9.48 d,J 7Hz,NH . 104 a 3 2 Benzyloxycarboxamido 2 benzyloxy carbonylethane sulphonamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c AEMI94.1 NMR DMSO d6,ppm 3.03 dd,J 2,6Hz,C4 ssH , 3.40 d,J 6Hz,C4 alpha H , 3.58 dd,J 6,14Hz, CH2 , 4.60 m, CH , C3 H , 5.07 s, CH2 , 5.16 s, CH2 , 7.36, 7,38 each s, aromaticH , 7.88 d,J 7Hz,NH , 8.02 broad s, NH , 8.34 d,J 7Rz,NH . 105 a 3 2 4 Ethyl 2,3, dioxo 1 piperazino carboxamido 3 1 methyl 5H tetrazol 5 yl thio proprionamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI94.2 NMR DMSO d6,ppm 1.10 t,J 7Hz,CH3 , 3.04 dd,J 2,6Hz, C4 ssH , 3.41 q,J 7Hz, CH2 , 3.92 s,CH3 , 4.74 m, CH , 4.82 m,C3 H , 8.01 broad s,NH , 8.97 d,J 7Hz,NH , 9.38 d,J 7Hz,NH . 106 a 3 D 2 2 Benzyloxycarboxamido 2 benzyloxy carbonylethanesulphonamido 2 phenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c EEMI94.3 NMR DMSO d6,ppm 2.96 dd,J 2,6Hz,C4 ssH , 4.40 m, CH , 4.78 m,C3 H , 5.04 s, CH2 , 5.11 s, CH2 , 7.2 7.6 m,aromatic H , 7.80 d,J 7Rz,NH , 7.96 broad s,NH , 8.20 d,J 7Ez, NH , 8.97 d,J 7Hz,NH . 107 a 3 D 2 2 Benzyloxycarboxamido 3 sulphamoylpropionamido 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI95.1 108 a 3 D 2 2 Benzyloxycarboxamido 3 4 methoxy phenyloxycarboxamido propionamido 2 phenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI95.2 109 a 3 D 2 3 Benzyloxycarboxamido 2 4 ethyl 2, 3 dioxo 1 piperazinocarboxamido propionamido 2 phenylacetanido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI95.3 110 a 3 2 2 Benzyloxycarboxamido 3 N methyl carbamoyl propionamido acetamido 3 methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 oxoazetidine c EEMI95.4 NMR DMSO d6,ppm 2.55 d,J 5Hz,CH3 , 2.40 2.60 m, CH2 , 3.30 s,CH3 , 3.40 ABq,J 6, 10Hz, C4 H , 3.75 d, J 6Hz, CH2 , 4.33 m, CH , 5.0l s, CH2 , 7.33 s,aromatic H , 7.70 m,NH , 8.04 d,J 5Hz,NH , 8.25 s,NH , 8.88 s,NH , 9.lO m,NH . 111 a 3 2 4 Ethyl 2,3 dioxo 1 piperazinocarbox amido acetamido 3 methoxy 2 oxoacetidine b 3 Amino 3 methoxy 2 oxoazetidine c EEMI96.1 NMR DMSO d6, ppm 1.18 t,J 7Hz, CH3 , 3.40 s, CH3 , 3.47 q, J 7Hz, CH2 , 3.57 3.80 m, CH2 , 3.65 ABq, J 5, 11Hz, C4 H , 3.93 4.20 m, CH2 , 4.07 d, J 6Hz, CH2 , 7.58 s, NH , 8.70 s, NH , 9.23 t, J 6Hz, NH . 112 a 3 D 2 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 3 N methylcarbamoyl propionamido 2 phenylacetamido 2 oxo azetidine b 3 4mino 2 oxoazetidine c BEMI96.2 113 a 3 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 3 N methylcarbamoyl propionamido 2 oxoazetidine b 3 Amino 2 otoazetidine c BEMI96.3 114 a 3 2 D 2 Benzyloxycarboxamido 2 phenylacetamido 3 N methylcarbamoyl propionamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c B EMI97.1 115 a 3 D 2 3 Furfurylideneamino 2 oxoimidazolidin 1 yl carboxamido 2 phenylacetamido 3 S methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 oxoazetidine c AEMI97.2 NMR DMSO d6, ppm 3.08 s,CE3 , 3,42, 3.56 d, J 6Hz, C4 H , 3.79 s, CH2 , 5.62 d, J 7Hz, CH , 6.5 7.9 m, aromatic H , 7.73 s, CH N , 8.35 s,NH , 9.04 d,J 7Hz,NH , 9.59 s,NH . 116 a 3 D 2 3 Furfurylideneamino 2 oxo imidazolidin 1 yl carboxamido 2 phenyl acetamido 3 R methoxy 2 oxoazetidine b 3 Amino 3 methoxy 2 oxoazetidine c AEMI97.3 NMR DMSO d6,ppm 3.26, 3.42 d,J 6Hz, C4 H , 3.34 s, CH3 , 3.78 s, CH2 , 5.61 d, J 7Hz, CR , 6.5 7.9 m,aromatic H , 7.73 s, CH N , 8.23 s,NH , 8.98 d,J 7Rz, NH , 9.54 s,NH . 117 a 3 D 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 2 4 octanoyloxyphenyl acetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI97.4 118 a 3 D 3 N Ethoxycarbonylmethyl carbamoyl 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido propionamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI98.1 119 a 3 D 2 4 Ethyl 2,3 dioxo 1 piperazino carboxamido 3 2 thienylacetamido propionamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI98.2 120 a 3 N mesly D phenylglycinamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI98.3 121 a 3 D 2 2 4 Ethyl 2,3 dioxo 1 piperazinocarboxamido acetamido 2 phenylacetamido 2 oxoazetidine b 3 Amino 2 oxoazetidine c BEMI98.4 NMR DMSO d6, ppm 1.10 t, J 7Hz, CH3 , 3.00 dd, J 3,5Hz, C4 H , 3.33 3.77 m, CH2 , 3.77 4.27 m, 5H2 , 4.05 d,J 6Hz, CH2 , 4.90 m,C3 H , 5.53 d,J 9Hz, CH , 7.37 s,aromatic H , 7.97 s,NH , 8.88 d, J 9Hz, NH 9.13 d,J 9Hz, NH , 9.32 t, J 6Hz, NH . Example 1 1.23 g of 3 phenylacetamido 2 oxoazetidine is dissolved in 15 ml of N,N dimethylformamide DMF , followed by addition of 1.15 g of pyridine sulphur trioxide complex. The mixture is stirred for 6 hours.After 50 ml of diethyl ether is added, the powdery precipitate is collected by filtration and washed with ether and, then, with ethanol. By the above procedure 1.47 g of pyridinium 3 phenylacetamido 2 oxoazetidine l sulphonate is obtained.EMI99.1 NMR d6 DMSO, ppm 3.25 dd, J 3, 6Hz, C4 H , 3.46 s, CH2 , 3.62 t, j 6Hz, C4 H , 4.84 ddd, J 3,6, 8Hz,C3 H , 7.29 s,aromatic H , 7.9 9.0 m, aromatic H , 8.83 d, J 8Hz, NH . Example 2 0.21 g of 3 thienylacetamido 9 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.318 g of pyridine sulphur trioxide complex. The mixture is stirred for one day. To the reaction mixture is added 20 ml of diethyl ether and the oily precipitate is purified by Amberlite XAD II pRohm and Haas Co., U.S.A. chromatography. 0.175 g of 3 thienylacetamido 2 oxoazetidine 1 sulphonic acid is obtained.EMI99.2 NMR d6 DMSO, ppm 3.32 dd, J 3, 6Hz, C4 H , 3.61 t, J 6Hz, C4 H , 3.69 s, CH2 , 4.84 ddd, J 3,6, 8Hz, C3 H , 6,8 7,4 m, aromatic H , 8.88 d, J 8Hz, NH . Example 3 0.631 g of 3 2 2 chloroacetamido 4 thiazolyl 2 methoxyiminoacetamido 2 oxoazetidine syn isomer is dissolved in 10 ml of DMF, followed by addition of 0.637 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days. To this reaction mixture is added 30 ml of dimethyl ether, and the oily precipitate is passed through Dowex 50W resin Na form Dow Chemical U.S.A. . The eluate is freeze dried to obtain 0.89 g of crude sodium 3 2 2 chloro acetamido 4 thiazolyl 2 methoxyiminoacetamido 2 oxoazetidine 1 sulphonate syn isomer .EMI100.1 The crude sodium 3 2 2 chloroacetamido 4 thiazolyl 2 methoxyiminoacetamido 2 osoazetidine 1 sulphonate syn isomer obtained above 0.556 g is dissolved in 8 ml of water, and to the solution is dissolved i g of sodium N methyl dithiocarbamate under ice cooling and stirring. The mixture is stirred for 3 hours, after which any insoluble matter is filtered off. The filtrate is purified by XAD II chromatography to yield 0.174 g of sodium 3 2 2amino 4 thiazolyl 2 methoxyiminoacetamido 2oxoazetidine l sulphonate syn isomer .EMI100.2 NMR D2O, ppm 3.89 dd, J 4, 6Hz, C4 H , 4.03 s, CH3 , 4.09 t, J 6Hz, C4 H , 5.16 dd, J 4, 6Hz, C3 H , EMI101.1 Example 4 0.515 g of 3 2 2 chloroacetamido 4 thiazolyl acetamido 2 osoazetidine is suspended in 20 ml of DMF, followed by addition of 0.325 g of pyridine sulphur trioxide complex. The mixture is worked up as described in Example 3 to obtain 0.569 g of sodium 3 2 2 chloroacetamido 4 thiazolyl acetamido 2 oxoazetidine l sulphonate.EMI101.2 0.436 g of sodium 3 2 2 chloroacetamido thizaolyl acetamido 2 oxoazetidine l sulphonate is dissolved in 6 ml of water, and to the solution is added 0.154 g of sodium N methyldithiocarbamate under ice cooling and stirring. The mixture is treated as described in Example 3 to obtain 0.144 g of sodium 3 2 2 amino 4 thiazolyl acetamido 2 oxoazetidine 1 sulphonate.EMI101.3 Example 5 o.46 g of 3 sulphophenyl acetamido 2 oxoazetidine sodium salt is dissolved in 5 ml of DMF, followed by addition of 0.478 g oi pyridine sulphur trioxide complex. The mixture is stirred for 3 days.To the reaction mixture 30 ml of diethyl ether are added and the oily precipitate is passed throughDowex 50 W resin Na form . The eluate is purified byAmberlite XAD II chromatography. By the above procedure 0.61 g of disodium 3 a sulphophenylacetamido 2 oxoazetidine 1 sulphonate is obtained.EMI102.1 NMR d6 DMSO, ppm 3.17 dd, J 3, 6Hz, C4 H , 3.58 t, J 6Hz, C4 H , 4.56 s, CH , 4.76 M, c3 h , 7.2 7.6 m, aromatic H , 8.55 d,J 8Rz,NH . Example 6 0.285 g of 3 2 4 thyl 2,3 dioxo l piperazino carboxamido 2 phenylacetamido 2 oxoazetidine is dissolved in 3 ml of DMF, followed by addition of 0.234 g of pyridine sulphur trioxide complex. The mixture is stirred for 4 days, after which it is worked up as described in Example 5. The above procedure yields 0.219 g of sodium 3 2 4 ethyl 2,3dioxo 1 piperazinocarboxamido 2 phenylacetamido 2oxoazetidine l sulphonate .EMI102.2 NMR do DMSO, ppm 1.10 t, 7Hz, CH3 , 3.13 dd,J 3,6Hz,C4 H , 3.41 q,J 7Hz, CH2 , 3.453.65 m, CH2 , 3.59 t, J 6Hz, C4 H , 3.80 4.00 m, CH2 , 4.85 ddd,J 3,6,8Hz,C3H , 5.45 d,J 8Hz, CH , 7.2 7.5 m,aromatic H , 9.20 d,J 8Hz,NH , 9.81 d,J 8Rz,NH . Example 7 0.177 g of 3 2 benzyloxycarboxamido 2 phenyl acetamido 2 oxoazetidine is dissolved in 1 ml of DMF, followed by addition of 0.16 g of pyridine sulphur trioxide complex. The mixture is stirred for 4 days.To this reaction mixture 10 ml of diethyl ether are added and the oily precipitate is treated with ethanol to obtain 0.092 g of pyridinium 3 2 benzyloxycarboxamido 2 phenylacetamido 2 oxoazetidine 1 sulphonate.EMI103.1 NMR d6 DMSO, ppm 3.16 dd, J 4, 6Hz, C4 H , 3.57 t, J 6Hz, C4 H , 4.83 ddd, J 4,6,8Hz, C3 H , 5.07 s, CH2 , 5.26 d,J 8Hz, CR , 3.36 s, aromaticH , 7.85 broad d, NH , 7.9 90 m,aromatic H . Example 8 0.25 g of 3 benzyloxycarboxamido 3 methoxy 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.318 g of pyridine sulphur trioxide eomplex. The mixture is stirred for 5 days. By working up as described in Example 3, 0.35 g of sodium 3 benzyloxycarboxamido 3 methoxy 2 oxoazetidinel sulphonate is obtained.EMI103.2 Example 9 0.825 g of 3 2 2 chloroacetamido 4 thiazolyl 2 methoxyiminoacetamido 3 methoxy 2 oxoazetidine synisomer is dissolved in 7 ml of DMF, followed by addition of 0.796 g of pyridine sulphur trioxide complex.The mixture is reacted for 3 days. By working up as described in Example 5, 0.568 g of sodium 3 2 2chloroacetamido 4 thiazolyl 2 methoxyiminoacetamido 3 methoxy 2 osoazetidine 1 sulphonate syn isomer is obtained.EMI104.1 0.478 g of the above sodium 3 2 2 chloroacetamido 4 thiazolyl 2 methoxyiminoacetamido 3 methoxy 2 oxoazetidine 1 sulphonate syn isomer is dissolved in 7 ml of water, followed by addition of 0.13 g of sodium N methyl dithiocarbamate. The mixture is stirred for one hour. The insoluble matter is filtered off and the filtrate is purified by Amberlite IAD II chromatography, whereupon 0.267 g of sodium 3 2 2 amino 4 thiazolyl 2 methoxyiminoacetamido 3 methoxy 2 oxoazetidine 1 sulphonate syn isomer is obtained.EMI104.2 Example 10 0.15 g of 3 cyanoacetamido 2 oxoazetidine is dissolved in 0.5 ml of DMF, followed by addition of 0.30 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days, and the reaction mixture is treated as described in Example 5, whereupon 0.183 g of sodium 3 cyanoacetamido 2 oxoazetidine l sulphonate is obtained.EMI105.1 NMR D20, ppm 3.91 dd,J 2, 6Hz ,C4 H , 3.96 s, CH2 , 4.05 t, J 6Hz, C4 H , 5.08 dd, J 2,6Hz, C3 H . Example 11 0.16 g of 3 2 1w tetrazol 1 yl acetamido 2 oxoazetidine is dissolved in 1 ml of DMF, followed by addition of 0.26 g of pyridine sulphur trioxide complex.The mixture is stirred at room temperature for 3 days.By working up as described in Example 5, 0.154 g of sodium 3 2 1H tetrazol l yl acetamido 2 oxo azetidine l slllphonate is obtained.EMI105.2 Example 12 0.214 g of 3 3 2,6 dichlorophenyl 5 methyl isoxazol 4 yl carboxamido 2 oxoazetidine is dissolved in 1 ml of DMF, followed by addition of 0.20 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days. By working up as described inExample 5, 0.212 g of sodium 3 3 2,6 dichlorophenyl 5 methylisoxazol 4 yl carboxamido 2 oxoazetidine 1sulphonate is obtained.EMI106.1 NMR d6 DMSO, ppm 2.77 s, CH3 , 3.25 dd, J 2,6Hz,C4 H , 3.57 t, J 6Hz, C4 H , 4.86 ddd, J 2,6,8Hz,C3 H , 7.53 s, aromatic H , 8.74 d, J 8Hz, NH . Example 13 A solution of 0.44 g of 3 benzyloxycarboxamido 2 oxoazetidine and 0.32 g of pyridine sulphur trioxide complex in 2 ml of DMF is allowed to stand at room temperature for 2 days. By working up as described inExample 1, 0.613 g of pyridinium 3 benzyloxycarboxamido 2 oxoazetidine l sulphonate is obtained as light yellow needles. m.p. 134 138 C decomp. Elemental analysis, C16H17N3065 Calcd. C, 50.65 H, 4.52 N, 11.08 Found C, 50.57 E. 4.51 N, 11.04EMI106.2 Example 14 A mixture of 2.185 g of 3 N carbobenzo.xy Dalaninamido 2 oxoazetidine, 2.39 g of pyridinesulphur trioxide complex and 10 ml of dry DMF is stirred at room temperature for 4 days. Diethyl ether is added to this reaction mixture whereby 2.7 g of pyridinium 3 N carbobenzoxy D alaninamido 2oxoazetidine l sulphonate is obtained as colourless needles. m.p. 120 1250C decomp. EMI107.1 NMR d6 DMSO, ppm 1.22 d, J 7Hz, CH3 , 3.27 dd,J 6,2Hz, C4 H , 3.63 t, J 6Hz, C4 H , 4.03 q, J 7Hz, H , 4.90 ddd,J 8,6,211z,C3 R , 5.03 s, CR2 , 7.33 s,aromatic H , 8.0 9.1 m,aromatic H . The above pyridium 3 N carbobenzoxy D alaninamido 2 oxoazetidine 1 sulphonate 0.15 g is treated with Dowex 50 W Na form to obtain the sodium salt.To the solution 20 mg of acetic acid and 50 mg of palladium black are added, and the mixture is stirred in a hydrogen gas stream for 20 minutes. The catalyst is filtered off and the filtrate is freeze dried to obtain 84 mg of sodium 3 D alaninamido 2 oxoazetidine 1 sulphonate acetate.EMI107.2 NMR D20, ppm 1.62 d, J 7Hz, CH3 , 1.98 s, CH3 , 3.80 dd, J 2,6Hz, C4 H , 3.99 t, J 6Hz, C4 H , 4.20 q, J 7Hz, CH , 5.00 dd, J 2, 6Hz, C3 H . Example 15A mixture of 0.30 g of 3 a benzyl N carbobenzoxy gamma D glutamyl D0alaninamido 2 oxoazetidine, 0.187 g of pyridine sulphur trioxide complex and 1 ml of DMF is stirred until a homegenous solution is obtained and the solution is allowed to stand at room temperature ior 12 hours. By working up as described in Example 7, 0.26 g of pyridinium 3 alpha benzyl N carbobenzoxy gamma D glutamy D alaninamido 2 oxoazetidine 1 sulphonate is obtained as crystals.EMI108.1 The above pyridinium 3 alpha benzyl N carbebenzoxy y D glutamyl D alaninamido 2 osoazetidine l 3allphonate 0.26 g is passed through Dowex 50 W Na form , and the eluate is freeze dried and dissolved in 20 ml of water. To the solution is added 0.20 g of palladium black and the mixture is stirred in a hydrogen gas stream for an hour. The catalyst is filtered off and the filtrate is freeze dried to yield 0.1 g of sodium 3 gamma D glutamyl D alaninamido 2 oxoazetidine 1 sulphonate.EMI108.2 NMR D2O, ppm 1.43 d, J 7Hz, CH3 , 2.16 q,J 7Hz, ch2 , 2.54 t, J 7Hz, CH2 , 3.74 dd, J 2,6Hz, C4 R , 3.80 t,J 6Ez, CH , 3.97 t,J 6Hz,C H , 4.34 q, J 7Hz, CH , 4.96 dd, J 2,6Hz, C3 H . Example 16 0.13 g of pyridinium 3 benzyloxycarboxamido 2oxoazetidine l sulphonate is dissolved in 4.5 ml of 60 ethanol, followed by addition of 0.3 g of 10 palladium carbon hydrous Nippon EngelhardIndustries Ltd. . The mixture is stirred in a hydrogen gas stream at room temperature for 1.5 hours. The catalyst is filtered off and the filtrate is concentrated to give 50 mg of 3 amino 2 oxoazetidine l sulphonic acid.EMI109.1 NMR D20, ppm 3.56 dd, J 3,6Hz, C4 H , 4.05 t, J 6Hz, C4 H , 4.45 dd, J 3,6Hz, C3 H . 50 mg of the above 3 amino 2 oxoazetidine 1 sulphonate are dissolved in 1 ml of water, followed by addition of a solution of 69 mg phenylacetyl chloride in i ml tetrahydrofuran and 101 mg of sodium hydrogen carbonate in alternate portions with ice cooling and stirring. After stirring at room temperature for 30 minutes, the mixture is adjusted to pR 5.8 with phosphoric acid. The tetrahydrofuran is then distilled off under reduced pressure. The water layer is washed with ethyl acetate and purified by XAD II chromatography, whereby 42 mg of sodium 3 phenyl acetamido 2 oxoazetidine l sulphonate is obtained.EMI109.2 NMR d6 DMSO, ppm 3,27 dd,J 3,6Hz,C4 H , 3.46 s, CF , 3.60 t,J 6Rz,C4 R , 4.84 ddd,J 3,6, 8Hz,C3 H , 7.29 s,aromatic H , 8.83 d, J 8Hz, NH . Example 17 0.349 g of 3 ureidophenyl acetamido 2 oxoazetidine is dissolved in 5 ml of DMF, followed by addition of 0.955 g of pyridine sulphur trioxide complex. The mixture is stirred for 4 days. By working up as described in Example 5, the following two products are obtained. Sodium 3 a ureidophenyl acetamido 2 oxoazetidine 1 sulphonate, 86 mg.EMI110.1 NMR d6 DMSO, ppm 3.14 dd, J 3,6Hz, C4 H , 3.54 t, J 6Hz, C4 H , 4.83 ddd, J 3,6,8Hz, C3 H , 5.28 d, J 8Hz, CH , 5.68 s, NH2 , 6.80 d, J 8Hz, NH , 7.35 broad s, aromatic H , 9.12 d, J 8Hz, NH .Disodium 3 a sulphonatoureidophenylacetamido 2 oxoazetidine l sulphonate, 0.455 g.TB KBrcm . 3440 1755 1660 1520 1 30 1140 max 1040.EMI110.2 Example 18 0.313 g oi 3 2 4 ethyl 2,3 dioxo 1 piperazino carbosamido 2 phenylacetamido 3 methoxy 2 oxoazetidine is dissolved in 3 ml of DMF, followed by addition of 0.359 g of pyridine sulphur trioxide complex. The mixture is stirred for 5 days, and the reaction mixture is treated in the manner as described in Example 5, 0.202 g of sodium 3 2 4 etbyl 2,3 dioxo 1 piperazinocarboxamido 2 phenylacetamido 3 methoxy 2osoazetidine l sulphonate is obtained. EMI111.1 Example 19 0.404 g of 3 2 4 ethyl 2,3 dioxo 1 piperazino carboxamido 4 hydroxyphenylacetamido 2 oxoazetidine is dissolved in 4 ml of DMF, followed by addition of 0.637 g of pyridine sulphur trioxide complex. The mixture is stirred for 4 days, and the reaction mixture is treated in the manner as described in Example 5, whereby 0.203 g of disodium 3 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 4 sulphonatoxyphenyl acetamido 2 oxoazetidine 1 sulphonate is obtained.EMI111.2 N R d6 DMSO, ppm 1.09 t, J 7Hz, CH3 , 3.19 dd,J 3, 5Hz,C4 H , 3.42 q, J 7Hz, CH2 , 4.86 m,C3 R , 5.40 d, J 7Hz, CH , 7.24 ABq, J 9,17Hz, aromaticH , 9.20 d, J 8Hz, NH , 9.76 d, J 7Hz, NH . Example 20 0.404 g of 3 2 4 ethyl 2,3 dioxo 1 piperazino carboxamido 2 4 hydroxyphenyl acetamido 2oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.191 g of pyridine sulphur trioxide complex. The mixture is stirred for 4 days. By working up as described in Example 5, 0.096 g of disodium 3 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 4 sulphonatoxyphenyl acetamido 2 oxoazetidine 1sulphonate and 0.08 g of sodium 3 02 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 4 hydroxyphenyl acetamido 2 oxoazetidine 1 sulphonate are obtained.Properties of the latter compound EMI112.1 NMR d6 DMSO, ppm 1.09 t, J 7Hz, CH3 , 2.97 dd,J 3, 5Hz,C4 E , 3.34 q, J 7Hz, CH2 , 3.35 t,J 5hZ, C4 H , 4.84 m, C3 H , 5.40 d, J 7Hz, CH , 7.24 ABq, J 8,16Hz, aromatic E , 7.99 s,OR , 9.l0 d,J 8Hz,NH , 9.77 d,J 7Rz,NH . Example 21 0.128 g of 3 4 ethyl 2,3 dioxo 1 piperazino carboxamido 2 oxoazetidine is dissolved in 3 ml of RDF, followed by addition of 0.16 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days.By working up as described in Example 5, 0.095 g of sodium 3 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 oxoazetidine 1 sulphonate is obtained.EMI112.2 Example 22 0.326 g of 3 N 4 ethyl 2,3 dioxo 1 piperazino carbonyl D alaninamido 2 oxoazetidine is dissolved in 3 ml of RIF, followed by addition of 0.319 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days, and the reaction mixture is treated in the manner as described in Example 5, whereby 0.253 g of sodium 3 N 4 ethyl 2,3 dioxo 1 piperazinocarbonyl D alaninamido 2 otoazetidine 1 sulphonate is obtained.EMI112.3 Example 23 0.152 g of 3 amino 2 oxoazetidine is added to 2 ml of DEIF, followed by addition of 0.315 g of 2,4 dioxo 5 phenyl l,3 dioxolan in small portions. After 10 minutes, 0.563 g of pyridine sulphur trioxide complex is added. The mixture is allowed to stand at room temperature for 3 days, and the reaction mixture is treated in the manner as described in Example 5.The above procedure yields 0.790 g of disodium 3 alpha sulphonatoxyphenylacetamido 2 oxoazetidine 1 sulphonate.EMI113.1 NMR d6 DMSO, ppm 3.32 dd, J 2,5.5Hz, C4 H , 3.52 t, J 5.5Hz, C4 H , 4.77 ddd, J 2,8,5.5Hz, C3 R , 5.39 s, CH , 7.33 s,aromatic H , 8.63 d, J 8Hz, NH . Example 24 0.157 g of 3 2 syn methoxyimino 2 phenyl acetarnido 2 oxoazetidine is dissolved in 1 ml of DMF, followed by addition of 0.202 g of pyridine sulphur trioxide complex. The mixture is allowed to stand at room temperature for 3 days, and the reaction mixture is treated in the manner as described in Example 5.The above procedure yields 0.183 g of sodium methoxyimino 2 phenylacetamido 2 oxoazetidine 1sulphonate.EMI113.2 NMR DMSO d6, ppm 3.67 t, J 5.5Hz, C4 H , 3.90 s, OCH3 , 4.95 ddd, J 2,8,5.5Hz, C3 H , 7.3 7.7 m, aromatic H , 9.38 d, J 9Hz, NH . Example 25 0.18 g of pyridinium 3 methoxy 3 benzyloxycarboxamido 2 oxoazetidine l sulphonate is dissolved in 3 ml of 60 ffi ethanol, followed by addition of 0.15 g of 10 palladium carbon. The mixture is stirred in a hydrogen gas stream at room temperature for an hour, and the catalyst is filtered off. The filtrate is concentrated to give 35 mg of 3 amino 3 methoxy 2 oxoazetidine l sulphonic acid.EMI114.1 NMR D20, ppm 3.76, 4.25 ABq, J 6Rz,C4 R , 3.52 s, OCH3 . 30 mg of the above 3 amino 3 methoxy 2 oxoazetidine 1 sulphonic acid are dissolved in 1 ml of water, and to the solution are added a solution of 89 mg of the acid chloride prepared from 2 2 chloroacetamido 4 thiazolyl 2 methoxyiminoacetic acid syn isomer in 1 ml of tetrahydrofuran and 36 mg of sodium hydrogen carbonate in alternate portions with ice cooling and stirring. The mixture is further stirred at room temperature for 20 minutes and adjusted to pH 5.8 with phosphoric acid. After rembval of tetrahydrofuran under reduced pressure, the water layer is washed with ethyl acetate and purified byAmberlite gAD II chromatography.The above procedure yields 28 mg of sodium 3 2 2 chloroacetamido 4thiazolyl 2 methoxyiminoacetamido 3 methoxy 2oxoazetidine l sulphonate syn isomer which is the same compound as the one described in Example 9. Example 26 0.126 g of 3 D 2 4 ethyl 2,3 dioxo 1 piperazinocarbosamido 2 4 methoxyphenyl acetamido 3 2 osoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.095 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days, after which it is treated as described in Example 5. The above procedure provides 0.071 g of sodium 3 D 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 4methoxyphenyl acetamido 2 oxoazetidine 1 sulphonate.EMI115.1 NMR d6 DMSO, ppm 1.10 t, J 7Hz, CH3 , 3.12 dd, J 3,6Hz, C4 H , 3.40 q, J 7Hz, CH2 , 3.57 t,J 6Ez,C4 E , 3.4 4.0 m, CH2 , 3.76 s,oCH3 , 4.84 ddd, J 3,6,8Hz, C3 H , 5.36 d, J 7Hz, CH , 6.92, 7.33 ABq, J 8Hz, aromatic H , 9.16 d, J 8Hz,NH , 9.73 d, J 7Hz, NH . Example 27 0.446 g of 3 D 2 2 2 chloroacetamido 4thiazolyl 2 methoxyiminoacetamido 2 phenylacetamido 2 oxoazetidine a mixture of syn and anti isomers, is dissolved in 4 ml of DMF, followed by addition of 0.297 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days and worked up in the manner as described in Example 5. The above procedure provides 0.327 g of sodium 3 D 2 2 2 chloro acetamido 4 thiazolyl 2 methoxyiminoacetamido 2 phenylacetamido 2 oxoazetidine l sulphonate a mixture of syn and anti isomers .EMI115.2 NMR d6 DMSO, ppm 3.17 dd, J 3,6Hz, C4 H , 3.62 t, J 6Hz, C4 H , 3.89, 4.04 s, CH3 , 4.40 s,ClCH2 , 4.90 ddd, J 3,6,8Hz, C3 H , 5.61, 5.63 d, J 8hZ, CH , 7.2 7.6 m, aromatic H , 7.46, 8.01 s, , 9.01, 9.14 d,J 8Hz,NH , 8.84, 9.32 d, J 8Hz, NH , 12.6 broad s, NH . 0.233 g of the above sodium 3 D 9 2 2 chloroacetamido 4 thiazolyl 2 methoxyiminoacetamido 2 phenylacetamido 2 oxoazetidine 1 sulphonate a mixture of syn and anti isomers is dissolved in 3 ml of water, and under ice cooling and stirring, 0.057 g of sodium N methyldithiocarbamate is added, followed by stirring for 45 minutes. The insoluble matter is filtered off and the filtrate is purified by Amberlite XAD II chromatography. The procedure provides 0.053 g of sodium 3 D 2 2 2 amino 4 thiazolyl 2 methoxy iminoacetamido 2 phenylacetamido oxoszetidine l sulphonate syn isomer and 0.087 g of the antiisomer. ayn isomer EMI116.1 Anti isomer EMI116.2 Example 28 0.302 g of 3 D 2 4 bromo 1,4 dihydro 1 ethyl 4 oxothieno 2,3 b pyridine 3 carboxamido 2 phenyl acetamido 2 oxoazetidine is dissolved in 4 ml of DMF, followed by addition of 0.191 g of pyridine sulphur trioxide complex. The reaction mixture is stirred for one day and worked up in the manner as described inExample 5. The above procedure provides 0.17 g of sodium 3 D 2 6 bromo 1,4 dihydro 1 ethyl 4 oxo thieno 2,9 b pyridine 3 carbo.xamido 2 phenylacetamido 9 oxoazetidine l sulphonate. EMI117.1 NMR d6 DMSO, ppm 1.43 t, J 7Hz, CH3 , 3.15 dd, J 3, 6Hz, C4 H , 3.59 t,J 6Hz,C4 H , 4.27 q,J 7Hz,4.86 ddd, J 3,68Hz, C3 H , 5.78 d,J 8Hz, CH , 7.2 7.5 m,aromatic H , 7.62 s,aromaticH , 8.69 s,aromatic H , 9.22 d, J 8Hz, NH , 10.95 d, J 8Hz, NH . Example 29 0.729 g of 3 2 4 ethyl 2,3 dioxo 1 piperazino carboxamido 2 2 chloroacetamido 4 thiazolyl acetamido 2 oxoazetidine is dissolved in 6 ml of DMF, followed by addition of 0.478 g of pyridine sulphur trioxide complex. The mixture is stirred for 2 days and, then, worked up as described in Example 5. The above procedure provides 0.434 g of sodium 3 2 4ethyl 2,3 dioxo 1 piperazinocarboxamido 2 2 chloroacetamido 4 thiazolyl acetamido 2 oxoazetidine 1sulphonate.EMI117.2 NMR d6 DMSO, ppm 1.10 t, J 7Hz, CH3 , 3.19 dd, J 3,6Hz, C4 H , 3.43 q, J 7Hz, CH2 , 3.56 t,J 6Hz,C4 R , 4.36 s, CE2Cl , 4,80 and 4.86 m, C3 H , 5.54 d, J 7Hz, CH , 7.21 s, , 9.01, 9.07 d, J 8Hz, NH , 9.74 d, J 7Hz, NH , 12.7 broad s,NH . 0.235 g of the above sodium 3 2 4 ethyl 2,3dioxo 1 piperazinocarboxamido 2 2 chloroacetamido 4 thiazolyl acetamido 2 oxoacetidine 1 sulphonate is dissolved in 3 ml of water and, under ice cooling and stirring, 0.057 g of sodium N methyldithiocarbamate is added. The mixture is stirred for 30 minutes, after which the insolubles are filtered off. The filtrate is purified by Amberlite XAD II chromatography to provide 0.13 g of sodium 3 2 4 ethyl 2,3 dioxo 1 piperazino carboxamido 2 2 amino 4 thiazolyl acetamido 2oxoazetidine l sulphonate.EMI118.1 Example 30 0.303 g of 3 2 4 ethyl 2,3 dioxo l piperazinocarboxamido 2 2 acetamido 4 thiazolyl acetamido 0 oxoazetidine is dissolved in 3 ml ofDMF, followed by addition of 0.213 g of Pyridine sulphur trioxide complex. The mixture is stirred for 3 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.101 g of sodium 3 2 4 ethyl 2,3 dioxo 1 piperazinocarbogamido 2 2 acetamido 4 thiazolyl acetamido 2oxoazetidine l sulphonate.EMI119.1 Example 31 0.635 g of 3 2 2 2 chloroacetamido 4 thiazolyl 2 methoxyiminoacetamido 2 2 chloroacetamido 4 thiazolyl acetamido 2 oxoazetidine syn isomer is dissolved in 5 ml of DMF, followed by addition of 0.35 g of pyridine sulphur trioxide complex. The mixture is stirred for one day and, then, worked up in the manner as described in Example 5. The above procedure provides 0.271 g of sodium 3 2 2 2chloroacetamido 4 thiazolyl 2 methoxyiminoacetamido 2 2 chloroacetamido 4 thiazolyl acetamido 2 oxoazetidine 1 sulphonate syn isomer .EMI119.2 0.204 g of the above sodium 3 2 2 2 chloro acetamido 4 thiazolyl 2 methoxyiminoacetamido 2 2chloroacetamido 4 thiazolyl acetamido 2 oxoazetidine 1 sulphonate syn isomer is dissolved in 3 ml of water and, while the solution is stirred under ice cooling, 0.085 g of sodium N methyldithiocarbamate is added.The mixture is stirred for an hour, after which the insoluble matter is filtered off. The filtrate is purified by Amberlite XAD II chromatography to provide 0.1 g of sodium 3 2 2 2 a.mino 4 thiazolyl 9 methoxyiminoacetamido 2 2 amino 4 thiazolyl acotamido 2 oxoazetidine l sulphonate syn isomer .EMI120.1 Example 32 0.283 g of 3 D 2 4 n octyl 2,3 dioxo1 piperazinocarboxamido 2 phenylacetamido 2 oxoazetidine is dissolved in 3 ml of DMF, followed by addition of 0.191 g of pyridine sulphur trioxide complex. The mixture is stirred for one day and worked up in the manner as described in Example 5. The above procedure provides 0.234 g of sodium 3 D 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2 phenylacetamido 2 oxoazetidine l sulphonate. EMI120.2 NMR d6 DMSO, ppm 0.86 t,CH3 , 3.12 dd,J 3,6Rz, C4 H , 3.4 4.1 m, CH2 , 4.86 ddd, J 3,6,8Hz, C3 H , 5.45 d, J 7Hz, CH , 7.40 s,aromatic H , 9.25 d, J 8Hz, NH , 9.81 d, J 7Hz, NH . Example 33 0.274 g of 3 D 2 coumarin 3 carboxamido 2 phenylacetamido 2 oxoazetidine is suspended in 3 ml of DMF, followed by addition of 0.223 g of pyridinesulphur trioxide complex. The mixture is stirred for 2 days and worked up in the manner as described inExample 5. The above procedure provides 0.094 g of sodium 3 D 2 courmarin 2 carboxamido 2 phenylacetamido 2 oxoazetidine 1 sulphonate.EMI121.1 NMR d6 DMSO, ppm 3.18 dd, J 3,6Hz, C4 H , 3.54 t, J 6Hz, C4 H , 4.90 ddd, J 3,6,8Hz, C3 H , 5.67 d, J 7Hz, CH , 7.3 8.1 m, aromatic H , 8.89 s, aromatic H , 9.32 d, J 8Hz,NH ,9.65 d,J 7Hz,NH . Example 34 0.454 g of 3 2 4 n octyl 2,3 dioso 1 piperazinocarboxamido 2 2 chloroacetamido 4thiazolyl acetamido 2 oxoazetidine is dissolved in 4 ml of DMF, followed by addition of 0.255 g of pyridine sulphur trioxide comples. The mixture is stirred for one day, and worked up in the manner ofExample 5. The above procedure provides 0.182 g of sodium 3 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2 2 chloroacetamido 4 thiazolyl acetamido 2 oxoazetidine 1 sulphonate.EMI121.2 1190, 1050. NMR d6 aiSO,ppm 0.86 t, CR3 , 4.36 s,ClCR2 , 4.82 m, C3 H , 5.53 d, J 7Hz, CH , 7.20 s, 8.98, 9.04 d, J 8Hz, NH , 9.72 d, J 7Hz,NH , 12.63 broad s,NH . 0.115 g of the above sodium 3 2 4 n octyl 2, 3 dioso 1 piperazinocarboxamido 2 2 chloroacetamido 4 thiazolyl acetamido 2 oxoazetidine 1 sulphonate is dissolved in 2 ml of water and, under ice cooling and stirring, 0.025 g of sodium monomethyldithiocarbamate i8 added. The mixture is stirred for 93 minutes, after which the insoluble matter is filtered off. The filtrate is purified by Amberlite SAD II chromato graphy to provide 0.046 g of sodium 3 2 4 n octyl 2 3 dioxo 1 piperazinocarboxamido 2 2 amino 4thiazolyl acetamido 2 oxoazetidine 1 sulphonate.EMI122.1 Example 35 0.161 g of 3 D 2 4 hydroxy 7 trifluoromethyl quinoline 2 carboxamido 2 phenylacetamido 2oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.112 g of pyridine sulphur trioxide complex. The mixture is stirred for one day and, then, worked up in the manne r of Example 5. The above procedure provides 0.095 g of sodium 3 D 2 4hydroxy 7 trifluoromethylquinoline 3 carboxamido 2 phenylacetamido 2 oxoazetidine 1 sulphonate.EMI123.1 NMR d6 DMSO, ppm 3.30 dd, J 3,6Hz, C4 H , 3.66 t,J 6Hz, C4 H , 4.88 ddd,J 3,6,8Hz,C3 H ,5.70 d,J 8Rz, CH , 7.3 8.9 m,aromatic H , 9.21 d, J 8Hz, NH , 10.80 d, J 8Hz, NH . Example 36 0.34 g of 3 D 2 2 oxo 3 furfurylideneamino imidazolidin 1 yl carboxamido 2 phenylacetamido 2oxoazetidine is dissolved in 5 ml of bS, followed by addition of 0.255 g of pyridine sulphur trioxide complex. The mixture is stirred for one day and, then, worked up in the manner of Example 5. The above procedure provides 0.071 g of sodium 3 D 2 oxo 3 furfurylideneaminoimidazolidin 1 yl carboxamido 2 phenylacetamido 2 oxoazetidine 1 sulphonate.EMI123.2 NMR d6 DMSO, ppm 3.12 dd, J 3,6Hz, C4 H , 3.58 t, J 6Hz, C4 H , 3.80 s, CH2 , 4.86 ddd, J 3,6, 8Hz, C3 H , 5.45 d, J 8Hz, CH , 6.5 7.9 m, aromatic H , 7.75 s, 5H N , 9.04 d, J 8Hz, NH , 9.24 d, J 8Hz, NH . Example 37 0.287 g of 3 2 4 n octyl 2,3 dioxo lpiperazino carboxamido 2 thienylacetamido 2oxoazetidine is dissolved in 2 ml of DINT, followed by addition of 0.191 g of pyridine sulphur trioxide complex. The mixture is stirred for one day and, then, worked up in the manner of Example 5. The above procedure provides 0.299 g oi sodium 3 2 4 n octyl2,3 dioxo 1 piperazinocarboxamido 2 thienylacetamido 2 oxoazetidine l sulphonate. EMI124.1 NMR d6 DMSO, ppm 0.86 t, CH3 , 3.4 4.1 m, CH2 , 4.86 m, C3 H , 5.72 d, J 7Hz, CH , 6.9 7.6 m, thienyl R , 9.26 and 9.30 d,J 8Rz,NH , 9.73 d, J 7Hz, NH . Example 38 0.439 g of 3 D 2 4 n octyl 2,3 dioxo l piperazinocarboxamido 2 4 hydroxyphenyl acetamido 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.172 g of pyridine sulphur trioxide complex. The mixture is stirred for 2 days and, then, worked up in the manner of Example 5. The above procedure provides the following two products Sodium 3 D 2 4 n octyl 2,3 dioxo 1piperazinocarboxamido 2 4 hydroxylphenyl acetamido 2 oxoazetidine 1 sulphonate 0.213 g .EMI124.2 NMR d6 DMSO, ppm 0.86 t, CH3 , 2.96 dd,J 3, 6Hz,C4 R , 4.86 m,C3 R , 5.40 d,J 7Hz, CH , 7.13 ABq, J 8,18Hz, aromatic H , 9.10 d, J 8Hz,NH , 9.78 d, J 7Hz, NH .Disodium 3 D 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2 4 sulphonatoxyphenyl acetamido 2oxoazetidine l sulphonate 0.12 g . EMI125.1 NMR d6 DMSO, ppm 0.86 t, CH3 , 3.16 dd, J 3,6Hz, C4 H , 4.86 m,C3 H , 5.38 d, J 7Hz, CH , 7.23 ABq,J S,15Hz, aromatic H , 9.19 d, J 8Hz, NH , 9.76 d,J 7Hz,NH . Example 39 0.441 g of 3 D 2 2 oxo 3 furfurylideneamino imidazolidin 1 yl carboxamido 2 4 hydroxyphenyl acetamido 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.191 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days and, then, worked up in the manner of Example 5. The above procedure provides the following two products Sodium 3 D 2 2 oxo 3 furfurylideneaminoimidazolidin 1 yl carboxamido 2 4 hydroxyphenyl acetamido 2 oxoazetidine 1 sulphonate 0.026 g .EMI125.2 Disodium 3 D 2 2 oxo 3 furfurylideneaminoimidazolidin 1 yl carboxamido 2 4 sulphonatoxyphenyl acetamido 2 oxoazetidine 1 sulphonate 0.025 g .EMI125.3 Example 40 0.25 g of 3 2 2 oxo 3 furfurylideneamino imidazolidin l yl carbosamido 2 thienylacetamido 2 oxoazetidine is suspended in 5 ml of DMF, followed by addition of 0.185 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days and, then, worked up in the manner of Example 5. The above procedure provides 0.121 g of sodium 3 2 2 oxo 3 furfurylideneaminoimidazolidin 1 yl carboxamido 2 thienylacetamido 2 oxoazetidine 1 sulphonate. EMI126.1 NMR d6 DMSO, ppm 3.19, 3.25 dd, J 3,6Hz, C4 R , 3.63, 3,65 t, J 6Hz, C4 H , 3.81 broad s, ring CH2 , 4.88 m, C3 H , 5.72 d, J 7Hz, CH , 6.5 7.9 m, aromatic H , 7.75 s, CH N , 8.97, 8.98 d, J 7Hz, NH , 9.26, 9.29 d, J 8Hz, NH . Example 41 0 .441 g of 3 rD 2 2 o.so 3 thiophene 2 aldoimino imidazolidin 1 yl carboxamido 2 phenyl acetamido 2 oxoazetidine is suspended in 6 ml of DMF, followed by addition of 0.319 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days, and then worked up in the manner of Example 5. The above procedure provides 0.208 g of sodium 3 D 2 2 oxo 3 thiophene 2 aldoimino imidazolidin 1 yl carboxamido 2 phenylacetamido 2 oxoazetidine 1sulphonate.EMI126.2 NMR d6 DMSO, ppm 3.14 dd, J 3,6Hz, C4 H , 3.59 t, J 6Hz, C4 H , 3.82 broad s, CH2 , 4.87 ddd, J 3,6,8Hz, C3 H , 5.45 d, J 8Hz, CH , 7.07.7 m,aromatic H , 8.10 s, CH N , 9.06 d,J 8Hz,NH , 9.24 d,J 8Hz,NH . Example 42 0.49 g of 3 2 4 ethyl 2,3 dioxo l piperazinocarboxamido 2 2 pyrrolyl acetamido 2oxoazetidine is dissolved in 5 ml of DMF, followed by addition of 0.312 g of pyridine sulphur trioxide complex. The mixture is stirred for 4 days and, then, worked up in the manner of Example 5. The above procedure provides 0.228 g of sodium 3 t2 4 ethyl 2, 3 dioxo 1 piperazinocarboxamido 2 2 pyrrolyl acetamido 2 oxoazetidine l sulphonate.EMI127.1 NMR d6 DMSO,ppm 1.09 t, J 7Hz, CH3 , 3.21 dd,J 3,6Hz, C4 H , 3.41 q, J 7Hz, CH2 , 3.4 4.1 m, CH2 , 4.86 m, C3 H , 5.44 d, J 7Hz, CH , 5.9 6.8 m,pyrrolyl H , 9.01 d,J 8Hz,NH , 9.55 d, J 8Hz, NH , 10.7 broad s, NH . Example 43 A 0.203 g of an equimolar mixture of 3 D 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2thienylacetamido 3 S methoxy 2 oxoazetidine and 3 L 2 4 n octyl 2,3 dioso 1 piperazinocarboxamido 2 thienylacetamido 3 R methoxy 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.128 g of pyridine sulphur trioxide complex. The mixture is stirred for 2 days and, then, worked up in the manner of Example 5.The above procedure provides 0.136 g of an equimolar mixture of sodium 3 D 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2 thienylacetamido 3 S methoxy 2 oxoazetidine 1 sulphonate and sodium 3 iL 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2 thienylacetamido 3 R methoxy 2 oxoazetidine l sulphonate. EMI128.1 NMR d6 DMSO, ppm 0.86 t, CH3 , 3.16 s, OCH3 , 3.56 and 3.72 ABq, J 6,16Hz, C4 H , 5.92 d, J 7Hz, CH , 6.9 7.6 m, thienyl H , 9.72 d, J 7Hz, NH , 9.80 s, NH . B 0.095 g of an equimolar mixture of 3 fI 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2 thienyl acetamido 3 R methoxy 2 oxoazetidine and 3 L 2 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2thienylacetamido 3 S methoxy 2 oxoazetidine is dissolved in 1 ml of DMF, followed by addition of 0.09 g of pyridine sulphur trioxide complex. The mixture is stirred for 2 days and, then, worked up in the manner of Example 5. The above procedure provides 0.06 g of an equimolar mixture of sodium 3 pD 2 4 n octyl 2, 3 dioxo 1 piperazinocarboxamido 2 thienylacetamido 3 R methoxy 2 oxoazetidine l sulphonate and sodium 3 pL,2 4 n octyl 2,3 dioso 1 piperazinocarbosamido 2 thientlacetamido 3 s methoxy 2 oxoazetidine 1sulphonate.EMI128.2 NMR d6 DMSO,ppm 0.86 t, CE3 , 3.35 s,0CH3 , 5.88 d, J 7Hz, CH , 6.9 7.6 m, thienyl H , 9.68 d,J 7Rz,NH , 9.78 s,NH . Example 44 0.202 g of a mixture of 3 D alpha sulphophenyl acetamido 3 R methoxy 2 oxoazetidine sodium salt and 3 D alpha p sulphophenylacetamido 3 S methoxy 2 oxoazetidine sodium salt is dissolved in 3 ml of DMF, followed by addition of 0.191 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days, after which it is treated as described in Example 5.The above procedure provides 0.039 g of a mixture of disodium 3 D alpha sulphophenylacetamido 3 R methoxy 2 oxoazetidine l sulphonate and sodium 3 D a sulphophenylacetamido 3 S methoxy 2 oxoazetidine 1sulphonate.EMI129.1 Example 45 0.500 g of 3 benzyloxycarbonyl D alanyl D phenylglycylamino 2 oxoazetidine and 0.375 g of pyridine sulphur trioxide complex are dissolved in 2 ml of DMF. The mixture is stirred for 3 days, after which diethyl ether is added. The resultant oily precipitate is passed through Dowex 50W Na form resin and the eluate is purified by Amberlite XAD II chromatography to provide 0.453 g of sodium 3 benzyloxycarbonyl D alanyl D phenylglycylamino 2 ozoazetidinel sulphonate.EMI129.2 NMR d6 DMSO, ppm 1.20 d, J 6Hz, CH3 , 3.10 dd,J 3,6Hz, C4 H , 3.54 t, J 6Hz, C4 H , 4.17 t, J 6Hz, 9H , 4.82 ddd, J 3,6,8Hz, C3 H , 4.99 5, CR2 , 5.40 d,J 9Rz, CR , 8.30 d,J 9Hz, NH , 9.08 d,J 9Hz,NH . 0.115 g of the above sodium 3 benzyloxycarbonyl D alanyl D phenylglycyclamino 2 oxoazetidine 1sulphonate is dissolved in 10 ml of water and, after the addition of 0.065 g of palladium black, the mixture is stirred in a hydrogen gas stream at room temperature for 45 minutes. The catalyst is filtered off and the filtrate is freeze dried, whereby 0.085 g of sodium 3 D alanyl D phenylglycylamino 2oxoazetidine l sulphonate is produced.EMI130.1 NMR d6 DMso,ppm 1.16 d,J 6Hz,CH3 , 3.13 dd, J 3,6Hz,C4 H , 3.55 t,J 6Hz,C4 E , 4.17 t,J 6Hz, CH , 4.82 ddd, J 3,6,8Hz, C3 H , 5.41 d,J 9Hz,NH , 7.31 s, aromatic H , 8.31 d,J 8Hz, NH , 9.16 d, J 8Hz, NH . Example 46 0.401 g of 3 rD 2 2 ureido 2 thienyladetamido 2 phenylacetamido 2 oxoazetidine and 0.239 g of pyridine sulphur trioxide complex are dissolved in 4 ml of DMF. The mixture is allowed to stand at room temperature for 3 days, after which it is treated as described in Example 1. The above procedure provides 0.180 g of pyridium 3 D 2 2 ureido 2 thienylacetamido 2 phenylacetamido 2 oxoazetidine 1 sulphonate. EMI130.2 Example 47 0.200 g of 3 cyanomethyl thioacetamido 2oxoazetidine and 0.318 g of pyridine sulphur trioxide complex are dissolved in I ml of DMF. The mixture is stirred for 3 days, after which diethyl ether is added.The resultant oily precipitate is passed through Dowex SOW Na form resin to obtain 0.390 g of sodium 3 cyanomethylthioacetamido 2 oxoazetidine 1 sulphonate . EMI131.1 NMR d6 DMSO, ppm 3.27 dd, J 3,6Hz, C4 H , 3.35 s, CH2 , 3.66 t,J 6Rz,C4 H , 3.70 s, CH2 , 4.80 ddd, J 3,6,8Hz, C3 H , 8.93 d, J 8Hz, NH . Example 48 0.330 g of 3 D 2 2 2 chloroacetamido 4 thiazolyl acetamido 2 phenylacetamido 2 oxoazetidine and 0.240 g of pyridine sulphur trioxide complex are dissolved in 3 ml of DMF. The mixture is stirred for 3 days, after which it is treated as described in Example 5. The above procedure provides 0.110 g of sodium 3 D 2 2 chloroacetamido 4 thiazolyl acetamido 2 phenylacetamido 2 osoazetidine l sulphonate.EMI131.2 NMR d6 DMSO, ppm 3.17 dd, J 3,6Hz, C4 H , 3.60 t,J 6Hz, C4 H , 3.66 s, CH2 , 4.39 s, ClCH2 , 4.86 ddd,J 3,6,8Hz,C3 H , 5.50 d,J 8Hz, CH , 6.99 s, thiazole H , 7.2 7.6 s,aromatic H , 8.60, 9.13 each d,J 8Hz,NH . 0.164 g of the above product is dissolved in 4 ml of water and, while the solution is stirred under ice cooling, 0.043 g of CE3NHCS2Na is added. Then, the mixture is stirred at room temperature for 20 minutes, and the precipitate is removed by filtration.The filtrate is purified by Amberlite XAD II chromatography to yield 0.075 g of sodium 3 tD 2 2 amino 4 thiazolyl acetamido 2 phenylacetamido oxoazetidine l sulphonate. EMI132.1 NMR d6 DMSO, ppm 3.16 dd, J 3,6Hz, C4 H , 3.48 s, CH2 , 3.63 t, J 6Hz, C4 H , 3.7 br. sNH2 , 4.85 ddd, J 3,6, 8Hz, C3 H , 5.47 d, J 7Hz, CH , 6.36 s, thiazole H , 7.37 br. s , 8.57 d, J 8Hz,NH , 9.10 d, J 7Hz, NH . Example 49 A 0.650 g of 3 DL 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 thienylacetamido 2oxoazetidine and 0.579 g of pyridine sulphur trioxide complex are dissolved in 2 my of DMF. The mixture is stirred for 30 hours, after which it is treated as described in Example 5. The above procedure provides 0.444 g of sodium 3 rDL 2 4 ethyl 2,3 dioxo l piperazinocarboxamido 2 thienylacetamido 2oxoazetidine 1 sulphonate. 25 alpha 3.5 c 0.627, H2O .D EMI132.2 NMR d6 DMSO, ppm 1.12 t, J 7Hz, CH3 , 3.13 dd, J 3, 6Hz, C4 H , 3.38 q, J 7Hz, CH2 , 3.78 t, J 6Hz, C4 H , 4.83 ddd, J 3, 6, 8Hz, C3 H , 5.68 d, J 7Hz, CH , 9.27, 9.30 1 1, d, J 8Hz, NH , 9.72 d, J 7Hz, NH . B 0.600 g of 3 rD 2 4 ethyl 2,3 dioxo l piperazinocarboxamido 2 thienylacetamido 2oxoazetidine, and 0.40 g of pyridine sulphur trioxide complex are dissolved in 2 ml of DMF. The mixture is treated as described in A to obtain 0.402 g of sodium 3 D 2 4 ethyl 2,3 dioxo 1 piperazinocarbox amido 2 thienylacetamido 2 oxoazetidine 1 sulphonate. 37.8 c 0.761,H2O . NMR d6 DMSO, ppm 9.30 d, J 8Hz, C3 CONH , other signals agreeing with those of the product obtained in A . C 0.473 g of 3 L 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 thienylacetamido 2oxoazetidine and 0.315 g of pyridine sulphur trioxide complex are dissolved in 2 ml of DMF. The mixture is treated as described in A to obtain 0.206 g of sodium 3 L 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 thenyl acetamido 2 oxoazetidine 1sulphonate. 42.4 c 0.321,H2O . NMR d6 DMSO, ppm 9.27 d, J 8Hz, NH , other signals agreeing with those of the product obtained in A . Example 50 0.290 g of 3 2 thienyl 2 methoxyiminoacetamido 2 oxoa zetidine and 0.437 g of pyridine sulphur trioxide complex are dissolved in 2 ml of DMF. The mixture is stirred for 19 hours, and diethyl ether is added. The oily precipitate is washed with methanol to obtain 0.310 g of pyridinium 3 2 thienyl 2 methoxyiminoacetamido 2 oxoazetidine l sulphonate.EMI133.1 NMR d6 DMSO, ppm 3.48 dd, J 3,6Hz, C4 H , 3.65 t, J 6Hz, C4 H , 4.07 s, CH3 , 4.95 ddd, J 3,6,8Hz, C H . 3 Example 51 0.300 g of 3 2 thienyl 2 3 morpholinopropoxy imino acetamido 2 oxoazetidine and 0.217 g of pyridine sulphur trioxide complex are dissolved in 1.5 ml of DMF. The mixture is stirred for 2 days, after which it is treated as described in Example 5.The above procedure provides 0.313 g of sodium 3 L2 thienyl 2 3 morpholinopropoxyimino acetamido 2 oxoazetidine l sulphonate.EMI134.1 NMR d6 DMSO,ppm 3.0 4.0 m , 4.96 ddd,J 3,6,8Hz, C3 H , 7.05 7.45, 7.6 7.9 m,aromatic E ,9.48 d, J 8Hz, NH . Example 52 0.223 g of 3 D 2 DL 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 thienylacetamido 2 phenyl acetamido 2 oxoazetidine and 0.141 g of pyridinesulphur trioxide complex are dissolved in 0.5 ml ofDMF. The mixture is stirred for 30 hours, after which it is treated as described in Example 5. The above procedure provides 0.290 g of sodium 3 LD 2 LDl 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 thienylacetamido 2 phenylacetamido 2 osoazetidine l sulphonate.EMI134.2 Example 53 0.167 g of 3 t2 2,5 dioso 1,2,4 triazino 6 carboxamido 2 thienylacetamido 2 oxoazetidine and 0.117 g of pyridine sulphur trioxide complex are dissolved in 1 ml of DMF. The mixture is stirred for 3 days, after which it is treated as described inExample 5. The above procedure provides 0.052 g of sodium 3 t2 2,5 dioxo 1,2,4 triazino 6 carboxamido 2 thienylacetamido 2 oxoazetidine 1 sulphonate.EMI135.1 Example 54 0.530 g of 3 t2 4 ethyl 2,3 dioso 1 piperazinocarboxamido 2 2 methyl 4 thiazolyl acetamido 2 oxoazetidine and 0.413 g of pyridinesulphur trioxide complex are dissolved in 2 ml of DMF.The mixture is stirred for 3 days, after which it is treated as described in Example 5. The above procedure provides 0.270 g of 3 r2 4 ethyl 2,3 dioxo l piperazinocarboxamido 2 2 methyl 4 thiazolyl acetamido 2 oxoazetidine l sulphonate, EMI135.2 NMR d6 DMSO, ppm 1.09 t, J 7Hz, CH3 , 2.64 s, CH3 , 3.4 4.1 m, CH2 , 3.4 3.8 m, C4 H , 3,83 q, J 7Hz, CH2 , 4.81 ddd, J 3,6,8Hz, C3 H , 5.52 d, J 7Hz, CH , 7.40 s, thiazol H , 9.05 br.d, J 8Hz, NH , 9.75 d, J 7Hz, NH . Example 55 0.170 g of 3 E2 4 chlorobenzoylureido 2 thienylacetamido 2 oxoazetidine and 0.133 g pyridinesulphur trioxide complex are dissolved in 1 ml of DMF.The mixture is allowed to stand at room temperature for 18 hours, and, then, worked up in the manner as described in Example 7 to obtain 0.085 g of pyridinium 3 2 4 chlorobenzoylureido 2 thienylacetamido 2 oxoazetidine 1 sulphonate.EMI136.1 NMR d6 DMSO, ppm 3.26 dd, J 3,6Hz, C4 H , 3.63 t, J 6Hz, C4 H , 4.85 ddd, J 3,6,8Hz, C3 H , 5.72 d,J 7Hz, CE . Example 56 0.500 g of 3 cyanomethylthioacetamido 3 methoxy . 2 oxoazetidine is added to 3 ml of DMF, followed by addition of 0.694 g of pyridine sulphur trioxide complex.The mixture is stirred for 21 hours and, then, worked up in the manner as described in Example 3. The above procedure provides 0.216 g of sodium 3 cyanomethylthioacetamido 3 methoxy 2 oxoazetidine l sulphonate.EMI136.2 Example 57 0.450 of 3 2 benzyloxycarbonyl 2 phenylacetamido 3 methoxy 2 oxoazetidine and 0.292 g of pyridinesulphur trioxide complex are dissolved in 1 ml of DMF.The mixture is treated as described in Example 49 A to obtain 0.286 g of sodium 3 2 benzyloxy carbonyl 2 phenylacetamido 3 methoxy 2 oxoazetidine l sulphonate. EMI136.3 NMR d6 DMSO, ppm 3.54 s,CE3 , 3.55, 3.75 dd, J 6Hz, C4 H , 4.96 s, CH , 5.13 s, CH2 , 7.30 s, aromatic H , 9.61, 9.65 each s,NE . 0.140 g of the above product is dissolved in 10 1 of water and, after the addition of 0.150 g of pallad All black, the mixture is stirred in a hydrogen gas stream for 25 minutes. The catalyst is filtered off and the filtrate is freeze dried to obtain 0.105 g of sodium 3 2 carboxy 2 phenylacetamido 3 methoxy 2oxoazetidine l sulphonate.EMI137.1 NMR d6 DMSO, ppm 3.50 s,CR3 , 3.50, 3.71 dd, J 6Hz, C4 E , 4.97 s, CR , 7.31 s,aromatic H , 9.50 s,NH . Example 58 0.450 g of 3 E2 5,6 dihydro 1,4 oxathiin 2 yl acetamido 2 oxoazetidine and 0.636 g of pyridinesulphur trioxide complex are dissolved in 3 ml of DMF.The mixture is allowed to stand at room temperature for 2 days, and treated as described in Example 5 to obtain 0.252 g of sodium 3 2 5,6 dihydro 1,4 oxathiin 2 yl acetamido 2 oxoazetidine 1 sulphonate.EMI137.2 NMR d6 DMSO, ppm 3.28 dd, J 3,6Hz, C4 H , 3.62 t, J 6Hz, C4 H , 4.84 ddd, J 3,6,8Hz, C3 H , 5.11 s, CH2 , 8.58 d, J 8Hz, NH . Example 59 0.450 g of 3 D N carbamoyltryptophyl D phenyl glycylamino 2 oxoazetidine and 0.240 g of pyridinesulphur trioxide complex are dissolved in 1 ml of DMF. The mixture is stirred for 20 hours, after which it is treated as described in Example 5. The above procedure provides 0.095 g of sodium 3 D N carbamoyltryptophyl D phenylglycylamino 2 oxoazetidine l sulphonate. EMI138.1 Example 60 0.450 g of 3 D N 4 ethyl 2,3 dioxo l piperazinocarbonyl phenylalanylamino 2 osoazetidine and 0.357 g of pyridine sulphur trioxide complex are dissolved in 2 ml of DMF. The mixture is allowed to stand at room temperature for 2 days, and treated as described in Example 5 to obtain 0.222 g of sodium 3 D N 4 ethyl 2,3 dioxo 1 piperazinocarbonyl phenylalanylamino 2 oxoazetidine l sulphonate. EMI138.2 NMR d6 DMSO,ppm 1.08 t, J 7Hz, CH3 , 2.93 dd, J 3,6Hz, C4 H , 3.38 q,J 7Hz, CE2 , 4.53 dd, J 6,8Hz, CH , 4.84 ddd, J 3,6,8Hz, C3 H , 7.22 s,aromatic H , 8.90 d,J 8Hz,NH , 9.16 d, J 8Hz,NH . Example 61 0.167 g of 3 2 2,4 dioxopyrimidino 5carboxamido 2 thienylacetamido 2 oxoazetidine and 0.117 g of pyridine sulphur trioxide complex are dissolved in 1 ml of DMF. The mixture is stirred for 3 days, after which it is treated as described inExample 5. The above procedure provides 0.052 g of sodium 3 2 2,4 dioxopyrimidino 5 carboxamido 2 thienyl acetamido 2 oxoazetidine l sulphonate. EMI138.3 Example 62 0.510 g of 3 D 2 2 ureido 2 thienylacetamido 2 4 hydroxyphenyl acetamido 2 oxoazetidine and 0.285 g of pyridine sulphur trioxide complex are dissolved in 2 ml of DMF. The mixture is stirred for 20 hours, after which it is treated as described in Example 5.The above procedure provides 0.036 g of disodium 3 ED 2 2 ureido 2 thienylacetamido 2 4 sulphonatoxy phenyl acetamido 2 oxoazetidine l sulphonate and 0.085 g of sodium 3 D 2 2 ureido 2 thienylacetamido 2 4 hydroxyphenyl acetamido 2 oxoazetidine 1sulponate. Disodium derivative Monosodium derivativeEMI139.1 Example 63 0.230 g of 3 ra D N 4 ethyl 2,3 dioxo l piperazinocarbonyl glutaminylamino 2 oxoazetidine and 0.199 g of pyridine sulphur trioxide complex are dissolved in 2 ml of DMF. The mixture is stirred for 4 days, after which it is treated as described in Example 5. The above procedure provides 0.015 g of sodium 3 alpha D N 4 ethyl 2,3 dioxo 1 piperazinocarbonyl glutaminylamino 2 oxoazetidine l sulphonate. EMI139.2 Example 64 0.391 g of 3 p2 4 ethyl 2,3 dioso 1 piperazinocarboxamido 2 1 cyclohexen 1 yl acetamido 2 oxoazetidine and 0.32 g of pyridine sulphur trioxide complex are dissolved in 2 ml of DMF.The mixture is stirred at room temperature for 4 days, after which it is treated as described in Example 5.The above procedure provides 0.345 g of sodium 3 f 2 4 ethyi 2,3 dioso 1 piperazinocarbosamido 2 1 cyclohexen l yl acetamido 2 osoazetidine 1 sulphonate. EMI140.1 Example 65 0.179 g of 3 2 4 ethyl 2,3 dioxo 1 piperazino carboxamido 2 4 chlorophenyl acetamido 2oxoazetidine and 0.14 g of pyridine sulphur trioxide complex are dissolved in 1 ml of DMF. The mixture is stirred at room temperature for 3 days, after which it is treated as described in Example 5. The above procedure provides 0.127 g of sodium 3 2 4 ethyl 2, 3, dioxo 1 piperazinocarboxamido 2 4 chlorophenyl acetamido 2 oxoazetidine 1 sulphonate.EMI140.2 Example 66 0.3 g of 3 rDL 2 4 ethyl 2,3 dioxo l piperazinocarboxamido 2 4 trimethylsilylphenyl acetamido 2 oxoazetidine and 0.21 g of pyridinesulphur trioxide complex are dissolved in 1 ml of DMF.The mixture is stirred at room temperature for 3 days, after which it is treated as described in Example 5.The above procedure provides 0.142 g of sodium 3 DL 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 4 trimethylsilylphenyl acetamido 2 oxoazetidine 1sulphonate.EMI141.1 NMR d6 DMSO, ppm 0.23 s,SiMe3 , 1.06 t,J 8Ez, CH3 , 3.85 m, CH2 , 4.80 m,C3 H , 5.36 d,J 8Hz, CH , 7.22 d,J 7Rz, aromatic H , 7.38 d,J 8Hz, aromatic H , 9.15, 9.20 each d,J 8Ez,NH , 9.76 d,J 8Hz,NH . Example 67 0.36 g of 3 D N 4 ethyl 2,3 dioxo 1 piperazinocarbonyl methionyl D phenylglyCYLAMINO 2oxoazetidine and 0.22 g of pyridine sulphur trioxide complex are dissolved in 3 ml of DMF. The mixture is stirred at room temperature for 5 days, after which it is treated as described in Example 5. The above procedure provides 0.3 g of sodium 3 iD N 4 ethyl 2, 3 di oxo l piperazinocarbonyl methi onyl I phenylglycyl amino 2 oxoazetidine l sulphonate. EMI141.2 NMR d6 DMSO, ppm 1.06 t, J 7Hz, CH3 , 2.04 s, SCH3 , 3.12 dd,J 3,6Hz,C4 3 R , 3.54 m, CH2 , 3.90 m, CH2 , 4.55 m, CH , 4.82 m,C3 H , 5.43 d, J 8Hz, CH , 7.31 aromatic H , 8.78 d J 8Hz, NH , 9.02 d,J 8Rz,NH , 9.22 d,J 8Rz,NH . Example 68 0.34 g of 3 r2 4 ethyl 2,3 dioxo l piperazino carboxamido 2 1 cyclohexen 1 yl acetamido 3 methoxy 2 osoazetidine and 0.26 g of pyridine sulphur trioxide complex are dissolved in 3 ml of DMF. The mixture is stirred for 3 days, after which it is treated as described in Example 5. The above procedure provides 0.17 g of sodium 3 r2 4 ethyl 2,3 dioxo l piperazinocarboxamido 2 1 cyclohexen 1 yl acetamido 3 methoxy 2 oxoazetidine l sulphonate.EMI142.1 Example 69 0.200 g of 3 D 2 3 methylcarbamoyl 3 methyl 1 ureido 2 phenylacetamido 2 oxoazetidine is dissolved in 3 ml of DIMF, followed by addition of 0.144 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days, and treated as described inExample 5. The above procedure provides 0.080 g of sodium 3 D 2 3 methylcarbamoyl 3 methyl 1 ureido 2 phenylacetamido 2 oxoazetidine 1 sulphonate.EMI143.1 NMR d6 DMSO, ppm 2.65 d, J 4Hz, CH3 , 3.06 s, CH3 , 3.10 dd, J 3,5Hz, C4 H , 3.53 t, J 5Hz, C4 H , 4.79 m C3 H , 5.30 d, J 7Hz, CH , 7.33 s, aromatic H,NH , 9.13 d,J 7Hz,NH , 9.90 d,J 7Ez, NH . Example 70 0.3 g of a diastereomeric mixture of 3 DL 2 3 methylcarbamoyl 3 methyl 1 ureido 2 thienylacetamido 2 oxoazetidine is dissolved in 3 ml of DMF, followed by addition of 0.2 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days and, then, worked up in the manner as described in Example 5.The above procedure provides 0.134 g of a diastereomeric mixture of sodium 3 DL 2 3 methylcarbamoyl 3 methyl 1 ureido 2 thienylacetamido 2 oxoazetidine 1 sulphonate.EMI143.2 NMR d6 DMSO, ppm 2.64 d, J 5Hz, CH3 , 3.07 s, CH3 , 3.18, 3.25 dd, J 3,6Hz, C4 H , 3.57, 3.58 t,J 6Hz, C4 R , 4.80 m C H , 5.58 d,J 7Rz, CR , 6.87 7.50 m,aromatic H,NH , 9.13, 9.18 D, J 8Hz, NH , 9.83, 9.88 d, J 7Hz, NH . Example 71 0.19 g of 3 D 2 3 methylcarbamoyl 3 methyl 1 ureido 2 4 benzyloxyphenyl acetamido 2oxoaxetidine is dissolved in 4 ml of DMF, followed by addition of 0.11 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days, then 30 ml of diethyl ether is added and the resultant crystals are collected and washed with ethanol pyridinium salt .This salt is treated with Dowex 50W Na form resin to obtain 0.138 g of sodium 3 D 2 3 methylcarbamoyl 3 methyl l ureido 2 4 benzyloxyphenyl acetamido 2oxoazetidine l sulphonate.EMI144.1 NMR d6 DMSO, ppm 2.63 d, J 5Hz, CH3 , 3.03 s, CH3 , 3.10 dd, J 3,5Hz, C4 R , 3.50 t,J 6Rz, C4 H , 4,78 m, C3 H , 5.03 s, CH2 , 5.21 d, J 7Hz, CH , 7.08 ABq, J 9.30Hz, aromatic H , 7.37 s,aromatic H , 9.03 d, J 8Hz, NH , 9.78 d, J 7Hz, NH . 43 mg of the above sodium 3 D 2 3 methylcarba moyl 3 methyl 1 ureido 2 4 benzyloxyphenyl acetamido 2 oxoazetidine l sulphone are added to 3 ml of water, followed by addition of 40 mg of palladium black. The mixture is stirred in a hydrogen gas stream for 40 minutes, and the catalyst is filtered off. The filtrate is freeze dried to provide 35 mg of sodium 3 D 2 3 methylcarbamoyl 3 methyl 1 ureido 2 4hydroxyphenyl acetamido 2 oxoazetidine l sulphonate.EMI144.2 NMR d6 DMSO, ppm 2.63 d, J 5Hz, CH3 , 3.05 s, CH3 , 3.12 dd, J 3,5Hz, C4 H , 3.51 t, J 5Hz, C4 H , 4.77 m,C3 H , 5.16 d,J 7Rz, CH , 6.88 ABq,J 9.40Hz, aromatic H , 7.32 q, J 5Hz, NH , 8.98 d, J 9Hz, NH , 9.33 s, OH , 9.72 d, J 7Hz, NH . Example 72 0.472 mg of 3 D 2 3 2 benzyloxybenzoyl l ureido 2 phenylacetamido 2 oxoazetidine is dissolved in 4 ml of DMF, followed by addition of 0.318 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days, after which it is treated as described in Example 5. The above procedure provides 0.13 g of sodium 3 D 2 3 2 benzyloxybenzoyl 1 ureido 2 phenylacetamido 2 osoazetidine 1 sulphonate. EMI145.1 NMR d6 DMSO, ppm 3.11 dd, J 3,6Hz, C4 H , 3.62 t,J 6Hz, C4 H , 4.86 m,C3 H , 5.30 s, CH2 , 5.40 d, J 8Hz, CH , 7.04 7.88 m, aromatic H , 9.28 d, J 7Hz, NH , 9.45 d, J 8Hz, NH , 10.32 s, NH . 60 mg of the above sodium 3 D 2 L3 2 benzyloxy benzoyl l ureido 2 phenylacetamido 2 osoazetidine 1 sulphonate are added to 4 ml of water, followed by addition of 60 mg of palladium black. The mixture is stirred in a hydrogen gas stream for 30 minutes, and the catalyst is filtered off. The filtrate is freezedried to provide 48.5 mg of sodium 3 D 2 3 2 hydroxybenzoyl l ureido 2 phenylacetamido 2 oxoazetidine l sulphonate.EMI145.2 NMR d6 DMSO, ppm 3.13 dd, J 3,6Hz, C4 H , 3.58 t,J 6Rz, C4 H , 4.87 m, C3 H , 5.48 d, J 8Hz, CH , 6.90 8.05 m, aromatic H , 9.28 d,J 9Hz,NH , 9.52 d, J 8Hz, NH , 10.52 s, NH . Example 73 A 0.3 g of 3 D 2 3 2 benzyloxybenzoyl 1 ureido 2 4 hydroxyphenylacetamido3 2 oxoazetidine is dissolved in 4 ml of DMF, followed by addition of 0.116 g of pyridine sulphur complex. The mixture is stirred for 3 days, after which it is treated as described in Example 5. The above procedure provides 0.021 g of disodium 3 D 2 3 2 benzyloxybenzoly 1 ureido 2 4 sulphonatoxyphenyl acetamido 2oxoazetidine l sulphonate.EMI146.1 NMR d6 DMSO,ppm 3.24 dd,J 3,6Rz, C4 R , 3.58 t, J 6Hz, C4 H , 4.88 m, C3 H , 5.28 s, CH2 , 5.38 d, J 7Hz, CH , 7.00 7.86 m, aromatic H , 9.21 d, J 9Hz, NH , 9.37 d, J 7Hz, NH , 10.28 s, NH . In addition, 0.059 g of sodium 3 D 2 3 2 benzyloxybenzoyl 1 ureido 2 4 hydroxyphenyl acetamido 2 oxoazetidine 1 sulphonate is also obtained.EMI146.2 NMR d6 DMSO, ppm , 3.10 dd, J 3,6Hz, C4 H , 3.49 t, J 6Hz, C4 H , 4.86 m, C3 H , 5,28 s, CH2 , 5.57 d, J 7Hz, CH , 6.70 7.88 m, aromatic H , 9.21 d, J 9Hz, NH , 9.33 s, OH , 9.37 d, J 7Hz, NH , 10.28 s,NH . B 40 mg of the above sodium 3 pD 2 t3 2 benzyloxy benzoyl l ureido 2 4 hydroxyphenyl acetamido 2 oxoazetidine l sulphonate are added to 3 ml of water, followed by addition of 40 mg of palladium black. The mixture is stirred in a hydrogen gas stream for 40 minutes, after which the catalyst is filtered off. The filtrate is freeze dried to provide 31 mg of sodium 3 D 2 E3 2 hydroxybenzoyl 1 ureidol 2 4 hydroxyphenyl acetamido 2 oxoazetidine 1 sulphonate.EMI147.1 NMR d6 DMSO, ppm 3.15 dd, J 2,6Hz, C4 H , 3.52 t,J 6Hz, C4 H , 4.88 m,C3 E , 5.48 d, J 7Hz, CH , 6.70 8.00 aromatic H , 9.09 d,J 9Hz,NH , 9.48 s,OH , 9.50 d,J 7Hz,NE . Example 74 0.4 g of 3 2 3 chloro 4 hydroxyphenyl 2 4 ethyl 2,3 dioxo 1 piperazinocarbosamido acetamido 2 oxoazetidine is dissolved in 4 ml of DMF, followed by addition of 0.175 g of pyridine sulphur trioxide complex. The mixture is stirred for 4 days, after which it is treated as described in Example 5. The above procedure provides 0.02 g of disodium 3 2 3 chloro 4 sulphonatoxyphenyl 2 4 ethyl 2,3 dioxo 1piperazinocarboxamido acetamido 2 oxoazetidine 1sulphonate.EMI147.2 In addition, o.o65 g of sodium 3 E2 3 chloro 4 hydroxyphenyl 2 4 ethyl 2, 3 dioxo 1 piperazino carboxamido acetamido 2 oxoazetidine 1 sulphonate is obtained.EMI147.3 NMR d6 DMSO, ppm 1.09 t, J 7Hz, CH3 , 3.10 dd, J 2,6Hz, C4 H , 3.40 q, J 7Hz, CH2 , 3.44 3.68 m, CH2 , C4 H , 3.82 4.04 m, CH2 , 4.84 m, C3 H , 5.32 d, J 7Hz, CH , 6.91 7.40 m, aromatic H , 9.17 d, J 9Hz, NH , 9.74 d, J 7Hz, NH , 10.22 s, OH . Example 75 0.3 g of 3 D 2 3 chloro 4 methoxyphenyl 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido acetamido 2 oxoazetidine is dissolved in 3 ml of DMF, followed by addition of 0.2 g of pyridine sulphur trioxide complex.The mixture is stirred for 4 days, after which it is treated as described in Example 5. The above procedure provides 0.196 g of sodium 3 LD 2 3 chloro 4 methoxy phenyl 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido acetamido 2 oxoazetidine 1 sulphonate.EMI148.1 NMR d6 DMSO, ppm 1.09 t, J 7Hz, CH30, 3.09 dd, J 3,5Hz, C4 H , 3.40 q, J 7Hz, CH30, 3.44 3,70 m, CH2 , C4 H , 3.76 4.04 m, CH2 , 3.86 s, CH3 , 4.83 m, C3 H , 5.36 d, J 7Hz, CH , 7.10 7.50 m,aromatic H , 9.21 d, J 9Hz, NH , 9.79 d,J 7Rz, NH . Example 76 0.35 g of a diastereomeric mixture of 3 D 2 2 benzyloxyearbamido 3 N methylcarbamoylpropionamido 2 phenylacetamido 2 oxoazetidine is dissolved in 4 ml ofDMF, followed by addition of 0.231 g of pyridine sulphur trioxide complex. The reaction mixture is stirred for 3 days, after which diethyl ether is added, whereupon the pyridinium salt is obtained as crystals.. These crystals are treated in the manner as described inExample 71. The above procedure provides 0.37 g of a diastereomeric mixture of sodium 3 D 2 2 benzyloxy carbamido 3 N methylcarbamoylpropionamido 2 phenylacetamido 2 oxoazetidine 1 sulphonate.EMI149.1 NMR d6 DMSO, ppm 2.40 2.70 m, CH2 , CH3 , 3.30 dd, J 2,6Hz, C4 H , 3,60 t, J 6Hz, C4 H , 4.46 m, CH , 4.86 m,C3 H , 5.03, 5.06 s, CH2 , 5 38, 5.40 d, J 8Hz, CH , 7.34 s, aromatic H , 7.35 s,aromatic H , 7.75 m,NH , 8.30 m,NH , 9.06 m,NH .NMR d6 DMSO D2O, ppm 2.40 2.70 m, CH2 , CH3 , 3.28 dd, J 2,6Hz, C4 H , 3.62 t, J 6Hz, C4 H , 4.46 m, CH , 4.86 m,C3 H , 5.04, 5.08 s, CH2 , 5.37, 5,39 s, CH , 7.35, 7.36 s,aromatic H . 102 mg of a diastereomeric mixture of the above sodium 3 D 2 2 benzyloxycarbamido 3 N methylcarbamoyl propionamido 2 phenylacetamido 2 oxoazetidine 1sulphonate are added to 5 ml of water, followed by addition of 60 mg of palladium black. The mixture is stirred in a hydrogen gas stream for 35 minutes, after which the catalyst is filtered off. The filtrate is freeze dried whereupon 69 mg of sodium 3 tD 2 2 amino 3 N methyl carbamoylpropi onamido 2 phenyl acetamido 2 oxoazetidine 1 sulphonate are obtained.EMI149.2 NMR d6 DMSO D2O, ppm 2.40 2.70 m, CH2 , 2.59 s, CH3 , 3.26 dd, J 3,6Hz, C4 H , 4.84 m, C3 H , 5.38 s, CH , 7.38 s, aromatic H . Example 77 0.24 g of a diastereomeric mixture of 3 LD 2 3 benzyloxyearbamido 3 N methylcarbamoyl propionamido 2 phenylacetamido 2 oxoazetidine is dissolved in 3 ml ofDMF, followed by addition of 0.16 g of pyridine sulphur trioxide complex. The mixture is stirred for 4 days, after which it is treated as described in Example 5. The above procedure provides 0.08 g of a diastereomeric mixture of sodium 3 D 2 benzyloxy carbamido 3 N methylcarbamoylpropionamido phenylacetamido 2 oxoazetidine 1 sulphonate.EMI150.1 NMR d6 DMSO, ppm 2.44 2.66 m, CH2 , CH3 , 3.24 m, C4 H , 3.54 m, C4 H , 4,30 m, CH , 4.83 m,C3 H , 5.00 and 5.02 s, CR2 , 5.43 d,J 7Hz, CH , 7.36 s, aromatic H , 7.76 m,NH , 8.46 m,NH , 9.06 m,NH . NMR d6 DMSO D2O, ppm 2.47 2.70 m, CH20, CH2 , CH3 , 3.28 m,C4H , 3.58 m, C4 H , 4.30 m, 5H , 4.82 m,C3 H , 5.01, 5.04 5, CR2 , 5.40 s, CR , 7.36 s, aromatic H . 60 mg of a diastereomeric mixture of the above sodium 3 D 2 3 benzyloxycarbamido 3 N methylcarbamoylpropionamido 2 phenylacetamido 2 oxoazetidine 1sulphonate are dissolved in 3 ml of water, followed by addition of 40 mg of palladium black. The mixture is stirred in a hydrogen gas stream for 40 minutes, after which the catalyst is filtered off. The filtrate is freeze dried, whereupon 41 mg of a diastereomeric mixture of sodium 3 LD 2 3 amino 3 N methylcarbamoyl propionamido 2 phenylacetamido 2 oxoazetidine 1 sulphonate is obtained.EMI151.1 NMR d6 DMSO D2O, ppm 2.42 2.60 m, CH2 , 2.61 and 2.62 s, CH30, 3.25 dd, J 2,5Hz, C4 H , 3.62 t, J 5Hz,C4 H , 4.83 m,C3 H , 5.37, 5.41 s, CH , 7.38 s,aromatic H . Example 78 1,3 g of 3 2 2,5 dioxopyrrolidin 3 yl acetamido 2 oxoazetidine is dissolved in 13 ml of DMF, followed by addition of 2.4 g of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 3 days, after which it is treated as described inExample 5. The above procedure provides 0.81 g of sodium 3 2 2,5 dioxopyrrolidin 3 yl acetamido 2oxoazetidine l sulphonate.EMI151.2 NMR D20 ppm 2.5 3.55 m, CH2 , 3.81 dd,J 3, 6Hz, C4 H , 4.05 t, J 6Hz, C4 H , 5.04 dd, J 3,6Hz, C3 H . Example 79 0.57 g of 3 2 succinimidoacetamido 2oxoazetidine is dissolved in 5 ml of DMF, followed by addition of 1.1 g of pyridine sulphur trioxide complex.The mixture is stirred for 4 days, after which it is treated as described in Example 5. The above procedure provides 0.259 g of sodium 3 2 succinimidoacetamido 2 oxoazetidine l sulphonate. EMI152.1 NMR D2O, ppm 3.01 s, CH2CH2 , 3.83 dd, J 4,6Hz, C4 H , 4.06 t, J 6Hz, C4 H , 4.43 s, CH2 , 5.08 dd,J 4,6Hz,C3 H . Example 80 2.5 g of pyridine sulphur trioxide complex are added to a solution of 1.63 g of 3 t2 2 carbobenzoxy aminomethylphenyl acetamido 2 oxoazetidine in 10 ml of DMF. The reaction mixture is stirred for 5 days, and treated as described in Example 5 to obtain 0.815 g of sodium 3 2 2 carbobenzoxyaminomethylphenyl acetamido 2 oxoazetidine 1 sulphonate.EMI152.2 NMR D2O, ppm 3.70 dd, J 3,5,6Hz, C4 H , 3.78 s, CH2 , 3.88 t, J 6Hz, C4 H , 4.37 s, CH2 , 4.87 dd,J 3.5,6Hz,C4 H , 5.19 s, CE2 , 7.42 s,aromatic H , 7.50 s, aromatic H . 0.30 g of the above sodium 3 p2 2 carbobenzoxy aminomethylphenyl acetamido 2 oxoazetidine 1 sulphonate is dissolved in 35 ml of 30 methanol, followed by addition of 0.68 ml of 6 acetic acid and 76 mg of palladium black. The mixture is stirred in a hydrogen gas stream at room temperature for 90 minutes.The catalyst is filtered off and the filtrate is purified on an Amberlite SAD II column. The above procedure provides 0.167 g of sodium 3 2 2 amino methylphenyl acetamido 2 oxoazetidine l sulphonate acetate.EMI152.3 NMR D2O, ppm 2.01 s, CH3 , 3.69 dd, J 3.5,6Hz, C4 H , 3.74 s, CE2 , 3.97 t, J 6Hz, C4 H , 4.41 s, CH2 , 4.98 dd, J 3.5,6Hz, C3 H , 7.48 s, aromatic E . Example 81 1.01 g of pyridine sulphur trioxide complex is added to a solution of 0.50 g of 3 2 methoxyimino 2 furylacetamido 2 osoazetidine in 2 ml of DMF. The reaction mixture is stirred for 2 days and treated as described in Example 5 to obtain 0.108 g of sodium 3 2 methoxyimino 2 furylacetamido 2 oxoazetidine 1 sulphonate.EMI153.1 Example 82 0.35 g of 3 r2 2 N trichloroacetylureidometh yl phenyl acetamido 2 oxoazetidine is dissolved in 4 ml of DMF, followed by addition of 0.70 g of pyridinesulphur trioxide complex. The reaction mixture is stirred at room temperature for 4 days and, then, worked up in the manner of Example 5. The resultant sodium 3 2 2 N trichloroacetylureidomethylphenyl acetamido 2 oxoazetidine l sulphonate is dissolved in 20 ml of water, and the solution is adjusted to pH 7.5 with sodium hydrogen carbonate and stirred at room temperature for 2 hours. The solution is adjusted to pH 6 and, then, purified on an Amberlite XAD II column.The above procedure provides 87 mg of sodium 3 2 2 ureidomethylphenyl acetamido 2 oxoazetidine 1 sulphonate. EMI154.1 Example 83 0.50 g of 3 2 3,5 dichloro 4 pyridon 1 yl acetamido 2 oxoazetidine is dissolved in 4 ml of DMF, followed by addition of 0.85 g of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 3 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.265 g of sodium 3 t2 3,5 dichloro 4 pyridon l yl acetamido 2 osoazetidine 1 sulphonate. EMI154.2 Example 84 0.676 g of 3 2 phenyl 2 benzyloxycarbonylacetamido 2 oxoazetidine is dissolved in 3 ml of DMF, followed by addition of 0.955 g of pyridine sulphur trioxide complex.The mixture is stirred at room temperature for 4 days and, then, worked up in the manner as described inExample 5. The above procedure provides 0.117 g of sodium 3 2 phenyl 2 benzyloxycarbonylacetamido 2 oxoazetidine l sulphonate.EMI154.3 NMR D20,ppm 3.52 dd,J 3.5,5.5Hz,C4 R , 3.75 t, J 5.5Hz, C4 H , 4.75 dd, J 3.5,5.5Hz, C3 H , S , 5.03 s, CR2 , 7.16 s,aromatic H , 7.26 s,aromatic E . Example 85 0.180 g of 3 2 N carbobenzoxyprolylamino 2 furylacetamido 2 oxoazetidine is dissolved in 3 ml of DMF, followed by addition of 0.19 g of pyridinesulphur trioxide complex. The mixture is stirred for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides 46 mg of sodium 3 r2 N carbobenzoxyprolylamino 2 furyl acetamido 2 oxoazetidine 1 sulphonateEMI155.1 Example 86 0.45 g of 3 2 1 acetyl 2,4 dioxoimidazolidin 3 yl acetamido 2 oxoazetidine is dissolved in 3 ml of dmf, followed by addition of 1.0 g of pyridine sulphur trioxide complex. The mixture is stirred for 2 days and then, worked up in the same manner as Example 5.The above procedure provides 0.38 g of sodium 3 2 1 acetyl 2,4 dioxoimidazolidin 3 yl acetamiDO 2 oxoazetidine l sulphonate.EMI155.2 NMR D2O, ppm 2.66 s, CH3 , 3.82 dd, J 3.5,6Hz, C4 H , 4.04 t, J 6Hz, C4 H , 4.50 s, CH2 , 4.59 s, CH2 , 5.08 dd, J 3.5,6Hz, C3 H . Example 87 0.30 g of 3 2 2 oxoimidazolidin 1 yl acetamido 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.45 g of pyridine sulphur trioxide complex. The mixture is reacted for 2 days and, then worked up in the manner as described in Example 5. The above procedure provides 65 mg of sodium 3 L2 2 oxoimidazolidin 1 yl acetamido 2 oxoazetidine 1 sulphonate.EMI156.1 NMR D2O, ppm 3.45 4.3 m, CH2 , C4 H , 5.02 dd, J 3.5,6Hz C H . Example 88 0.30 g of the sodium 3 t2 2 carbobenzoxyamino methylphenyl acetamido 2 oxoazetidine 1 sulphonate obtained in Example 80 is dissolved in 70 ml of 30 methanol, followed by addition of 0.68 ml of 6 acetic acid and 75 mg of palladium black. The mixture is stirred in a hydrogen gas stream at room temperature for 90 minutes, after which the catalyst is filtered off. The filtrate is concentrated under reduced pressure, followed by addition of 30 ml of tetra hydrofuran. Then, under ice cooling, 0.15 g of 1 chlorocarbonylimidazolid 2 one is added to the above tetrahydrofuran solution. The mixture is stirred for 90 minutes its pH being maintained at 8.5 with a 1 ffi aqueous solution of sodium hydrogen carbonate .The reaction mixture is adjusted to pH 6.5 with phosphoric acid, and the tetrahydrofuran is distilled off under reduced pressure. The residue is purified on an Amberlite XAD II column to provide 0.24 g of sodium a 2 2 2 oxoimidazolidin 1 yl carbonylaminomethyl phenyl acetamido 2 oxoazetidine 1 sulphonate. EMI156.2 Example 89 The sodium 3 2 2 carbobenzoxyaminomethylphenyl acetamido 2 oxoazetidine l sulphonate 0.30 g obtained in Example 80 is treated in the manner as described inExample 88 except that 0.15 g of l chlorocarbonyl 3benzylideneaminoimidazolid 2 one is used instead of 1chlorocarbonylimidazolid 2 one. The procedure provides 0.21 g of sodium 3 2 2 2 oxo 3 benzylideneamino imidazolidin l yl carboxyaminomethylphenylacetamido 2oxoazetidine l sulphonate.EMI157.1 Example 90 0.80 g of 3 2 4 ethyl 2,3 dioxo 1 piperazino carboxamido 2 furylacetamido 2 oxoazetidine is dissolved in 4 ml DMF, followed by addition of 1.35 g of pyridine sulphur trioxide complex. The mixture is stirred for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.20 g of sodium 3 r2 4 ethyl 2,3 dioxo l piperazino carboxamido 2 furylacetamido 2 oxoazetidine 1sulphonate.EMI157.2 Example 91 1.0 g of 3 D N thienylmethylcarbonyl alanylamino 2 oxoazetidine is dissolved in 5 ml of DMF, followed by addition of 1.7 g of pyridine sulphur trioxide complex.The mixture is stirred for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.325 g of sodium 3 tD N thienyl methylcarbonyl alanylamino 2 osoazetidine l sulphonate. EMI158.1 Example 92 0.33 g of 3 N carbobenzoxy D alaninamido 3methoxy 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.32 g of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides 52 mg of sodium 3 N carbobenzoxy D alanin amido 3 methoxy 2 oxoazeti.dine l sulphonate. EMI158.2 NMR DMSO d6, ppm 1.22 d, J 7Hz, CH3 , 3.30 s, CH3 , 3.54, 3.70 dd, J 7Hz, CH2 , 4.26 m, J 7Hz, CH , 5.03 s, CH2 , 7.36 s, aromatic H , 9.12 d, J 7Hz . Esample 93 0.393 g of 3 fN 4 ethyl 2,3 dioxo l piperazino carbonyl D alaninamido 3 methoxy 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.350 g of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 4 days and, then, worked up in the manner as described in Example 5. The above procedure provides 45.5 mg of sodium 3 N 4 ethyl 2,3 dioxo 1 piperazinocarbonyl Dalaninamido 3 methoxy 2 oxoazetidine 1 sulphonate.EMI159.1 NMR DMSO d6, ppm 1.10 t, J 7Hz, CH3 , 1.32 d, J 7Hz, CH3 , 3.35 s, CH3 , 3.43 q, J 7Hz, CH2 , 3.60 m, CH2 , 3.90 m, CE2 , 4.47 m, CH , 9.23 d,J 7Hz, NH , 9.40, 9.44 each s,NH . Example 94 516.5 mg of 3 N N carbobenzoxy D phenylglycyl D phenylglycinamido 3 methoxy 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 320 mg of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 4 days and, then, worked up in the manner as described in Example 5. The above procedure provides 145 mg of sodium 3 p N carbobenzoxy D phenylglycyl D phenylglycinamido 3 methoxy 2 oxoazetidine l sulphonate. EMI159.2 NMR DMsO d6 D20,ppm 3.08, 3.26 each s,CH3 , 3.40 m, CH2 , 5.06 s, CH2 , 5.45 s, CH , 5.59 s, CH , 7.2 7.55 m,aromatic H . Example 95 0.300 g of 3 N 4 ethyl 2,3 dioxo 1 piperazino carbonyl 3 methioninamido 2 oxoazetidine is dissolved in 1.5 ml of DMF, followed by addition of 0.250 g of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 4 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.168 g of sodium 3 tN 4 ethyl 2,3 dioso 1 piperazinocarbonyl D methioninamidou 2 oxoazetidine 1 sulphonate.EMI160.1 NMR DMSO d6, ppm 1.10 t, J 7Hz, CH30, 1.96 m, CH2 , 2.06 s, CH3 , 2.44 t, J 7Hz, CH2 , 3.42 q, J 7Hz, CR2 , 3.58 m, CH2 , 3.92 m, CH2 , 4.42 m, CH , 4,84 m, C3 H , 8.92 d, J 7Hz, NH , 9.22 d, J 7Hz, NH . Example 96 0.186 g of 9 r2 D r4 2 phenethyl 2,3 dioxo l piperazinocarboxamido 2 phenylacetamido 2oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.128 g of pyridine sulphur trioxide complex.The mixture is stirred for I day and, then, worked up in the manner as described in Example 5. The above procedure provides 0.180 g of sodium 3 L2 D 4 2 phenethyl 2,3 dioxo 1 piperazinocarboxamido 2 phenylacetamido 2 oxoazetidine l sulphonate.EMI160.2 NMR d6 DMSO, ppm 2.84 t, J 7Hz, CH2 , 3.13 dd, J 3,6Hz, C4 H , 4.85 ddd, J 3,6,8Hz, C4 H , 5.44 d,J 7Hz, CH , 7.2 7.5 m,aromatic H , 9.24 d,J 8Rz,NH , 9.78 d,J 7Hz,NH . Example 97 0.178 g of 3 r2 D 4 ethyl 2,3 dioxo l piperazinocarboxamido 2 4 benzoyloxyphenyl acetamido 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.112 g of pyridine sulphur trioxide complex. The mixture is stirred for 1 day and, then, worked up in the manner as described in Example 5. The above procedure provides 0.125 g of sodium 3 L2 D 4 ethyl 2,3 dioso 1 piperazinocarboxamido 2 4 benzoyloxyphenyl acetamido 2 oxoazetine 1sulphonate.EMI161.1 NMR d6 DMSO, ppm 1.10 t, CH3 , 3.18 dd, J 3,6Hz, C4 H , 3.62 t, J 6Hz, C4 H , 3.4 4.1 m, CH2 , 4.90 ddd, J 3,6,8Hz, C3 H , 5.52 d, J 7Hz, CH , 7.2 8.2 m,aromatic H , 9.32 d,J 8Rz,NH , 9.87 d,J 7Hz,NH . Example 98 0.278 g of 3 2 benzyloxycarboxamido 3 N methyl carbamoyl propionamido 3 methoxy 2 oxoazetidine is dissolved in 3 ml of DMF, followed by addition of 0.175 g of pyridine sulphur trioxide complex. The mixture is stirred for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides 32 mg of sodium 3 2 benzyloxy carboxamido 3 N methylcarbamoyl propionamido 3methoxy 2 oxoazetidine l sulphonate.EMI161.2 NMR DMSO d6, PPM 2.33 2.67 m, CH2, CH30, 3.40 s,CH3 , 3.50 m,C4 R , 4.37 m, CH , 4.99 s, CR2 , 7.31 s,aromatic H , 7.70 m,NH , 9.07 s,NH . Example 99 0.785 g of 3 p2 E 3 furfurylideneamino 2 oxoimidazolidin l yl carbosamido 2 2 chloroacetamido 4 thiazolyl acetamido 2 oxoazetidine is suspended in 10 ml of DMF, followed by addition of 0.478 g of pyridine sulphur trioxide complex. The mixture is reacted for 1 day and, then, worked up in the manner as described in Example 5. The above procedure provides 0.465 g of sodium 3 p2 p 3 furfurylideneamino 2 oxoimidazolidin 1 yl carboxamido 2 2 chloro acetamido 4 thiazolyl acetamido 2 oxoazetidine 1 sulphonate.EMI162.1 0.25 g of the above sodium 3 t2 p 3 furfurylidene amino 2 oxoimidazolidin l yl carboxamido 2 2 chloro acetamido 4 thiazolyl acetamido 2 oxoazetidine 1 sulphonate is dissolved in 5 ml of water, followed by addition of 0.057 g of sodium N methyldithiocarbamate under stirring and ice cooling. The solution is stirred for 75 minutes. The insoluble matter is filtered off and the filtrate is purified by anAmberlite XAD II column. The above procedure provides 0.089 g of sodium 3 t2 p 3 furfurylideneamino 2 oxoimidazolidin l yl carboxamido 2 2 amino 4 thiazolyl acetamido 2 oxoazetidine l sulphonate. EMI162.2 EMI163.1 Example 100 0.20 g of 3 D 2 2 phenylacetamido propionamido 3 methoxy 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.208 g of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides 20 mg of sodium 3 ED 2 2 phenylacetamido propionamido 3 methoxy 2 oxoazetidine 1 sulphonate.EMI163.2 NMR DMSO d6, ppm 1.23, 1.24 each d,J 7Hz,CE3 , 2.80, 3.00 each s, CH2 , 3.47 s,CH3 , 4.45 m, CH , 7.29 s, aromatic H . Example 101 0.33 g of 3 N carbobenzoxy D alaninamido 3 methoxy 2 oxoazetidine, which is obtained in ReferenceExample 15 is dissolved in 2 ml of DMF, followed by addition of 0.32 g of pyridine sulphur trioxide complex.The mixture is stirred at room temperature for 3 days and, then, worked up in the manner as described in Example 5.The above procedure provides 16.5 mg of sodium 3 N carbobenzoxy D alaninamido 3 methoxy 2 osoazetidine 1 sulphonate.EMI163.3 NMR DMSO d6,ppm 1.22 d,J 7Hz,CH3 , 3.29 s, CH3 , 3.54, 3.64 each d,J 7Hz, CH2 , 4.10 m, CH , 5.03 s, CH2 , 7.36 s, aromatic H . Example 102 0.447 g of 3 2 2 oxo 3 thiophene 2 aldoimino imidazolidin 1 yl carboxamido 2 thienylacetamido 2oxoazetidine is dissolved in 8 ml of DMF, followed by addition of 0.319 g of pyridine sulphur trioxide complex. The mixture is stirred for 1 day and, then, worked up in the manner as described in Example 5. The above procedure provides 0.234 g of sodium 3 L2 LL2 oxo 3 thiophene 2 aldoimino imidazolidin 1 yl carboxamido 2 thienylacetamido 2 oxoazetidine 1 sulphonate.EMI164.1 NMR d6 DMSO, ppm 3.20, 3.25 dd, J 3,6Hz, C4 H , 3.63, 3,65 t, J 6Hz, C4 H , 3.83 s,ring CH2 , 4.89 m,C3 H , 5.72 d,J 7Hz, CH , 6.9 7.7 m,thienyl H , 8.10 s, CR , 8.99 d, J 7Hz, NH , 9.26, 9.30 d, J 8Hz, NH . Example 103 0.307 g of 3 D 2 3 mesyl 2 oxoimidazolidin 1yl carboxamido 2 phenylacetamido 2 oxoazetidine is dissolved in 4 ml of 1B, followed by addition of 0.239 g of pyridine sulphur trioxide complex. The mixture is stirred for 1 day and, then, worked up in the manner as described in Example 5. The above procedure provides 0.244 g of sodium 3 D 2 3 mesyl 2 oxoimidazolidin 1 yl carboxamido 2 phenyl acetamido 2 oxoazetidine l sulphonate.EMI164.2 1350, 1255, 1160, 1050. NMR d6 DMSO, ppm 3.14 dd, J 3,6Hz, C4 H , 3.36 s, CH3 , 3.58 t, J 6Hz, C4 H , 3.79 s, CH2 , 4.85 ddd, J 3,6,8Hz, C3 H , 5.43 d, J 7Hz, CH , 7.39 s,aromatic H , 8.77 d,J 7Ez,NH , 9.25 d,J 8Hz, NH . Example 104 0.313 g of 3 r2 r 3 mesyl 2 oxoimidazolidin l yl carboxamido 2 thienylacetamido 2 oxoazetidine is dissolved in 4 ml of DMF, followed by addition of 0.239 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.19 g of sodium 3 L2 E 3 mesyl 2 oxoimidazolidin 1 yl carboxamido 2 thienylacetamido 2 oxoacetidine l sulphonate.EMI165.1 NMR d6 DMSO, ppm 3.18 dd, J 3,6Hz, C4 H , 3.35 s, CH30, 3.61, 3.63 t, J 6Hz, C4 H , 4.85 m, C3 H , 5.79 d, J 7Hz, CH , 6.7 7.6 m, thientl H , 8.65 d, J 7Hz, NH , 9.26, 9.30 d, J 8Hz, NH . Example 105 0.658 g of 3 TD 2 2,6 dichlorophenylthioglycol amido 2 phenylacetamido 2 oxoazetidine is dissolved in 5 ml of DMF, followed by addition of 0.480 g of pyridine sulphur trioxide complex. The mixture is stirred for 2 days and, then, worked up in the manner as described in Example 7. The above procedure provides 0.774 g of pyridinium 3 tD 2 2,6 dichloro phenylthioglycolamido 2 phenylacetamido 2 oxoazetidine 1 sulphonate.EMI166.1 NMR DMSO d6, ppm 3.20 dd, J 3,6Hz, C4 H , 3.60 t, J 6Hz, C4 H , 3.09, 3.90 AB1q, J 15Hz, CH2 , 4.86 dd, J 3,6Hz, C3 H , 5.49 d, J 8Hz, CH , 8.95 d, J 7Hz, NH , 9.18 d, J 8Hz, NH . Example 106 0.172 g of 3 hexahydro 1H azepin 1 yl methylen amino 2 oxoazetidine is dissolved in 1 ml of DMF, followed by addition of 0.183 g of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides o.o56 g of sodium 3 p hexahydrolE azepin l yl methylenamino 2 oxoazetidine 1 sulphonate.EMI166.2 NMR DMSO d6ppm 1.4 1.9 m, CH2 , 3.72 t, J 6Hz, C4 H , 4.90 dd, J 3,6Hz, C3 H , 8.19 s, CH . Example 107 0.440 g of 3 rD 2 4 ethyl 2,3 dioxo l piperazinocarboxamido 3 phenylpropionamido 3 methoxy 2 oxoazetidine is dissolved in 1.8 ml of 1EF, followed by addition of 0.320 g of pyridine sulphur trioxide complex. The mixture is stirred for 42 hours and, then, worked up in the manner as described inExample 5. The above procedure provides 0.152 g of sodium 3 D 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 30phenylpropionamido 3 methoxy 2 oxoazetidine l sulphonate. EMI167.1 NMR DMSO d6,ppm 1.09 t, J 7Hz, CH3 , 3.22, 3.30 each s, CH3 . 4.70 m, E , 8.90, 9.17 each d, J 7Hz,NH . Example 108 0.35 g of 3 2 dichloroacetoxyimino 2 thienylacetamido 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.289 g of pyridine sulphur trioxide complex. The mixture is stirred for 24 hours and, then, worked up in the manner as described inExample 5. The procedure provides 0.28 g of sodium 3 2 dichloroacetoxyimino 2 thientlacetamido 2 oxoazetidine l sulphonate.EMI167.2 NMR DMSO d6, ppm 3.37 dd, J 3,6Hz, C3 H , 3.68 t,J 6Hz, C4 H , 4.93 ddd, J 3,6,8Hz, C3 H , 7.10 s, CHCl2 . 0.25 g of the above sodium 3 2 dichloro acetoxyimino 2 thienylacetamido 2 oxoazetidine I sulphonate is dissolved in 10 ml of water and the solution is stirred at room temperature for 3 hours, the pH of the solution being maintained at 7 to 8 with sodium hydrogen carbonate. The reaction mixture is then purified on an Amberlite XAD II column to obtain 0.1 g of sodium 3 2 oxyimino 2 thienyl acetamido 2 oxoazetidine l sulphonate.EMI167.3 1050. NMR DMSO d6,ppm 3.35 dd, J 3,6Hz, C4 H , 3.65 t, j 6Rz, C4 4.85 ddd,J 2,6,8Rz,C3 H . Example 109 0.320 g of 3 2 phenyl 2 sulphamoylacetamido 2oxoazetidine is dissolved in 1 ml of DMF, followed by addition of 0.336 g of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.085 g of sodium 3 2 phenyl2 sulphamoylacetamido 2 oxoazetidine l sulphonate,EMI168.1 NMR DMSO d6ppm 3.22 dd,J 3,6Hz,C4 E , 3.65 t,J 6Hz,C4 H , 4.85 m,C3 H , 5.04 s, CH , 7.3 7.7 m,aromatic H . Example 110 0.197 g of 3 2 N,N dimethylsulphamoyl 2 phenylacetamido 2 oxoazetidine is dissolved in 1 ml of DMF, followed by addition of 0.202 g of pyridinesulphur trioxide complex. The mixture is stirred at room temperature overnight and, then, worked up in the manner as described in Example 5. The above procedure provides 0.125 g of sodium 3 2 N,N dimethylsulphamoyl2 phenylacetamido 2 oxoazetidine l sulphonate.EMI168.2 NMR DMSO d6,ppm 2.66, 2.70 each s,CH3 , 3.22 dd, J 3,6Hz, C4 H , 3.69 t, J 6Hz, C4 H , 4.87 ddd, J 3,6,8Hz, C3 H , 5.30 s, CH , 9.19, 9 .22 each d, J 8Hz, NH , 7.3 7.8 m,aromatic ii . Example 111 0.465 g of 3 2,5 bis 4 ethyl 2,3 dioxo 1 piperazinocarboxamido pentanamido 2 oxoazetidine is dissolved in 1.5 ml of DMF, followed by addition of 0.284 g of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.145 g of sodium 3 2,5 bis 4 ethyl 2,3 dioxo 1 piperazinocarboxamido pentanamido 2 oxoazetidine 1 sulphonate.EMI169.1 NMR DMSO d6, ppm 1.12 t, J 7Hz, CH3 , 3.27 dd, J 3, 6Hz, C4 H , 4.38 m, CH , 4.86 ddd, J 3,6,8Hz, C3 H , 8.7 9.1 m, NH , 9.21 d, J 8Hz, NH . Example 112 0.405 g of 3 2,5 bis 4 ethyl 2,3 dioxo 1 piperazinocarboxamido pentanamido 3 methoxy 2oxoazetidine is dissolved in 1.5 ml of ThF, followed by addition of 0.284 g of pyridine sulphur complex. The mixture is stirred at room temperature for 3 days and, then, worked up in the manner as described in Example 5.The above procedure provides 0.105 of sodium 3 2,5 bis 4 ethyl 2,3 dioxo 1 piperazinocarboxamido pentanamido 3 methoxy 2 oxoazetidine 1 sulphonate.EMI169.2 NMR DMSO d6, ppm 1.09 t, J 7Hz, CH30, 3.27 dd, J 3, 63Iz,C4 H , 3.52 t,J 7Hz, C4 R , 8.79 m, NH , 9.20 d, J 8Hz, NH . Example 113 0.421 g of 3 D 2 4 2 chloroethyl 2,3 dioxo 1 piperazinocarboxamido 2 phenylacetamido 2oxoazetidine is dissolved in 5 ml of DMF, followed by addition of 0.30 g of pyridine sulphur trioxide complex.The mixture is stirred at room temperature for 2 days and, then, worked up in the manner as described inExample 5. The above procedure provides 0.32 g of sodium 3 D 2 4 2 chloroethyl 2,3 dioxo 1piperazinocarboxamido 2 phenylacetamido 2oxoazetidine l sulphonate. EMI170.1 NMR DMSO d6, ppm 3.12 dd, J 3,6Hz, C4 H , 3.40 t, J 7Hz, CH2 , 3,80 4.00 m, CH2 , 4.72 m, CR , 4.92 m,C3 H , 7,2 7.5 m,aromatic H , 9.20 d,J 8Hz,NE . 9.80 d,J 8Hz,NH . Example 114 0.36 g of 3 LD 3 chloro 2 4 ethyl 2,3 dioxo l piperazinocarboxamido propionamido 2 oxoazetidine is dissolved in 2 ml of,F, followed by addition of 0.32 g of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 4 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.28 g of sodium 3 D 2 chloro 2 4 ethyl 2,3 dioxo 1 piperazinocarboSamido propuionamido 2 oxoazetidine 1 sulphonate.EMI170.2 NMR DMSO d6, ppm 1.10 t, J 7Hz, CH3 , 3.42 q, J 7Hz, CH2 , 3.62 m, CH2 , 3.94 m, CR2 , 4.71 m, CH 0, 4.90 m, C3 H , 9.05 d, J 7Hz, NH , 9.42 d, J 7Hz, NH . Example 115 0.47 g of 3 2 benzyloxycarboxamido 2 benzyloxycarbonylethanesulphonamido 2 oxoazetidine is dissolved in 2 ml of DE, followed by addition of 0.32 g of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.39 g of sodium 3 2 benzyloxycarboxamido 2 benzyloxycarbonylethane sulphonamido 2 oxoazetidine 1 sulphonate.EMI171.1 NMR DMSO d6, ppm 3.64 m, CH2 , 4.58 m, CH , C3 H , 5.06 s, CH2 , 5.15 s, CH2 , 7.34, 7.36 each s, aromatic H 7.86 d, J 7Hz, NH , 8.38 broad s,NH . In 15 ml of water 0.14 g of the above sodium 3 2 benzyloxycarboxamido 2 benzyloxycarbonylethane sul phonamido 2oxoazetidine l sulphonate is dissolved, followed by addition of 0.10 g of palladium black. The mixture is stirred in a hydrogen gas stream for 1 hour, and the catalyst is filtered off. The filtrate is freeze dried to provide 90 mg of sodium 3 2 amino 2carboxyethanesulphonamido 2 oxoazetidine 1 sulphonate.EMI171.2 NMR DMSO d6, ppm 3.34 dd, J 2,6Hz, C4 ssH , 3.68 m, CH2 , 4.60 m, CH , C3 H . Example 116 0.27 g of 3 D 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 3 L l methyl 5H tetrazo l 5 yl thio propionamido 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.195 g of pyridinesulphur trioxide complex. The mixture is stirred at room temperature for 3 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.144 g of sodium 3 D 2 4 ethyl 2,3 dioxo l piperazinocarboxamido 2 1 methyl 5H tetrazol 5 yl thio propionamido 2 oxoazetidine 1 sulphonate.EMI172.1 NMR DMSO d6, ppm 1.10 t, J 7Hz, CH3 , 3.90 s, CH3 , 4.73 m, CH ,C3 H , 9.07 d,J 7Rz,NH , 9.36 d,J Hz,NH . Example 117 0.40 g of 3 LD 2 2 benzyloxycarboxamido 2 benzyloxycarbonylethanesulphonamido 2 phenylacetamido 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.214 g of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 3 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.24 g of sodium 3 D 2 2 benzylosycarboxamido 2 benzyloxyearbonylethanesulphonamido 2 phenylacetamido 2 oxoazetidine l sulphonate. EMI172.2 NMR DMSO d6, ppm 3.12 dd, J 2,6Hz, C4 ssH , 4.56 m, CH , 4.74 m, CH , 5.04, 5.12 each s, CH2 , 7.36 s,aromatic H , 7.80 d,J 7Hz,NH , 8.21 broad s,NH , 9.12 d,J 7Hz,NH . 0.18 g of the above sodium 3 D 2 2 benzyloxy carboxamido 2 benzyloxycarbonylethanesulphonamido 2 phenylacetamido 2 oxoazetidine 1 sulphonate is dissolved in 15 ml of water, followed by addition of 0.10 g of palladium black. The mixture is stirred in a hydrogen gas stream for 1 hour, and the catalyst is filtered off. The filtrate is freeze dried to provide 0.13 g of sodium 3 D 2 2 amino 2 carboxyethane sulphonamido 2 phenylacetamido 2 oxoazetidine 1sulphonate.EMI173.1 NMR DMSO d6, ppm , 3.42 dd, J 2,6Hz, C4 ssH , 3.62 m, CH2 , 4.78 m, CH , 7.40 broad s, aromatic H 9.22 d, J 7Hz, NH . Example 118 0.523 g of 3 D 2 2 benzyloxycarboxamido 3 sulphamoylpropionamido 2 phenylacetamido 2 oxoazetidine is dissolved in 7 ml of DMF, followed by addition of 0.30 g of pyridine sulphur trioxide complex. The mixture is stirred at room temperature for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.360 g of sodium 31TD 2 2 benzyloxycarboxamido 3 sulphamoylpropionamido 2 phenylacetamido 2oxoazetidine l sulphonate.EMI173.2 Example 119 0.50 g of 3 D 2 2 benzyloxycarboxamido 3 p methoxybenxyloxycarboxamido propionamido phenyl acetamido 2 oxoazetidine is dissolved in 6 ml of DMF, followed by addition of 0.264 g of pyridine sulphur trioxide complex. The mixture is stirred for 2 days and, then, worked up in the manner as described inExample 5. The above procedure provides 0.45 g of sodium 3 D 2 2 benzyloxycarboxamido 3 p methoxybenzyloxycarboxamido propionamido 2 phenylacetamido 2 oxoazetidine l sulphonate.EMI174.1 NMR DMSO d6, ppm 3.10 3.30 m, CH2 , C2 H , 3.56 t, J 6Hz, C4 H , 3.74 s, CH3 , 4.22 m, CH , 4.84 m,C3 R , 4.96 s, CH2 , 5.04 s, CH2 , 5.42 d, J 8Hz, CH , 6.90, 7.31 each d, J 8Hz, aromatic H , 7.34 s,aromatic H , 8.40 d,J 7Hz, NH , 9.06 d, J 8Hz, NH . 0.160 g of the above sodium 3 D 2 2 benzyloxy carboxamido 3 p methoxybenzyloxycarboxamido propionamido 2 phenylacetamido 2 oxoazetidine 1sulphonate is dissolved in a solution of 10 ml of water and 2 ml of ethyl alcohol, followed by addition of 0.115 g of palladium black. The mixture is stirred in a hydrogen gas stream for 80 minutes, and the catalyst is filtered off. The filtrate is freeze dried to provide 90 mg of sodium 3 LD 2 2,3 diamino propionamido 2 phenylacetamido 2 oxoazetidine l sulphonate.EMI174.2 NMR DMSO d61D20,ppm 3.26 dd,J 3,6Hz,C4 H , 3,63 t, J 6Hz, C4 H , 4.82 dd, J 3,6Hz, C3 H , 5.39 s, CH , 7.38 s,aromatic H . Example 120 0.30 g of 3 D 2 2 benzyloxycarboxamido 3 4 ethyl 2,3 dioxo 1 piperazinocarboxamido propionamido 2 phenylacetamido 2 oxoazetidine is dissolved in 4 ml of DMF, followed by addition of 0.159 g of pyridinesulphur trioxide complex. The mixture is stirred for 3 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.147 g of sodium 3 D 2 2 benzyloxycarboxamido 3 4 ethyl 2,3dioxo 1 piperazinocarboxamido propionamido 2phenylacetamido 2 oxoazetidine 1 sulphonate.EMI175.1 NMR DMSO d6, ppm , 1.07 t, J 7Hz, CH3 , 3.07 dd,J 3,5Hz, C4 H , 3.30 3.70 m, CH2 0, 3.38 q, J 7Hz, CH2 , 3.87 m, CH2 , 4.30 m, CH , 4.80 m, C3 H , 5.00 s, CH2 , 5.40 d, J 8Hz, CH , 7.31 s,aromatic H , 7.60 d,J 8Rz,NH , 8.45 d,J 8Hz, NH , 8.98 t, J 6Hz, NH , 9.08 d, J 8Hz, NH . 88.4 mg of the above sodium 3 D 2 2 benzyloxy carboxamido 3 4 ethyl 2, 3 dioxo l piperazinocarboxamido propionamido 2 phenylacetamido 2 o xoazetidine l sulphonate is dissolved in 10 ml of water, followed by addition of 90 mg of palladium black. The mixture is stirred in a hydrogen gas stream for 1 hour, and the catalyst is filtered off. The filtrate is freezedried to provide 70 mg of sodium 3 D 2 2 amino 3 4 ethyl 2,3 dioxo 1 piperazinocarboxamido propion amido 2 phenylacetamido 2 oxoazetidine 1 sulphonate. EMI176.1 NMR DMSO d6 D2O, ppm 1.11 t, J 7Hz, ch3 , 3.20 dd, J 3,6Hz, C4 H , 3.82 4.0 m, CH2 , 4.81 dd, J 3,61Iz,C3 E , 5.43 s, CE , 7.36 s,aromatic H . Example 121 0.34 g of 3 2 2 benzyloxycarboxamido 3 N methylcarbamoylpropionamido acetamido 3 metho sy 2 oxoazetidine is dissolved in 5 ml of DMF, followed by addition of 0.211 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days and, then, worked up in the manner as described in Example 5.The above procedure provides 0.015 g of sodium 3 2 2 benzyloxycarboxamido 3 N methylcarbamoylpropi on amido acetamido 3 methoxy 2 oxoazetidine 1 sulphonate.EMI176.2 Example 122 0.343 g of 3 r2 4 ethyl 2,3 dioxo l piperazino carboxamido acetamido 3 methoxy 2 oxoazetidine is dissolved in 5 ml of DMF, followed by addition of 0.287 g of pyridine sulphur trioxide complex. The mixture is stirred for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.076 g of sodium 3 p2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido acetamido 3methoxy 2 oxoazetidine l sulphonate.EMI176.3 NMR DMSO d6,ppm 1.10 t, J 7Hz, CH3 3.30 s, CH3 , 3.42 q, J 7Hz, CH2 , 3.60 m, CH2 , 3.61 ABq, J 4,6Hz, C4 R , 3.90 m, CE2 , 3.97 d, J 5Hz, CH2 . 9.09 t, J 5Hz, NH , 9.27 s, NH . Example 123 0.30 g of 3 D 2 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 3 N methylcarbamoyl propion amido 2 phenylacetamido 2 oxoazetidine is dissolved in 4 ml of DMF, followed by addition of 0.184 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days and, then, worked up in the manner as described in Example 45. The above procedure provides 0.141 g of sodium 3 D 2 2 4 ethyl 2,3 dioso l piperazinocarbo tamido 3 N methylcarbamoyl propionamido 2 phenylacetamido 2 oxoazetidine 1sulphonate.EMI177.1 NMR DMSO d6, ppm 1.08 t, J 7Hz, CH3 , 2.40 2.75 m, CH2 , CH3 , 3.25 dd, J 2,5Hz, C4 H , 3.38 q, J 7Hz, CH2 , 3.53 m, CH2 , 3.90 m, CH2 , 4.60 m, CH , 4.83 m, C3 H , 5.38 d, J 9Hz, CH , 7.33 s,aromatic H , 7.86 m,NH , 8.55 d,J 9Rz,NH , 8.93, 8.95 each d,J 9Rz,NH , 9.31,9.42 each d, J 7Hz,NH . Example 124 0.35 g of 3 2 4 ethyl 2,3 dioxo 1 piperazino carboxamido 3 N methylcarbamoyl propionamido 2 oxoaxetidine is dissolved in 5 ml of DMF, followed by addition of 0.234 g of pyridine sulphur trioxide complex. The mixture is stirred for 3 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.178 g of sodium 3 t2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 3 N methyl carbamoyl propionamido 2 oxoazetidine 1 sulphonate. EMI178.1 NMR DMSO d6ppm 1.10 t, J 7Hz, CH30, 2.58 d, J 5Hz, CH3 , 2.40 2.67 m, CH2 , 3.42 q, J 7Hz, CH2 , 3.57 m, CH2 , 3.93 m, CE2 , 4.55 m, CH , 4.80 m,C3 R , 7.83 q,J SHz,NH , 8.72 d, J 8Hz, NH , 9.31, 9.35 d, J 8Hz, NH . Example 125 0.40 g of 3 r2 D 2 benzyloxycarboxamido 2 phenylacetamido 3 N methylcarbamoyl propionamido 2oxoazetidine is dissolved in 8 ml of DMF, followed by addition of 0.264 g of pyridine sulphur trioxide complex. The mixture is stirred for 4 days and, then, worked up in the manner as described in Example 45.The above procedure provides 0.212 g of sodium 3 t2 D 2 benzyloxycarboxamido 2 phenylacetamido 3 N methyl carbamoyl propionamido 2 oxoazetidine 1 sulphonate.EMI178.2 NMR DMSO d6ppm 2.27 2.63 m, CH2 , CH3 , 3.27 m,C4 H , 3.52, 3.57 t, J 6Hz, C4 H , 4.53 m, CH , 4.80 m,C3 H , 5.03 s, CH2 , 5.22, 5.23 d,J 8Hz, CH , 7.33 s,aromatic H , 7.50 7.93 m,NH , 8.27 8.63 m,NH . 0.10 g of the above sodium 3 2 D 2 benzyloxy carboxamido 2 phenylacetamido 3 N methylcarbamoyl propionamido 2 oxoazetidine 1 sulphonate is dissolved in 8 ml of water, followed by addition of 50 mg of palladium black. The mixture is stirred in a hydrogen gas stream for 1 hour, and the catalyst is filtered off.The filtrate is freeze dried to provide 68 mg of sodium 3 t2 D 2 amino 2 phenylacetamido 3 N methylcarbamoyl propionamido 2 oxoazetidine 1 sulphonate.EMI179.1 NMR DMSO d6 D2O, ppm 2.47 2.83 m, CH2 , CH3 , 3.48 m,C4 H , 4.53 s, CR 4.63 m, CH , 4.87 m,C3 R , 7.42 s,aromatic H . Example 126 A 0.228 g of 3 r2 D 2 oxo 3 furfurylideneamino imidazolidin l yl carboxamido 2 phenylacetamido 3 S methoxy 2 oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.199 g of pyridine sulphur trioxide complex. The mixture is stirred for 1 day and, then, worked up in the manner as described inExample 5. The above procedure provides 0.11 g of sodium 3 2 D 2 oxo 3 furfurylideneaminoimidazolidin l yl carbosamido 2 phenylacetamido 3 S methoxy 2 oxoazetidine l sulphonate.EMI179.2 NMR d6 DMSO, ppm 3.03 s,CR3 , 3.54, 3.72 d,J 6Hz,C4 H , 3.80 5, CR2 , 5.63 d,J 7Hz, CR , 6.5 7.9 m,aromatic H , 7.74 s, CR N , 9.02 d, J 7Hz,NH , 9.71 s,NH . Example 126 B 0.114 g of 3 2 D 2 oxo 3 furfurylideneamino imidazolidin 1 yl carboxamido 2 phenylacetamido 3 R methoxy 2 oxoazetidine is dissolved in 1 ml of DMF, followed by addition of 0.1 g of pyridine sulphur trioxide complex. The mixture is stirred for 1 day and, then, worked up in the manner as described inExample 5. The above procedure provides 0.044 g of sodium 3 2 D 2 oxo 3 furfurylideneaminoimidazolidin1 yl carboxamido 2 phenylacetamido 3 R methoxy 2oxoazetidine l sulphonate.EMI180.1 NMR d6 DMSO, ppm 3.32 s,CE3 , 3.46, 3.55 d,J 6Hz, C4 H , 3.80 s, CH2 , 5.59 d, J 7Hz, CH , 6.5 7.9 m,aromatic H , 7.74 s, CR N , 8.96 d, J 7Hz, NH , 9.65 s, NH . Esample 127 0.096 g of 3 2 4 ethyl 2,3 dioxo 1 piperazino carboxamido 2 4 n octanoyloxyphenyl acetamido 2oxoazetidine is dissolved in 1.5 ml of DMF, followed by addition of 0.058 g of pyridine sulphur trioxide complex. The mixture is stirred for 1 day and, then, worked up in the manner as described in Example 5.The above procedure provides 0.096 g of sodium 3 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 2 4 noctanoyloxyphenyl acetamido 2 oxoazetidine 1sulphonate.EMI180.2 NMR d6DMSO, ppm 0.87 t, CH3 , l.O9 t,CH3 , 1.2 2.6 m, CH2 , 3.13 dd, J 3,6Hz, C4 H , 3.41 q, CH2 , 3.4 4.1 m, CH2 , 4.86 ddd, J 3,6,8Hz,C3 H , 5.46 d,J 7Hz, CH , 7.10,7.44 d,J 8Hz, aromatic H , 9.28 d, J 8Hz, NH , 9.82 d,J 7Hz,NH . Example 128 0.35 g of 3 2 4 ethyl 2,3 dioxo 1 piperazino carboxamido 3 N ethoxycarbonylmethyl carbamoyl propionamido 2 oxoazetidine, is dissolved in 5 ml ofDMF, followed by addition of 0.23 g of pyridinesulphur trioxide complex. The mixture is stirred for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.165 g of sodium 3 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 3 N ethoxyearbonylmethylcarbamoyl propionamido 2 oxoazetidine l sulphonate.EMI181.1 NMR DMSO d6,ppm 1.10 t, J 7Hz, CH3 , 1.19 t, J 7Hz, CH3 , 2.66 m, CH2 , 3.35 DD, j 3,6Hz, C4 H , 3.43 q, J 7Hz, CH2 , 3.50 3.73 m, CH2 , 3.74 4.00 m, CH2 , 3.81 d, J 6Hz, CH2 , 4.09 q, J 7Hz, CH2 , 4.58 m, CH , 4.82 m,C3 E , 8.36 t, J 6Hz, NH , 8.75 d, J 8Hz, NH , 9.34 d, J 8Hz, NH . Example 129 0.464 g of 3 D 2 4 ethyl 2,3 dioxo 1 piperazino carboxamido 3 2 thienylacetamido propionamido 2oxoazetidine is dissolved in 5 ml of I MF, followed by addition of 0.30 g of pyridine sulphur trioxide complex.The mixture is stirred at room temperature for 2 days and, then, worked up in the manner as described inExample 5. The above procedure provides O.31 g of sodium 3 D 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido 3 2 thienylacetamido propionamido 2 oxoazetidine 1 sulphonate. EMI182.1 NMR DMSO d6, ppm 1.10 t, J 7Hz, CH3 , 3.20 dd, J 2.5, 6Hz, C4 H , 3.40 q, J 7Hz, CH2 , 3.60 3.90 m, CH2 , 3.70 s, CH2 , 4.60 m, CH , 4.82 m, C3 H , 6.7 7.4 m, thienyl H , 8.68 d, J 8Hz, NH , 9.30 d,J 8Hz,NH . Example 130 0.28 g of 3 N mesyl D phenylglycinamido 2 oxoazetidine is dissolved in 4 ml of DMF, followed by addition of 0.30 g of pyridine sulphur trioxide complex.The mixture is stirred for 2 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.12 g of sodium 3 N mesyl Dphenylglycinamido 2 oxoazetidine 1 sulphonate.EMI182.2 NMR DMSO d6,ppm 3.10 dd, J 3,6Hz, C4 H , 3.32 s,CE3 , 4.52 m, CH , 4.75 m, 9R , 7.35 s,aromatic H , 8.30 broad s, NH , 9.20 d,J 7Hz, NH . Example 131 0.30 g of 3 LP 2 L2 4 ethyl 2,3 dioxo l piperazinocarboxamido acetamido 2 phenylacetamido 2oxoazetidine is dissolved in 4 ml of DMF, followed by addition of 0.215 of pyridine sulphur trioxide complex.The mixture is stirred for 4 days and, then, worked up in the manner as described in Example 5. The above procedure provides 0.239 g of sodium 3 D 2 2 4 ethyl 2,3 dioxo 1 piperazinocarboxamido acetamido 2 phenyl acetamido 2 oxoazetidine 1 sulphonate.EMI182.3 NMR DMSO d6ppm 1.10 t, J 7Hz, CH3 , 3.15 dd, J 3,5Hz, C4 H , 3.28 q, J 7Hz, CH2 , 3.30 3.70 m, CR2 , 3.804.10 m, CH2 , 3.98 d,J SHz, CR2 , , 4.83 m,C3 H , 5.47 d,J 8Hz, CH , 7.37 s,aromatic H , 8.68 d,J 8Hz, NH , 9.05 d,J 8Hz, NH , 9.16 d,J 5Hz, NH . Example 132 0.287 g of 3 L2 D 4 n octyl 2,3 dioxo lpiperazinocarboxamido 2 thienylacetamido 2oxoazetidine is dissolved in 2 ml of DMF, followed by addition of 0.191 g of pyridine sulphur trioxide complex. The mixture is stirred for one day and, then, worked up in the manner as described in Example 5.The above procedure provides 0.314 g of sodium 3 2 D 4 n octyl 2,3 dioxo 1 piperazinocarboxamido 2thienylacetamido 2 oxoazetidine 1 sulphonate.EMI183.1 NMR d6 DMso,ppm 0.86 t,CR3 , 3.17 dd,J 3,6Hz, C4 H , 3.4 4.1 m, CH2 , 3.62 t,J 6Hz,C4 H , 4.86 ddd, J 3,6,8Hz, C3 H , 5.72 d, J7Hz, CH , 6.9 7.6 m, thienyl H0, 9.30 d, J 8Hz, NH , 9.73 d, J 7Hz, NH .